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1.0 Abstract 
 
 
Background 
Adjuvant chemotherapy, endocrine therapy, anti-HER2 therapy and radiotherapy 
significantly improve recurrence free and overall survivals in early breast cancers. Indications 
for a particular therapy have been well defined. Examples include oestrogen receptor 
positivity for endocrine therapy; HER2/Neu protein overexpression for anti-HER2 therapy; 
young age group, lymph node positivity, nuclear grade 3 and triple negativity (ie, 
ER/PR/HER2 negative) etc for chemotherapy; lumpectomy, > 5 cm tumour size, > 4 lymph 
nodes involvement etc for radiotherapy. Compared to no chemotherapy adjuvant 
chemotherapy can reduce the 10 years breast cancer mortality risk by one third although the 
absolute benefit depends on the absolute risk before the adjuvant chemotherapy as the risk 
reduction is proportional.  The absolute risk depends on the various clinical and 
histopathological risk factors such as age, nuclear grade, tumour size, lymph node 
involvement, oestrogen hormone and HER2 receptor expressions. Various clinical guidelines, 
prognostic/ predictive tools and tests have been developed to calculate the absolute breast 
cancer specific survival risks and chemotherapy benefits to help in making the decision of 
“potential benefit outweighs the potential treatment toxicities” to recommend the adjuvant 
chemotherapy on  individual basis. This principle aims to identify patients with very good 
prognosis for whom the toxic chemotherapy could be safely omitted and also patients with 
prognosis poor enough to justify offering toxic chemotherapies. However, no studies have 
specifically focussed on identifying patients in whom the chemotherapy could not deliver the 
expected benefit. Analysing molecular biomarker proteins that are functionally important in 
the cancer biology and chemotherapy cell killing mechanism using readily available and 
relatively inexpensive immunohistochemistry (IHC) method might be able to identify this 
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group of patients and find the targets against which novel therapy could be developed to 
improve their survival outcomes.  
Objective 
This study aims to identify potential molecular biomarkers that indicate a failure of adjuvant 
chemotherapy in early breast cancers in terms of cancer recurrence within five years and to 
create hypotheses relating to the use of effective novel targeted adjuvant therapy to improve 
the outcomes. 
Methods 
A matched case control, exploratory study was performed. Cases were patients relapsing 
within 5 years from the date of curative surgery and received adjuvant chemotherapy (with or 
without hormone/radiotherapy). Controls were patients who remained recurrence free for a 
minimum of 5 years from the date of surgery and had adjuvant chemotherapy (with or 
without endocrine/radiotherapy). Controls were matched to the cases by 10 years recurrence 
risk (RR) using “Adjuvant!” prognostic tool.  “Matched controls” should also have positive 
axillary lymph nodes, Adjuvant RR at least > 50% and not more than 10% absolute points 
lower than their matched cases. “Low risk control” group (patients who are recurrence free 
for 5 years following surgery, have RR < 50%, and had adjuvant chemotherapy) was also 
included for the exploratory analysis purpose.   Clinicopathological data was collected from 
the case notes. Formalin fixed paraffin embedded (FFPE) tumour blocks were retrieved from 
the storage and H & E slides were prepared. The most suitable part of the invasive cancer was 
marked on the slide guided by an experienced pathologist. Depending on the tissue 
availability, up to three tissue cores each measuring 0.6 mm in diameter were collected from 
the different parts of the block corresponding to the area marked on the H & E slides. Tissue 
microarray (TMA) blocks were constructed using a manual Beecham tissue arrayer®. 
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TMAs were cut into 4 micrometers thick slices and then mounted on super frost glass slides. 
IHC staining was optimised before performing final staining using Ventana automated 
staining machine, as per manufacturer’s instruction after antigen optimisation for each 
proteins biomarkers namely ER, PR, EGFR, HER2, Ki-67, CK-5/6, Bcl-2, MCM-2, Bag-1, 
Aurora A, PDGFR alpha, CD-68, CD-71, VEGFR-2, Cathepsin L2, Plk-1 and GSTM-1. The 
TMA slides were scanned and digitalised images were obtained using a Mirax® scanner. The 
biomarker proteins expression was analysed using 20x power fields. 10% of cores were 
randomly examined by the second independent observer. Associations between survival 
outcomes and individual biomarkers or molecular subtypes (Luminal A, Luminal B, HER2 
enriched, Core Basal, 5-Negative classified according to expressions of 6 biomarkers namely 
ER, PR, HER2, EGFR, Ki-67 and CK-5/6) were analysed by Chi-square test, independent 
samples Student t test, Log Rank test, Kaplan-Meier and Cox multivariate regression model 
using SPSS 16v software. Correlations between survival outcomes, molecular subtypes and 
RR according to the prognostic tools (“Adjuvant” & “OPTION”) were also evaluated. The 
study was approved by the local ethic committee. The project was funded by the research 
grant from Pfizer. 
Findings 
The study includes a total of 178 patients (72 patients each in “cases” and “matched 
controls”, 34 patients in “low risk control” groups). Molecular subtyping was possible for 
170 patients as IHC assessment had failed in 7 patients. Luminal A (LA) is seen more 
commonly in the control group while Luminal B (LB), HER2 enriched (H), Core Basal (CB) 
and 5 markers negative (5N) are seen more commonly in the cases group.  
There are no differences between the cases and the matched controls in their mean and 
median RR by “Adjuvant!” (10-years)/ “OPTION” (5-years). There are also no differences in 
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mean and median “Adjuvant!” or “OPTION” RR among different molecular subtypes. No 
correlation could be established between “Adjuvant!”/ “OPTION” RR and the survival 
outcomes in the matched controls and cases cohort.  
There are statistically significant differences in RFS and OS between molecular subtypes. 
The median RFS and OS (months) for LA: LB: H: CB: 5N are: not reached: 58.1: 28: 15.4: 
19.9 (p = <0.001); and not reached: 86.1: 55.9: 30.4: 26 (p = <0.001) respectively.  
In univariate analysis better RFS and OS were observed for IHC positive Bcl-2 (p = 0.036 
& 0.058), positive MCM-2 (p = 0.01 & 0.03), positive Bag-1 (p = 0.018 & 0.018) and 
negative Aurora A (p = 0.001 & 0.001) expressions. Trends for better RFS and OS were 
observed for negative PDGFR-α (p = 0.07 & 0.085) and negative CD-71 (p = 0.097 & 0.081) 
expressions.  
In multivariate analysis, statistically significant factors (hazard ratios in the bracket) for RFS 
are as follows:  CB (5.7) compared to LA; Bag-1+ (0.26); MCM-2+ (0.169); Aurora A+ 
(3.494); T3 (3.596); N1 (0.305). Significant factors for OS are: LB (2.37), CB (11.29), H 
(3.14), 5N (7.71); Bag-1+ (0.5); CD-68+ (0.45); MCM-2+ (0.38); Aurora A+ (2.64); N1 
(0.035).  
25% of Luminal A patients are cases (ie, RFS < 5 years). The 5-years recurrence risk of 25% 
is a lot higher than that reported for LA cancers from other studies with different risk 
populations. No biomarkers that could predict disease recurrence within 5-years in LA were 
found.  
In non-luminal cancers (ie. both ER and PR negative) positive expressions of CK-5/6 and 
Aurora A were associated with worse RFS while positive expressions of Bag-1 and MCM-2 
were associated with better RFS.  
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Negative Aurora A expression is associated with the better RFS and OS in non-LA patients. 
(No statistical significance was achieved for LA cancers.) 
The IHC expressions of proteins coded for by the genes used in Oncotype Dx assays (ER, 
PR, HER2, Bcl-2, Bag-1, Ki-67 and Aurora A) show similar positive/ negative impact on 
RFS except CD-68 (as tumour associated macrophages infiltration) that is associated with the 
good prognosis similar to other published studies.   
Conclusion 
This study identified Bag-1 protein expression as a predictor for better survival, in keeping 
with the contribution of Bag-1 mRNA to Recurrence Score within the Oncotype-Dx tool. 
 The finding of a trend for lower CD-71 expression (<=17) relates to better RFS (p=0.097) 
and OS (p=0.081) is the first observation that CD-71 (the iron transporter transferrin receptor 
which has been equated with proliferative capacity of tumours) may relate to its association 
as a poor prognostic factor, rather than a predictive factor for therapy (although a 
combination is probable), even in patients who had adjuvant chemotherapy. This adds to our 
knowledge that CD-71 relates to worsened endocrine outcome in breast cancer patients.  
This study showed that 5 IHC defined molecular subtypes can predict differing survival 
outcomes in patients with similar “Adjuvant!” 10-years and “OPTION” 5-years RR treated 
with adjuvant chemotherapy. This suggests the superiority of this IHC based assessment over 
and above the globally utilised Adjuvant! RR score. In this patient population, LA was found 
to have the best survival while CB and 5N have the poorest survivals. This is in agreement 
with the results from previous publications. However, Luminal A cancers with OPTION 5 
years RR > 40% should be offered chemotherapy due to the high 5 years recurrence rate 
(although this may need to be validated in an independent study) and predictive molecular 
markers are needed for better patient selection. 
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Subtypes CB & 5N, positive CD-71, Aurora A, PDGFR-α, and negative Bag-1, Bcl-2 and 
MCM-2 expressions were predictive of poor RFS and OS and should be used as stratification 
factors for novel prospective biomarker led adjuvant studies. Novel theraputic agents that 
modify the biological functions of these proteins should be explored in the well designed 
clinical trials. 
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2.0 Epidemiology 
 
Over the last few decades “cancer” has become one of the most common medical illnesses in 
the developed world. (http://info.cancerresearchuk.org/cancerstats published in April 2011) 
One in 3 people in the UK will develop cancer during their lifetime and one in four people 
will die from it. Around 320,500 people were diagnosed with cancer in the UK in 2009, 
equating to a crude rate of 519 cases per every 100,000 people. The European age-
standardised rate for UK is 429 per 100,000 for men and 372 per 100,000 for women. Breast, 
colorectal, lung and prostate cancers account for half of all cancers. (Cancer Stats Incidence 
2009 - UK, CRUK, published in May 2012) In women, breast cancer is the most common 
type of cancer, accounting for 31% of all cancers. The age standardised rate is 124 per 
100,000 women and the life-time risk is 1 in 8.  In 2009, a total of 48,417 women were 
diagnosed with breast cancer in UK. (Cancer Stats Incidence 2009 – UK) 
The risk of having breast cancer increases with age. 81% of cancers were diagnosed in 50 and 
over age group while 48% of cancers were diagnosed in the 50-69 year age group. (Cancer 
Stats Incidence 2009 – UK) Some of the other known risk factors include BRCA 1 & 2 genes 
mutation, early onset of menstruation, late menopause, low number of live-born children 
(parity), older age at first completed pregnancy, some forms of benign breast disease, 
exposure of developing breast tissue to radiation, use of products containing oestrogen and 
progestrone (either oral contraceptives or hormone replacement therapy), lifestyle parameters 
such as obesity, high intake of meat, saturated, monounsaturated and polyunsaturated fat.   
Improvements in breast cancer management since the 1970s led to the prevention of 25-30% 
breast cancer deaths in the year 2000. (Peto, 2000) Estimated 10 and 20 years survival rates 
have improved from 54% and 44%, respectively, for women diagnosed in early 1990’s to 
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72% and 64%, respectively, for women diagnosed in 2001 – 2003. Age standardised 5 year 
survival rate for 2005 – 2009 is 85.1% for England with the very similar rate for the rest of 
the UK. (http://info.cancerresearchuk. org/cancerstats/ types/ breast/survival/) Yet 11,556 
women and 77 men died from breast cancer in year 2010 in UK. To push the current survival 
successes to the next level, it is of paramount importance to identify patients who are at 
especially high risk of recurrence and death despite adjuvant therapies, so that novel 
treatments can be explored for these patients. This study aims to achieve this goal by 
analysing biomarkers to predict failure from adjuvant chemotherapy, a treatment that can be 
applied to any type of cancer.  
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3.0 Early Breast cancer and its treatments 
 
Breast cancer is highly curable when it is diagnosed at an early stage where the cancer is 
macroscopically confined to the breast and the regional lymph nodes namely ipsilateral 
axillary, internal mammary and the supra clavicular nodes. Surgery – either mastectomy or 
wide local excision - is the mainstay of the curative treatment. However, in some patients 
cancer would recur locally or at a distant site at a later date due to the spread of 
micrometastases before surgery. When micrometastases grow and become macrometastases 
over a variable period of time, the disease is rarely curable and most patients die from it. The 
Surveillance, Epidemiology and End Results (SEER) database from United States for 2003 – 
2009 showed that 61% of breast cancer cases were diagnosed at an early stage while being 
confined to the breast; 32% were diagnosed after the regional spread (regional lymph nodes 
or directly beyond the primary site) and 5% were diagnosed at the metastatic stage with 
corresponding 5-year relative survival rates of 98.6%, 84.4% and 24.3%, respectively. 
(http://seer.cancer.gov/statfacts/html/breast.html#survival assessed on 08.07.13) Average 
survival after the identification of metastatic disease is around 22 months and the intention of 
treatment at this stage is to relieve symptoms and improve quality of life, although the 
prolongation of life is often possible. (Chia, 2007) (Gennari, 2005) To prevent such 
devastating outcomes, patients at risk of developing metastatic disease are offered and 
administered so-called adjuvant therapies with the aim of clearing “micrometastases”. 
Currently there are chemotherapy, endocrine therapy, anti-HER2 therapy and radiotherapy 
available and they have been shown to improve both short and long term survivals. 
(EBCTCG, 2005, 2011, 2012) (Baselga, 2006) 
In the past, breast cancer was treated as a single disease with mutilating extensive surgery. By 
the first half of the 20th century, clinicians had become aware that not all breast cancers 
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shared the same prognosis or required the same treatment, and attempts were made to define 
characteristics that could reliably distinguish those tumours that required aggressive treatment 
from those that did not. Clinical staging systems were introduced to classify patients for an 
appropriate treatment. The tumour-node-metastasis (TNM) system was developed by Pierre 
Denoix in the 1940s (www.uicc.org/system/files/.../History_Evolution_Milestones_0.pdf 
assessed on 27.11.2012) and was later updated by the International Union Against Cancer 
and the American Joint Committee on Cancer to divide breast cancer into different stages that 
have significant differences in survival. Five year survival data from US National Cancer 
Database for patients diagnosed in 2001 and 2002 is shown in the table below. 
(http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-survival-by-stage 
assessed on 08.07.13) 
AJCC staging and 5 years survival rate for breast 
cancer 
AJCC Stage 5-year Survival Rate 
0 93% 
I 88% 
IIA 81% 
IIB 74% 
IIIA 67% 
IIIB 41% 
IIIC 49% 
IV 15% 
(Please see appendix 1 for AJCC staging.) 
 
The choice of adjuvant treatments depends on the patient and tumour characteristics, 
potential benefits, potential toxicities and acceptability to the patient. Early Breast Cancer 
Treatment and Collaborative Group (EBCTCG) overviews demonstrated that some taxane-
plus-anthracycline-based or higher-cumulative-dosage anthracycline-based regimens (not 
requiring stem cells) reduced breast cancer mortality, on average, by about one-third. 
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(EBCTCG, 2012) This means that the remaining two thirds of patients who really need 
adjuvant therapies to clear micrometastases did not achieve the expected benefit from even 
most effective adjuvant chemotherapy regimes. This is because although the adjuvant 
chemotherapy is proven to be effective, “one size fit for all” approach can’t be applied. In the 
absence of 100% effective therapies, the best way of improving treatment outcome in the 
future is to give the right treatment to the right patients - a “personalised” approach. 
However, it remains a major challenge to identify at the individual patient level who is likely 
or unlikely to benefit from specific chemotherapy.  
Risk can be assessed by the presence of prognostic factors. A prognostic factor is any feature 
of the patient or the tumour that can be used to foresee the patient's natural history in terms of 
cancer survival. Prognostic factors correlate with the survival in the absence of specific 
theraputic intervention, and are used to select patients at risk. Currently the strongest 
prognostic factors for the survival in the breast cancer include presence or absence of distant 
metastases, histologic grade, nodal status, tumour size, age, oestrogen receptor and HER2/neu 
status. Various prognostic tools have been developed to combine these factors for higher 
accuracy in risk calculation. For example, Nottingham Prognostic Index (NPI), by using 
tumour size, grade and lymph node status, stratifies patients into different groups that have 
different survival outcomes. (Rampaul, 2001) 
NPI Group NPI Score 15 years overall survival 
Good >2.4 80% 
Moderate 2.4 – 5.4 42% 
Poor >5.4 23% 
                     NPI and 15 years overall survival 
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Freely available internet web-based decision-making tools such as Adjuvant!, (Ravdin, 2001) 
PREDICT (Wishart, 2010) and OPTION (Campbell, 2010) became available to estimate 5 -
20 years disease recurrence and mortality risk as well as the benefit from various systemic 
adjuvant therapies based on the clinicopathological parameters such as mode of diagnosis 
(symptomatic or screen detected cancer), age, general health status, hormone receptor status, 
HER2 status, nodal status, tumour grade and size.  
In contrast to the prognostic factors, the predictive factors correlate outcomes from the 
therapeutic intervention independent of prognosis, and have a significant impact in selected 
patient populations. A marker has a predictive value only if its presence or absence could 
foretell the outcome from a particular therapy such as response or survival; it may or may not 
have a prognostic value. In early breast cancer, predictive factors for systemic adjuvant 
therapies benefit include age, hormone receptor status and Ki-67 expression for adjuvant 
chemotherapy, oestrogen receptor (ER) and progesterone receptor (PR) status for endocrine 
therapy and HER2 expression status for anti-HER2 trastuzumab therapy.  
Although a large number of molecular proteins have been extensively investigated, no 
tumour biological factor has any useful predictive value for response to any specific 
chemotherapy regime. There are some reports on predictive value of molecular markers to 
response to some chemotherapies such as HER2 expression for some chemotherapy 
regimens, (Cheang, 2012) triple negative cancers (ie. ER/ PR, HER2 expression) for classical 
CMF chemotherapy, (Colleoni, 2010) ER status for paclitaxel (Henderson, 2003) and ER, Ki-
67, HER2 status for docetaxel (Hugh, 2009) but these are not yet fully validated to be used as 
a standard practice.  
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4. Adjuvant chemotherapy 
 
Systemic adjuvant chemotherapy was first introduced in early 1970s, initially with single 
agents such as Melphalan. (Carpenter, 1983) In 1975, Bonadonna et al reported distant 
recurrence benefit from 12 months treatment with adjuvant polychemotherapy CMF 
(Cyclophosphamide, Methotrexate, 5-FU). (Bonadonna, 1976) (Bonadonna, 1995) After 27 
months of study, only 5.3% of 207 women treated with CMF relapsed while 24% of 179 
women without chemotherapy relapsed. The benefit was seen across all the subgroups. Since 
then CMF had become a standard for many years and studies have been carried out to answer 
various questions such as optimal number of CMF cycles (1 or 3 or 6 or 12) and its 
effectiveness in node negative or ER negative tumours. 
 
After a median follow up of 28.5 years with a minimum follow up of 25.4 years, adjuvant 
CMF was found to significantly reduce the relapse with hazard ratio (HR) = 0.71, 95% 
confidence interval (95%CI) = 0.56 to 0.91; P = 0.005 and death (HR = 0.79; 95%CI = 0.63 
to 0.98; P = 0.04), compared to no chemotherapy. (Bonadonna, 2005) In the node negative 
and oestrogen receptor negative trial, intravenous CMF significantly reduced the relapse (HR 
= 0.65; 95%CI = 0.47 to 0.90; P = 0.009) and death (HR = 0.65; 95%CI = 0.47 to 0.92; P = 
0.01) at a median follow up of 20 years. The patients who received optimal doses of CMF 
(85% of the planned doses) showed a long lasting, superior benefit (RFS= 42%; 95% CI = 
26% to 59%; OS = 40%; 95% CI = 26% to 55%) compared with patients who received lower 
doses (RFS = 26%; 95% CI = 19% to 33%; OS = 21%; 95% CI = 14% to 26%, respectively). 
No detrimental effect of adjuvant chemotherapy was seen for any of the subsets of patients.  
After a median follow up of 25 years, 6 cycles of CMF was found equally effective as 12 
cycles. (Bonadonna, 2005) 3 cycles of CMF was found to be as effective as 6 cycles for 
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disease free survival in ER positive women aged over 40. But it was not as effective as 6 
cycles in women younger than 40 years and ER negative tumours. (Colleoni, 2002) The 
IBCSG Trial V also showed that a single cycle of perioperative CMF improved the outcome 
compared with no chemotherapy in node negative disease, but it was found to be less 
effective than 6 cycles of CMF in node positive disease. (Ludwig Breast Cancer Study 
Group, 1988) EBCTCG overview in 1998 showed that the improvement in 10-year survival 
from CMF chemotherapy in premenopausal women younger than 49 years of age was 
between 7% and 11%, depending on the nodal status (improvement from 71% to 78% in 
node-negative and from 42 to 53% in node-positive patients). The figures in node-positive 
and node-negative women aged between 50and 69 years were 3% (46 to 49%) and 2% (67 to 
69%), respectively. (EBCTCG, 1998)  
EBCTCG’s extended 15-year follow-up meta-analysis involving more than 14,000 patients 
found that anthracycline-containing regimens were significantly
 
more effective at preventing 
recurrence (HR = 0.89) and decrease mortality (HR = 0.84) than were CMF regimens 
regardless of menopausal status, age, nodal and ER status. (EBCTCG, 2005b) However only 
two types of anthracycline based regimens - FAC or FEC like and sequential anthracycline - 
Epirubicin or Doxorubicin - followed by CMF (E-CMF or D-CMF) - have shown to be 
superior to CMF. (De Placido, 2005) (Bonneterre, 2005) Four cycles of doxorubicin + 
cyclophosphamide were shown to be equally effective as 6 cycles of CMF chemotherapy. 
(EBCTCG, 2012) The
 
French Adjuvant Study Group (FASG) demonstrated that the optimal
 
epirubicin-based chemotherapy in premenopausal, node-positive
 
breast cancer patients was 
six cycles of FEC50 rather than three
 
cycles. (Fumoleau, 2003) In a planned pooled efficacy 
analysis of the National Epirubicin
 
Adjuvant Trial and the Scottish Cancer Trials Breast 
Group BR9601
 
trials, where 28% of the 2,391 patients enrolled were node-negative, it 
showed that E-CMF gave significantly better RFS (HR = 0.70) and
 
OS (HR = 0.64), 
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compared to 8 cycles of classical CMF, irrespective of the nodal status. (Poole, 2006) 
Cameron et al showed that D-CMF is as effective as AC-Taxol and days 1 and 8 ECF in their 
audit of 329 women with early breast cancer with at least 4 axillary lymph nodes 
involvement. (Cameron, 2002) 
Newer chemotherapies that contain taxane (docetaxel or paclitaxel) are shown to further 
improve the survival in both node negative and positive breast cancer patients compared to 
chemotherapies without taxane. (EBCTCG, 2012) The anti HER2 monoclonal antibody 
trastuzumab added to chemotherapy improves pathological complete response rate in 
neoadjuvant setting (Buzdar, 2005) (Wildiers, 2011) and survival in adjuvant setting in 
patients with cancer that over-expresses HER2 protein. (Viani, 2007)  
In premenopausal women, chemotherapy can deliver its effect via ovarian suppression in 
addition to the direct cell killing as shown by the high incidence of chemotherapy induced 
amenorrhoea in 50% to more than 65% of patients and equal effectiveness of ovarian 
suppression with or without tamoxifen compared to chemotherapies. (Jakesz, 2002) 
(Kaufmann, 2003)  However, pathological complete response rate of up to 54.6% to 
neoadjuvant chemotherapy (docetaxel + carboplatin) in triple negative breast cancers – higher 
than ER/PR negative, HER2 positive and ER/PR positive patients – (Chang, 2010) and 
benefit of chemotherapy in postmenopausal patients confirmed the importance of direct cell 
killing effect of chemotherapy independent of hormonal manipulation. (EBCTCG, 2008) 
Drug-induced cell death is a result of checkpoint response to DNA and other cellular 
damages. Apoptosis as a mechanism of chemotherapy induced cell killing was first suggested 
in 1975. (Searle, 1975) Conventional nonspecific cytotoxic anticancer agents cause DNA 
damage, genome destabilization, cell cycle arrest,
 
and cytotoxic cell stress on rapidly
 
dividing 
cancer cells, activating p53, and killing the cells
 
by indirectly activating the intrinsic 
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apoptotic pathway. Thus, the efficacy of anticancer treatments depends not only on the drugs’ 
ability to cause cellular damage but also on the cells’ ability to detect and respond to such 
damages. Non-proliferating cells are less sensitive to chemotherapy drugs because the cells 
have more time to repair the damaged DNA and the converse is true for the rapidly 
proliferating cells. 
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5. Patient selection for adjuvant chemotherapy 
 
Whether or not to recommend adjuvant chemotherapy to a patient is the balance between 
potential benefits and potential side effects.  Benefit from adjuvant chemotherapy depends on 
breast cancer mortality risk before chemotherapy. The low absolute risk implies low absolute 
benefit.  Therefore only patients with high risk features are often offered adjuvant 
chemotherapy as the benefit is deemed to outweigh the potential risk of unpleasant treatment 
toxicities. However, there is no consensus on the amount of benefit for which toxic 
chemotherapy is justified.  Half of the patients who participated in two clinical surveys 
claimed that they would take chemotherapy for 0.5 - 1% absolute benefit in the recurrence 
risk. (Ravdin, 1998) (Jansen, 2001)  
St. Gallen’s consensus and NCCN guidelines provide clear treatment pathways for adjuvant 
therapies.  Prognostic tools such as Nottingham’s Prognostic Index (NPI), OPTION, 
PREDICT and Adjuvant are useful to estimate the risk of cancer recurrence, mortality and the 
benefit from adjuvant chemotherapies for an individual patient. Recently developed 
molecular subtyping identifies different types of cancer based on the gene or protein 
expressions. (Perou, 1999) (Cheang, 2009) These subtypes have different risk levels and 
potential benefits from chemotherapy regardless of other known risk factors such as age, size, 
grade and lymph node status. (Houssami, 2012) (Caudle, 2012) Commercialised multi-gene 
assays such as Oncotype Dx and Mammaprint utilise the expressions of various genes in 
cancer cells to calculate the recurrence and mortality risk and an estimate of the benefit from 
chemotherapy for an individual patient. (Paik, 2004) (vant’ Veer, 2002) Different assays use 
different sets of genes and divide patients into different risk groups for recommendation of 
chemotherapies. These gene assays, costing in the excess of £2000 per test, claimed to be 
superior to the previously mentioned freely available conventional methods and tools to 
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select patients who could get benefit from the adjuvant chemotherapy.  
(www.oncotypedx.com) (www.mammaprint.com) However, none of these gene assays are 
designed or able to identify patients who would get metastatic disease despite adjuvant 
chemotherapies. The way forward to improve this is to develop and utilise various 
biomarkers – prognostic, diagnostic, metabolic, etc. – for better selection of patients and 
treatments. Cancer Biomarker Collaborative Consensus made recommendations in eight 
critical areas for biomarker development - bio specimens, analytic performance, 
standardization and harmonization, bioinformatics, collaboration and data sharing, 
regulations, stakeholder education and communication, and science policy - and put forward 
27 recommendations with corresponding action plans to enable integration of biomarkers into 
development of safer, more effective and less costly drugs. (Khleif, 2010) 
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(A) Conventional methods 
 
Conventionally, the risks of cancer recurrence and mortality were assessed on an individual 
risk factor to make decision for a particular adjuvant therapy. The St. Gallen consensus 2009 
(Goldhirsch, 2009) set out the criteria for systemic adjuvant therapies as below.  
St. Gallen consensus, 2009 treatment recommendation guide table 
 Relative indications 
for chemoendocrine 
therapy 
Factors not useful 
for decision 
Relative indications 
for endocrine 
therapy alone 
Clinicopathological 
features  
ER and PgR 
Lower ER and PgR 
level 
 
Higher ER and PgR 
level 
Histological grade Grade 3 Grade 2 Grade 1 
Proliferation High
a
 Intermediate
a
 Low
a
 
Nodes 
Node positive (four 
or more involved 
nodes) 
Node positive (one 
to three involved 
nodes) 
Node negative 
PVI (peritumoural 
vascular invasion) 
Presence of 
extensive PVI 
 
Absence of 
extensive PVI 
pT size >5 cm 2.1–5 cm ≤2 cm 
Patient preference 
Use all available 
treatments 
 
Avoid 
chemotherapy-
related side-effects 
Multigene assays 
Gene signature 
High score Intermediate score Low score 
a = 
Conventional measures of proliferation include assessment of Ki67-labelling index (e.g. 
low, ≤15%; intermediate, 16%–30%; high, >30%)] and pathological description of the 
frequency of mitoses.  
(This table was borrowed from the published article by Goldhirsch, 2009) 
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Well established cancer organisations such as National Cancer Institute (www.cancer.gov) 
and National Comprehensive Cancer Networks (www.nccn.org) published clear guidances 
and treatment pathways in a similar way to St. Gallens guidelines.  
 
 
A slide from NCCN guideline for treatment of breast cancer (This slide was borrowed from 
NCCN guidelines version 1.2012 – “www.nccn.org” accessed in June 2012) 
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(B) Clinical Prognostic/ predictive tools 
 
Various clinical tools have been developed to combine the different risk factors to give the 
best estimate of the risk and the benefits from various adjuvant treatments.  The most 
commonly used and well-validated tools are described below. 
   
PREDICT 
The “PREDICT” tool was developed based on the outcome of 5,694 breast cancer patients 
from Eastern Cancer Registration and Information Centre (ECRIC), UK dataset. (Wishart, 
2010) The tool is available free of charge at www.predict.nhs.uk/predict.shtml. Based on the 
age at diagnosis, mode of diagnosis (screening or symptomatic), tumour size, grade, nodal 
status, ER and HER2 status and different chemotherapies, the tool can produce 5 years and 
10 years overall survival and the benefit from adjuvant endocrine therapy and chemotherapy. 
In ER negative disease, the 8 year actual breast cancer mortality rate was 25.0% compared to 
30.6% predicted by the tool; for ER positive tumours, 8 years actual and predicted breast 
cancer mortality were within one percentage (8.9% vs. 9.2%). Overall model fit was good, 
although the fit was less good for some sub-groups. Specifically, for ER positive disease, the 
fit was not so good in women aged <49 years. For ER negative disease, the model fits in node 
negative disease, 30 to 49 mm tumours size category and high-grade tumours were not so 
good.   The latest version incorporated the effect of HER2 status. The prediction of breast 
cancer specific survival was claimed to be superior to that of Adjuvant! (Wishart, 2012) 
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Adjuvant!  
“Adjuvant!” is a web-based prognostication and treatment benefit tool for various cancers 
including breast cancer. (Ravdin, 2001) Based on the age, comorbidity, tumour size, grade, 
lymph node and ER status, it calculates 10 years risk of cancer recurrence and death, and the 
estimate of benefits from adjuvant therapies. The SEER (Surveillance, Epidemiology and 
End Results) data on 30,000 women aged 36 to 69 who were diagnosed between 1988 and 
1992 and recorded in SEER registry in the United States were used to calculate the breast 
cancer related 5-year and 10-year mortality. Considering that on average, mortality occurs 
approximately 3 years after the relapse and that the annual hazard of contralateral breast 
cancer is approximately 0.65%, the annual hazard of relapse is estimated 1.3 times the breast 
cancer mortality hazard plus 0.65%. This formula is used to calculate 10 years cancer 
recurrence risk. The estimates of benefit from adjuvant therapies are obtained by applying 
proportional risk reduction (PRR) from Oxford overview or indirectly from these estimates.  
The PRR for combined chemotherapy and endocrine therapy is derived from the following 
formula. 
 
PRR chemoendocrine therapy = 1 – [(1 – PRR chemotherapy) x (1 – Endocrine 
therapy)]  
The tool is being updated to incorporate the impact of HER2 expression, anti-HER2 
treatment and genomic assays risks. Although the “Adjuvant!” has been validated in various 
centres around the world, there are some uncertainties about how applicable “Adjuvant!” is to 
current patients diagnosed and treated in the UK. It has been shown that “Adjuvant!” 
overestimated the overall survival by 6% in a UK cohort of 1,065 women with early breast 
cancer treated in Oxford between 1986 and 1996. (Campbell, 2009) 
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OPTION 
Using parametric regression-based survival analysis on the prognostic characteristics and 
outcomes of 1,844 women treated for early breast cancer at Churchill Hospital in Oxford 
between 1986 and 2001, “OPTION” prognostic model was developed to predict recurrence 
free survival. (Campbell, 2009) (Campbell, 2010) The model was able to separate patients 
into distinct prognostic groups, and predicted well at the patient level.  It has been externally 
validated. When compared with the NPI, the model was able to better discriminate between 
women with excellent and good prognoses, and it did not overestimate the 10-year recurrence 
free survival to the extent observed for “Adjuvant!”  
The OPTION tool can calculate estimated probability of 5, 10, 15 and 20 years RFS, before 
and after adjuvant treatments - radiotherapy, chemotherapy (none, CMF, Anthracycline and 
taxane) and endocrine therapy - using age, number of affected nodes, nuclear grade, tumour 
size and ER status.   (www.herc.ox.ac.uk) 
 
Nottingham Prognostic Index (NPI) 
The Nottingham Prognostic Index (NPI), a prognostic scoring system developed based on a 
large cohort of early breast cancer (<50mm tumour size) patients treated between 1990 – 
1999 in Nottingham City Hospital, UK, estimates the 10 – 15 years overall survival using 
tumour size, grade and lymph node status.  NPI is calculated as below. 
 
NPI = Nuclear Grade (grade 1 – 3) + Nodal status (1 = 0 nodes; 2 = 1 – 3 nodes; 3 = >4 
nodes) + (tumour size in millimeter x 0.02) 
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The NPI index has been validated in various cancer centres. Initially, NPI index assigned 
patients to good (NPI score < 3.4), moderate (NPI = 3.4 – 5.4) and poor risk (NPI > 5.4) 
groups with 15 years survival of 80%, 42% and 13%, respectively. (Galea, 1992) Later it was 
extendedto six prognostic groups and the latest version divided patients into 10 different 
prognostic groups that have an excellent inverse correlation between median NPI value for 
each group and the 10 years overall survival. (Blamey, 2007a & b)  
 
 
NPI prognostic index and breast cancer survival (This table was borrowed from the article by 
Blamey, 2007b) 
 
The estimated survival for an individual NPI score is also available from the following 
formula (Blamey, 2007b): 
10 year % survival for the individual = -3.0079 x NPI
2
 + 12.30 x NPI + 83.84.  
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(C) Molecular subtype profiling 
 
Intrinsic genes are genes showing significant variations in the expressions across different 
tumours from different patients but not between paired samples from the same tumour. Based 
on the intrinsic gene sets analysed by cDNA arrays, breast cancers were classified into 4 main 
molecular groups (Perou, 2000):  
 ER+/luminal like group characterized by the relatively high expressions of many 
genes expressed by the breast luminal cells;   
 Basal like group that expresses genes characteristic of breast basal epithelial cells 
such as CK-5/6, CK-14, CK-17, integrin b4 and laminin; 
 ErbB2-positive group that overexpresses ErbB2 genes cluster that includes ErbB2 
and GRB7; and 
 Normal like group that has high expression of genes characteristic of basal epithelial 
cells and adipose cells, and the low expressions of luminal epithelium genes.  
Luminal cancers are again divided into Luminal A and B for negative or positive, 
respectively, expressions of ERα gene, GATA binding protein 3, X-box binding protein 1, 
trefoil factor 3, hepatocyte nuclear factor 3 α, oestrogen-regulated LIV-1m MIK57 and / or 
HER2 (Sorlie, 2001) or Ki-67 protein IHC expression (at the cut-off point of 13.25% staining 
index).  (Cheang, 2009)  
Most commonly used platforms for gene expression profilings have been spotted 
complementary DNA and high density oligonucleotide microarrays. Both techniques need 
careful extraction of good quality RNA from the tumour. (reviewed by Cheang, 2008a) 
Similar molecular subtyping has been successfully performed using IMAC 30 (immobilized 
metal affinity capture) Protein Chip arrays. (Brozkova, 2008)    
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Using IHC expressions of six different molecular markers (ER, PR, HER2, EGFR, CK-5/6, 
Ki-67) breast cancers were classified into 5 different molecular subtypes that have different 
risks and survival outcomes (Cheang, 2009) (Cheang, 2008a, b):  
 Luminal (ER and/or PR positive)  
o Luminal A (LA) - both Ki-67 and HER2 negative 
o Luminal B (LB) - Ki-67 and/ or HER2 positive 
 HER2+/ER-PR-  (H) 
 Triple negatives phenotype (TNP) – ER/ PR/ HER2 negative. TNPs were again 
divided into:  
o Core Basal Phenotype (CB) for positive EGFR and / or CK-5/6 expression 
o 5 Markers Negative Phenotypes (5N) for negative ER/ PR/ HER2/ EGFR/ 
CK-5/6 expressions  
Blows et al classified more than 10,000 patients from 12 studies into 6 molecular subtypes in 
a similar method. Luminal A was subdivided into basal marker CK-5/6 positive and negative. 
(Blows, 2010) Basal like breast cancers defined by IHC molecular markers were shown to 
have better prediction for the breast cancer survival than that defined by the gene analysis.  
(Cheang, 2008b) The concordances between IHC protein expressions and RT-PCR genes 
expressions were high for ER and HER2 but poor for PR, Ki-67 (Cobleigh, 2005) and CK-
5/6. (Kordek, 2010) 
There are significant differences in the incidence, survival, metastatic site specificity, and the 
treatment responses among molecular subtypes. LA cancers tend to have late recurrences 
while the basal and HER2+ groups have early recurrences. (Sorlie, 2003) The mortality rate 
is found to be constant over the time for LA cancers while it tends to peak within 5 years of 
the diagnosis and declines after that and reverses at 5–10 years in LB and non-luminal 
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subtypes. By 8 years after the diagnosis, there were no differences in the prognosis between 
LA and LB tumours; between basal marker positive and negative tumours within LA 
subgroup. Luminal subtypes have poor prognosis with longer follow-up time with the worst 
prognosis at 15 years being in the Luminal HER2 positive tumours. (Blows, 2010) In a study 
of molecular subtyping using gene profiling on 357 breast cancer patients, the 10-year relapse 
free survivals were 78% for LA cancers, 67% for LB cancers, and 64% for Luminal HER2 
positive tumours. The 10-year breast cancer specific survivals (BCSS) were 92% for LA 
cancers, 79% for LB cancers, and 78% for Luminal HER2 positive tumours. (Cheang, 2009)  
Differences in prognoses between TNP and non-TNP groups were reported to be most 
marked at 3 years (76.8% vs 93.5%, p < .0001). (Tischkowitz, 2007) CB has a slightly poorer 
prognosis than 5N with an absolute 10% lower 10-year BCSS. (Conforti, 2007) (Cheang, 
2008b)  Non-luminal HER2 positive tumours have a poorer prognosis than Luminal HER2 
positive tumours, and the CB tumours have a poorer prognosis than the CK-5/6 positive LA 
tumours regardless of the adjuvant chemotherapy or endocrine therapy. Basal markers seem 
to have no prognostic significance within the HER2 positive subtypes.  
In the neoadjuvant setting, LB, HER2 positive and TNP have higher pathological complete 
response (pCR) rate to chemotherapy than LA cancers. TNPs with higher Ki-67 expression 
have higher rate of pCR but the presence of residual disease is a very strong risk factor for the 
relapse. (Darb-Esfahani, 2009) (Carey, 2007) In the adjuvant setting the additional survival 
benefit from docetaxel containing chemotherapy over non-docetaxel chemotherapy was 
reported for LB cancers, LA cancers that had tamoxifen but not for other LA, TNP and 
HER2+ cancers. (Hugh, 2009) CB seemed to have less benefit from anthracycline based 
chemotherapy compared to 5N. (Conforti, 2007) (Cheang, 2008b)  
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Crabb et al used IHC expressions of eight molecular proteins (ER, PR, EGFR, HER2, CK-
5/6, carbonic anhydrase IX, p53, Ki-67) to classify 4 or more lymph node positive patients 
treated with adjuvant chemotherapy into 3 different groups with mean 10-year RFS of 75.4%, 
35.3% and 19.3%, respectively. In the validation set, differences in RFS for these subgroups 
remained statistically significant but were less marked. (Crabb, 2008a) 
Because of the poor prognosis, basal like breast cancers were investigated extensively. The 
basal like cancers were characterised by the expressions of genes associated with 
myoepithelial basal cells: KRT5 (keratin 5), KRT17 (keratin 17), CNN1 (calponin 1), CAV1 
(caveolin) and LAMB1 (laminin). (Perou, 2000) (Sorlie, 2001) (Sorlie, 2004) They are also 
characteristically negative for ER, PR and HER2 expressions but may express EGFR, KIT 
(CD117), Fascin and CD109, (Rodriguez-Pinilla, 2006) (Hasegawa, 2008) and frequently 
have mutated TP53 and BRCA1 genes. (Sorlie, 2003) (Laakso, 2006) The criteria of ER/PR 
negative, HER2 negative/low, CK-5/6 positive and/or EGFR positive IHC expressions can 
identify 76% of basal like cancers defined by the gene expression methods and it is 100% 
specific. (Nielsen, 2004) On the other hand, as much as 15-54% of basal like tumours defined 
on mRNA level still express at least one of ER, PR and HER2. (Reis-Filho, 2008) (Nielsen, 
2004) (Calza, 2006) (Sotiriou, 2003) (Jumppanen, 2007)  
The basal like cancers occur with peaks in the <35 and 51 to 65 years age groups. It is 
associated with many poor clinicopathologic features such as younger age, dense breast, 
oestrogen receptor negativity and p53 expression (Ihemelandu, 2007) (Collett, 2005) but less 
likely to have axillary nodal involvement (odd ratio 0.53). (Crabb, 2008b) Basal like cancers 
more often present as interval cancers while LA cancers present more often as screen 
detected cancers. (Sihto, 2008) (Collett, 2005) Basal like cancers are more often detected as 
an ill-defined mass (61%) while non-basal type cancers are detected as a spiculated mass 
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(49%). (Luck, 2008) Most of the metaplastic carcinomas and breast cancers that metastasise 
to the brain are more likely to to be core basal like cancers and have high nuclear grade. 
(Gilbert, 2008) (Hicks, 2006) Post mastectomy radiotherapy reportedly failed to improve the 
survival in basal like cancers although the benefit was clearly seen in ER/ PR positive 
patients in a study involving high risk breast cancers. (Kyndi, 2008)  
BRCA1 associated cancers are more likely to be basal like subtypes compared to non-BRCA 
associated cancers (90% vs. 15%) (Nielsen, 2004) (Foulkes, 2003) (Lakhani, 2005) There are 
similarities between BRCA1 associated and sporadic basal like breast cancers such as ER 
negativity, high nuclear grade, high Ki-67, CK-5/6, EGFR expressions, and poor prognosis 
regardless of the nodal status (Foulkes, 2004)  although P-cadherin and vimentin - markers 
associated with basal like breast cancers- are more often seen in BRCA1 associated cancers.  
(Arnes, 2005) (Rodriguez-Pinilla, 2007) BRCA1 mRNA expression was found to be two fold 
lower in sporadic basal breast cancers (as defined by CK-5/6 IHC positivity) compared to the 
age and grade matched non-basal ductal cancers. ID4, a negative regulator of BRCA1, was 
expressed at 9.1 folds higher level, suggesting a potential mechanism of BRCA1 down 
regulation. (Turner, 2007) 
In-vitro studies of BRCA1 associated breast cancers have shown a marked sensitivity to 
agents such as bifunctional alkylating agent, mitomycin-C and platinum drugs that cause 
interstrand cross-links of DNA, etoposide and bleomycin that cause double strands breaks, 
but showed resistance to taxane and vinca alkaloids that target mitotic spindles and 
microtubules.  
St. Gallen consensus 2011 recommended the use of ER, PR, HER2 and Ki-67 to subtype 
Luminal A, Luminal B, HER2 enriched and triple negative cancers. No adjuvant 
chemotherapy was recommended for Luminal A. Chemotherapies containing anthracycline 
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and taxane were recommended for Luminal B. For triple negative cancers, cyclophosphamide 
in addition to anthracycline and taxane was recommended, preferably in the dose dense form, 
while routine use of cisplatin or carboplatin was not recommended. Chemotherapy, anti-
HER2 therapy and endocrine therapy were recommended for HER-2 positive luminal cancers 
and combination of chemotherapy and anti-HER2 therapy was indicated for non-luminal 
HER2 positive cancers. (Goldhirsch, 2011) 
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(D) Multigene assays 
 
Multiple genes profilings had led to the development of various assays that offered prognosis, 
diagnosis and prediction of treatment outcomes in the management of breast cancer. These 
assays used different techniques and different combination sets of gene expressions. 
Although none of them has 100% sensitivity and specificity, they claimed to be superior to 
existing conventional methods that use clinical and histopathological features. These assays 
are said to give additional informations that change the direction of the treatment decisions 
for or against adjuvant chemotherapies in approximately 30% of the time. (Albain, 2009) 
 
Oncotype Dx 
OncotypeDx is an assay that utilises expressions of 16 cancer related genes and 5 reference 
genes (Table 1) in formalin fixed paraffin embedded tissues using quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR). (Paik, 2004) The genes are related to 
‘‘ER cluster,’’ whose expressions were associated with longer distant relapse free survivals 
(DRFS) compared to lower or absent expressions, and ‘‘proliferation cluster’’, ‘‘macrophage 
cluster’’, “invasion cluster” and “HER2 cluster” whose expressions were associated with 
shorter DRFS. Different weights were given to different cluster genes expressions in the 
calculation of the recurrence score as shown in the table 1. Oncotype Dx also provides 
quantitative values for proliferation, luminal (ESR1, PGR) and ERBB2gene expressions. 
 
RS is calculated as follow: 
RS = 0 if RSu < 0; RS = 20 x (RSu - 6.7) if 0 ≤RSu ≤100; RS = 100 if RSu > 100. 
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Table: Oncotype Dx genes list (a), individual group score calculation (b) and Recurrence 
score unscaled calculation (c).  (This table was borrowed from the published article by Habel, 
2006) 
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Oncotype Dx calculates the recurrence score (RS) that ranges from 0 to 100, the 10 years 
DRFS for an individual patient, and an estimate of adjuvant chemotherapy benefits. The 
assay classifies RS into 3 different risk levels: low risk for RS <18, intermediate risk for RS = 
18 – 31, and high risk for RS >31. RS was associated with 10 years breast cancer death risk 
in patients who had adjuvant tamoxifen and also in patients who did not have any adjuvant 
treatment. There was also a significant association between RS and the risk for locoregional 
relapse. (Mamounas, 2010) (Habel, 2006) 
High risk patients get most benefits from CMF chemotherapy in terms of 10 years distant 
disease recurrence (27.6% absolute risk reduction) while low risk patients get only minimal, 
if any, benefits among the participants of NSABP 20 trial. (Paik, 2006) The benefit was 
uncertain for the intermediate risk patients. The disease free and breast cancer specific 
survival benefits from CAF chemotherapy added to tamoxifen were seen in node positive 
patients from high risk but not low risk groups. The benefit was most significant in the first 5 
years with no additional prediction beyond 5 years. Patients with a high ER expression 
(Allred score >6) and HER2 negative disease did not seem to gain any benefits from CAF. 
(Albain, 2010) RS was predictive of distance recurrence risk in tamoxifen or anastrozole 
treated node negative and positive postmenopausal patients.  (Dowsett, 2010) The high RS 
was positively associated with the increased likelihood of pCR to neoadjuvant chemotherapy 
with doxorubicin + cyclophosphamide followed by paclitaxel in locally advanced breast 
cancer patients. (Gianni, 2005) 
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80 genes assay 
Expressions of 80 different genes were analysed to predict a response to neoadjuvant 
chemotherapies in locally advanced breast cancers. pCR was shown to be more likely with 
high expressions of proliferation  (including CDC20, E2F1, MYBL2, TOP2A, FBXO5, 
MCM2, MCM6, CDC25B) and immune related genes (including MCP1, CD68, CTSB, 
CD18, ILT-2, CD3z, FasL, HLA.DPB1, GBP1), and low expressions of ER related genes 
cluster (including PR, SCUBE2, ER, NPD009, GATA3, IGF1R, IRS1). Other genes 
predictive of pCR are related to apoptosis (BBC3, BAD, DR4, TP53BP1), invasion/ 
metastasis (FYN and MMP12), and drug resistance/metabolism (ABCC5, ALDH1A1, 
CYP3A4). (Gianni, 2005) 
 
Mammaprint (70 genes assay) 
Mammaprint, known as the 70 genes signature, was derived from a set of 231 genes that were 
differentially expressed in tumours that metastasised versus those that did not. (Vant’ Veer, 
2002) The proliferation is the main biological function of most of the genes. Some are 
associated with invasion, metastases, stromal integrity and angiogenesis. The assay divides 
patients into poor and good prognosis groups. It has shown that poor prognosis patients are 
15 times more likely to develop distant metastases within 5 years compared to good 
prognosis patients among T1 – T2, N0 breast cancer patients younger than 55 years of age. 
(Isaacs, 2001) (Vant’ Veer, 2002) 10 years distant metastases free and overall survivals for 
poor and good prognosis patients were 85.2% & 94.5% and 50.6% & 54.6%, respectively. 
(van de Vijver, 2002) The assay was also strongly predictive of survival in pT1 tumours with 
up to 3 positive nodes regardless of the ER status.  (Mook, 2010) The test requires freshly 
frozen tissue or tissue collected in RNA preservative solution for the analysis. The test can’t 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 38 
 
be done on the FFPE tissue. The assay is currently marketed for invasive breast cancers T2 or 
smaller, any ER expressions and up to 3 positive lymph nodes. 
 
PAM50 
Prediction Analysis of Microarray (PAM) on 50 genes was developed from the original genes 
set that classified breast cancers into different molecular subtypes by Perou et al. (Perou, 
2000) In a study that evaluated PAM50 against Oncotype Dx, 83% of Oncotype Dx low RS 
patients are LA cancers while 90% of high RS patients are LB cancers as classified by 
PAM50.  70% of LA cancers have low RS and the rests have intermediate RS. 33% and 48% 
of LB cancers have high and intermediate RS, respectively. There is a good agreement 
between the two assays for high (i.e., LB or RS > 31) and low (i.e., LB or RS < 18) 
prognostic risk assignments but PAM50 assigns more patients to the low risk category. About 
half of the intermediate RS group was reclassified as LA by PAM50. (Kelly, 2012) 
PAM50 can be applied on FFPE tissues. It can calculate risk of recurrence (ROR) either 
based on the subtype classification alone (ROR-S) or in conjunction with the clinical features 
(ROR-C). The sum of the coefficients from the Cox model is the ROR score for the 
individual patient. The patients were categorized as low risk (ROR-S score < 23), moderate 
risk (score 23 – 53), and high risk (score > 53). ROR-S model has 94% sensitivity and 97% 
negative predictive value for identifying non-responders and pCR to taxol/FAC 
chemotherapy. (Parker, 2009) 
ROR-S = (0.05 x basal) + (0.12 x HER2) + (-0.34 x Lum A) + (0.23 x LumB) 
ROR-C = (0.05 x basal) + (0.11 x HER2) + (-0.23 x LumA) + (0.09 x LumB) + (0.17 x T) 
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Wound Response Signature 
Chang et al. (Chang, 2004) identified a set of ‘‘core serum response’’ (CSR) genes – 512 cell 
cycle independent genes expressed by fibroblasts in response to serum exposure – that 
includes genes for  entry into and progression through the cell cycle, induction of cell 
motility, extracellular matrix remodelling, cell–cell signalling and acquisition of a 
myofibroblast phenotype.  Wound response signature that utilises CSR was shown to be 
predictive of poor overall survival and increased risk of metastases in several tumours such as 
breast, lung, and gastric cancers.  In breast cancers with the size of <2.0 cm and any nodal 
status, the activated wound response signature was predictive of worse distant metastasis free 
and overall survival compared to the quiescent wound signature independently of any other 
known risk factors in the multivariate model. (Chang, 2005)  
The fibroblast CSR genes set contains only 20 out of 456 genes from ‘‘intrinsic gene list’’ 
that was used for molecular subtyping by Perou et al. (Perou, 2000), 4 out of 128 genes that 
define the general metastasis signature reported by Ramaswamy et al (Ramaswamy, 2003) 
and only 11 out of 231 genes that van’t Veer et al analysed for Mammaprint. (van’t Veer, 
2002) 
Rotterdam 76 genes signature 
Rotterdam 76 genes signature can predict the development of metastatic disease within 5 
years in the absence of any adjuvant treatments for node negative patients with tumours 10 – 
20 mm size, any ER and menopausal status. (Wang, 2005) The 5 and 10 years distant 
metastasis free survivals for good and poor prognosis groups were 98% & 94% and 76% & 
73%, respectively. Corresponding overall survival rates were 98% & 87% and 84% & 72%, 
respectively. (Desmedt, 2007) 
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IE-IIE assay 
IE-IIE assay, using 76 genes Affymetrix Human U133a Gene Chips (initially developed from 
supervised analyses on 822 genes), defined ER/PR positive patients into poor prognosis 
group (IIE) that showed high expressions of cell proliferation and anti-apoptosis genes, and 
the good prognosis group (IE) that showed high expressions of oestrogen and GATA3 
regulated genes. IE and IIE are also associated with other known risk factors such as nuclear 
grades and molecular subtypes. IE tumours showed high expressions of XBP1, FOXA1, PR 
and many ribosomal genes. Hazard ratios for RFS and OS for group IIE compared to IE are 
2.9 and 3.64, respectively. (Oh, 2006)  
 
SET index 
The SET (Sensitivity to Endocrine Therapy) index was developed from the analysis of 165 
genes co-expressed with ESR1 in 437 microarray profiles from newly diagnosed breast 
cancers unrelated to the treatments or outcomes. (Symmans, 2010) It was significantly 
associated with the distant relapse or death risks in patients who had adjuvant tamoxifen or 
neoadjuvant chemotherapy followed by adjuvant tamoxifen (regardless of any pathologic 
response status), but was not prognostic in patients who did not receive any adjuvant 
treatments. No distant relapse or death was observed in node negative and high SET patients 
treated with adjuvant tamoxifen alone, and in intermediate or high SET patients treated with 
the neoadjuvant chemotherapy and adjuvant tamoxifen. The endocrine predictive utility of 
SET index was independent of pathologic response from chemotherapy. At 5 years of follow 
up, disease free survival rates were 100% for high or intermediate and 82.4% for low index 
groups using cut off SET values of 3.66 and 2.68. However, the prognosis of those with high 
residual disease following neoadjuvant therapies remained poor, irrespective of the SET 
value. 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 41 
 
Triple Negative Breast Cancer genes assay 
For triple negative breast cancers, 264 and smaller 26 genes sets can identify good and poor 
prognosis cancers with the hazard ratios of 4.03 and 4.08, respectively, for event free 
survival. The 10 years event free survival rates for good and poor risk groups are 70% and 
20%, respectively. The 26-genes signature in combination with B-cell metagene can predict 
the response to the neoadjuvant chemotherapy. Most of the genes in the assay are related to 
metagenes for inflammation and angiogenesis, and are not related to other known genes 
signatures. (Karn, 2011) 
 
MGH2-gene signature: 2-gene (HOXB13:IL17BR) ratio predictor 
Homeobox gene B 13 (HOXB13) was shown to regulate a pathway in conjunction with the 
EGF signalling to promote cancer cell motility and invasion. (Ma, 2004) HOXB13 gene 
expression was associated with the shorter RFS while interleukin 17B receptor gene 
(IL17BR) expression was associated with the longer RFS in patients treated with adjuvant 
tamoxifen.  The HOXB13:IL17BR index (cut off point of 0.06) predicted clinical outcomes 
in ER positive patients independently of adjuvant tamoxifen treatment in node negative but 
not in positive patients. (Ma, 2006)  Two-gene index was a highly significant factor for 
predicting RFS with a hazard ratio of 3.9 in the same study.  On the continuous scale, an 
untreated patient with a two-gene index of -2.0 has a 5-year recurrence risk of 15% (95% CI, 
9.8% to 20.5%), whereas a patient with an index of +2.0 has a significantly higher 5-year 
recurrence risk of 36% (95% CI, 26.5% to 45.2%). (Ma, 2006) It is also predictive of an early 
relapse and death. (Goetz, 2006)  
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Other assays 
Other assays include:  
 eXagenBC, a prognostic (recurrence) test using 3 genes (CYP24, PDCD6IP, BIRC5) 
for ER positive and 3 genes (NR1D1, SMARCE1, BIRC5) for ER negative patients   
with any nodal status. (Davis, 2007) 
 Celera metastatic score, a prognostic test that uses 14 genes multiplex RT-PCR to 
predict the distant metastatic disease. (Tutt, 2008) 
 The Breast BioClassifier, a qRT-PCR assay that uses 55 genes for molecular 
subtyping. (Perrard, 2006) 
 Invasive gene signature that analyses 186 genes using Affymetrix U-133 Gene Chip 
for any nodal and ER status. (Liu, 2007) 
 Novoselect which is a combination of several pharmacogenomics gene sets (200 
genes) such as the one that predicts response to neo-adjuvant chemotherapy. (Ayers, 
2004) (Rouzier, 2005 a & b) 
 MapQuant Dx (formerly known as the genomic grade index) that uses 97 unique 
genes to grade the tumour. (Sotiriou, 2006)  
 Molecular grade index (MGI) that uses a set of 5 genes namely BUB1B, CENPA, 
NEK2, RACGAP1, and RRM2 that can differentiate histology grade 2 into MGI 
grade 1 and 2 (low and high risk group respectively). (Ma, 2008)  
 Theros Breast Cancer Index which is a combination of MGI and 2 genes 
(HOXB13:IL17BR) ratio that can identify poor prognosis patients treated with 
adjuvant chemotherapy and endocrine therapy. (Ma, 2008)  
 7-genes immune response module, down regulation of which is associated with the 
high risk of distant metastases. (Teschendorff, 2007) 
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 Stroma derived prognostic predictor that is composed of 163 genes reflecting clusters 
reflecting hypoxia and angiogenesis (linked to poor outcomes) and a TH1-like 
immune response (linked to good outcomes). (Finak, 2008)  
 Medullary like signature by Support Vector Machine (SVM) classifier that is based on 
368 genes to define the low risk and high risk recurrence groups. (Sabatier, 2011) 
 Cytochrome p450, 2D6 (CYP2D6) genotyping to predict a response to tamoxifen 
although there is still a debate on its prediction.  (Fleeman, 2011) (Regan, 2012)         
 
Phase 3 radomised trials comparing adjuvant chemotherapy against no chemotherapy based 
on results of genes profiling assays such as Oncotype Dx (TAILORx trial), Mammaprint 
(MINDACT trial), Genomic Grade (GERICO11/PACS10 trial) and PAM50 (NCI-2011-
02623 trial) are currently underway to determine the best use of these assays.     
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6.0  Prognostic/ Predictive biomarkers 
 
As previously mentioned, the success of chemotherapy depends not only on its cell damaging 
effect but also on the cell’s ability to undergo cell death or repopulate through growth 
signalling pathways. Any functional aberration of proteins involved in these pathways will be 
the important factors to make chemotherapy successful or not. Correction of any aberrant 
proteins function by suitable drugs might be beneficial in this situation. Expression of these 
proteins can be therefore used as prognostic or predictive markers or both. Due to the 
complexity and multiplicity of pathways and the number of various proteins involved, 
targeting only one pathway or a few proteins had resulted in a very modest improvement in 
the outcome so far. In this sense, analysing and targeting functionally important proteins as 
many as possible from different cellular pathways seems to be the most logical way forward 
to improve the survival from the breast cancer. The biomarkers/ proteins included in this 
study are from different cellular pathways, some being involved in several pathways. 
1. Cellular growth signalling pathway (ER, PR, EGFR, HER2, PDGFR-α, VEGFR-2)  
2. Cell proliferation (ER, PR, EGFR, HER2, Ki-67, MCM-2, Aurora A, Plk-1) 
3. Apoptosis (Bcl-2, Bag-1) 
4. Cell cycle phase progression (Aurora A, MCM-2, Plk-1) 
5. Angiogenesis (PDGFR-α, VEGFR-2) 
6. Others (CK-5/6, CD-68, CD-71, GSTM-1, Cathepsin L2) 
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Oestrogen Receptor (ER) 
 
There are two isoforms of ER – α and β - coded for by 2 different genes. ERα is expressed in 
epithelial cells whereas ERβ is expressed in epithelial and stromal cells, including fibroblasts 
and endothelial cells. About 50% of breast cancer patients express both ERα and ERβ. After 
the oestrogen binds to the ligand binding sites, two ERs form a dimer and attach to the 
oestrogen response element (ERE) on the DNA leading to increased or decreased 
transcriptions of certain genes. The overall activity of ER is determined by not only ER levels 
but also by the associated co-activators and co-repressors involved in this process. ERα is 
involved in the oestrogen-stimulated proliferations and ERβ is involved in counteracting the 
ERα action leading to a decrease in the proliferation. ER reviewed in this chapter refers to 
ERα. 
Oestrogen receptors locate in the nucleus and near the plasma membrane. The action through 
the nuclear ER is known as the “nuclear initiated steroid signalling (NISS)” and through the 
plasma membrane ER is known as the “membrane initiated steroid signalling (MISS)”. NISS 
can be activated not only by the oestrogen but also by other factors such as insulin like 
growth factor-I (IGF-I), epidermal growth factor (EGF), heregulin, transforming growth 
factor alpha and neurotransmitters such as dopamine. NISS can also be activated, 
independently of ligand binding, by signalling molecules such as cyclic adenosine 
monophosphate and membrane permeable phosphatase inhibitors. This activation is believed 
to be through the phosphorylation of ER or its co-regulators at the specific sites by the growth 
factors and kinases such as extracellular regulated kinase (ERK 1 & 2), p38 mitogen-
activated protein kinases (MAPKs), cyclin dependent kinases (CDK –2, CDK-7), c-SRC, 
protein kinase A, pp90rsk1 and AKT. Acquired resistance to the anti-oestrogen therapy is 
reported to be due to the change of ER activity from NISS to MISS. The cross talk between 
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ER and the growth factors is suggested to be one of the causes for the resistance to the 
antioestrogen therapy. Increased HER2 activity reportedly results in more ERs outside the 
nucleus leading to the high levels of membrane and cytoplasmic ER with the development of 
the resistance to tamoxifen induced apoptosis. (Chung, 2002) Therefore a treatment with 
EGFR or HER2 inhibitors could overcome the resistance to the tamoxifen treatment. Loss of 
ER in breast cancers is in part a result of the hypermethylation and repression of the ER 
promoter, which prevents ER productions. The ER pathway is therefore very complex and 
contains co-activators, co-repressors, transcription factors that modify binding of ER to its 
targets and the crosstalks between ER and the growth factor receptor pathways. 
ER is a prognostic factor as seen in the molecular subtypes where luminal cancers have better 
survival than non-luminal cancers. (Cheang, 2008a) ER positive cancers have better 
prognosis than ER negative cancers regardless of the PR status. ER is also a predictive factor 
for benefits from anti-oestrogen treatments. However, not all ER positive tumours are 
responsive to the anti-oestrogen therapy, and 30–40% of ER positive breast cancers will 
relapse or develop distant metastases despite the anti-oestrogen (tamoxifen) adjuvant 
treatment. (Loi, 2008) The likelihood of having benefits from the anti-oestrogen treatment 
depends on the degree of ER expression. No benefit was seen in cancers with poor ER 
expression (<10 fmol/mg cytosol protein). (EBCTCG, 2011b) “Allred score” that combines 
scores on the percentage of stained cells (0 – 5) and the staining intensity (0 – 3) is a useful 
tool to decide for or against the use of anti-oestrogen therapy. (Harvey, 1999) It has been 
suggested that patients with inherited nonfunctional alleles of the cytochrome P450 
(CYP2D6) gene that codes for the enzyme that converts the tamoxifen into its active 
compounds inside the body, may not get any benefits from the tamoxifen. However this 
wasn’t confirmed in all studies. (Fleeman, 2011) (Regan, 2012) 
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Low ER status is an indicator of a better response to chemotherapies compared to stronger 
ER positive status. In women with low ER breast cancers, the polychemotherapy significantly 
reduced 10 years risk of recurrence, for <50 years and 50 – 69 years age groups, by 27% & 
18%, breast cancer mortality by 27% & 14%, and any cause mortality by 25% & 13% , 
respectively, compared to no chemotherapy. (EBCTCG, 2008)  
 
 
 
 
 
 
 
ER signalling pathway (Borrowed from a published article by Tiano, 2012) 
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Cross talks between ER and EGFR/HER2 signalling pathways (Borrowed from the published 
article by Johnston, 2010) 
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Progesterone Receptor (PR) 
 
Progesterone receptor (PR) is a member of the nuclear steroid receptor family. It is 
synthesized by the oestrogen through the ER pathway and the presence of PR usually 
indicates a functioning ER pathway. PR exists in two isoforms - PRα and PRβ - both of 
which are coded for by a single gene. Both PRs are found to express in the normal and 
malignant breast tissues. PR is made up of a central DNA binding domain and a carboxy 
terminal ligand binding domain. Upon ligand binding, two PRs (same or different PRs) 
become homo- or heterodimers that attach to the progestin response elements (PRE) in the 
promoters of target genes leading to the transcriptions of genes. PR has also been shown to 
mediate rapid activation of the Src/Ras/Raf/MAPK and also STAT signalling pathways. 
Positive PR expression is an independent prognostic marker in patients treated with 
tamoxifen or chemotherapy or no systemic adjuvant therapy. (Liu, 2010) Fisher et al reported 
that the prognostic significance of PR was comparable to that of ER in NSABP B-06 study. 
(Fisher, 1988) PR expression, not ER expression, regardless of the HER2 expression status, 
was shown to be significantly and inversely associated with the stage of the breast cancer at 
the diagnosis which is a strong correlative of survival not affected by the intervening 
endocrine therapy or chemotherapy, in the multivariate analysis in a study. (Coyle, 2007) 
Like ER, the prognostic value of PR was lost after 10 years. (EBCTCG, 2011b) Stendahl et al 
reported RFS and OS benefits only for the premenopausal patients with >75% PR positive 
nuclei. The PR was a stronger predictor than the ER for the treatment response. (Stendahl, 
2006) However, Badve et al reported that OXA1 is better than PR in predicting prognosis 
following an endocrine therapy. (Badve, 2007) No prognostic or predictive effect of PR was 
reported for a given ER status although there is a trend for benefits for ER-/PR+ patients. 
(EBCTCG, 2011b) (Dowsett, 2006) 
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PR-α expression is believed to increase the resistance to paclitaxel by up regulating 
antiapoptotic gene BCL-XL in breast cancer cells. (Richer, 2002) Serum depletion induced 
apoptosis was shown to be inhibited by the progesterone treatment. (Ory, 2001) Radiation-
induced apoptosis could be antagonised via PR in breast cancer cell lines. (Vares, 2004) 
Progesterone was shown to inhibit the growth of MDA-MB-231 breast cancer cells 
inoculated into a mice transfected with the PR cDNA and also increased the cellular 
differentiation of these cells probably by modifying the genome expressions. (Lin, 2001) 
(Leo, 2005) 
Although PR expression is expected to be positive alongside ER, there are breast cancers 
with ER+/PR- and ER-/PR+ phenotypes. EBCTCG overview found that PR was positive in 
76% of ER positive and 21% of ER negative (strictly, ER-poor) breast cancers. (EBCTCG, 
2011b) The breast cancer recurrence risk was higher for the ER negative disease regardless of 
the PR status. ER+/PR- breast cancers may simply result from the low circulating levels of 
endogenous oestrogens in postmenopausal women that are insufficient to induce PR 
expression even though the ER pathway is intact. Therefore, a brief treatment of ER+/PR- 
patients with the oestrogen may restore the PR in some of the patients. Absent or low PR 
expression could also be due to the down regulation of PR by the overexpressed growth 
factor signalling, hypermethylation or genetic loss at the PR gene locus (chromosome 11q23) 
rather than the non-functional oestrogen receptor pathway.  
ER-/PR+ expression was reported in 21% of breast cancer patients in EBCTCG’s overview. 
(EBCTCG, 2011b) In these cancers, PR expression may be driven by the cross talks between 
various growth factor signalling pathways. These cancers have significantly poorer 
differentiation, larger tumour size and younger age compared to the ER+/PR+ cancers. 
ER+/PR- cancers are more commonly found in the postmenopausal and older patients. Up to 
60% of ER+/PR- patients were more than 60 years old, and have worse DFS and OS 
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compared to ER+/PR+ cancers. (Yu, 2007) ER+/PR- status was also reported to be an 
independent predictor for the lymph node positivity especially in younger women. (Neven, 
2004) ER+/PR- breast cancers respond less well to tamoxifen than ER+/PR+ tumours but 
respond better to oestrogen deprivation with aromatase inhibitors according to the ATAC 
trial. (Dowsett, 2005) Therefore a combination of aromatase inhibitor with growth factor 
inhibitors may be a better treatment option in ER+/ PR- tumours.  
Statistically significant change of PR status from positive to negative was found following 
neoadjuvant chemotherapies. (Kasami, 2008) Distant metastases of some originally ER+/PR+ 
primary tumours lost PR expression and became ER+/PR-. These cancers have more 
aggressive course, poor survival and are resistant to the endocrine therapy. (Cui, 2005) So far, 
the gain of PR by metastases from originally PR negative primary tumours has not been seen 
yet. (Thompson, 2010) In the IHC molecular subtyping, ER+/PR-, ER-/PR+ and ER+/PR+ 
cancers are not sub-divided into separate groups (all were grouped together as “luminal 
cancers”) suggesting absence of either receptor may have very little, if any, significant impact 
on the survival. (Perou, 2000) 
 
PR pathway (Borrowed from the published article by Hagan, 2012) 
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EGFR 
 
 
EGFR is a member of type one transmembrane tyrosine kinase receptors EGFR/ErbB/HER 
family that includes ErbB1/HER1 to ErbB4/HER4 proteins. These receptors play an essential 
role in the organ development and the growth by regulating differentiation, proliferation and 
morphology of cells and tissues. Activation of extracellular EGFR domain by its ligand 
causes homo- or heterodimerization of EGFRs with another EGFR molecule, or a different 
member of the ErbB family (e.g. HER2), which in turn induces the amplified signalling 
cascade.  
EGFR overexpression was found in a number of different cancers including lung, colorectal 
and breast cancers. EGFR overexpression in invasive breast cancers ranged from 14% to 91% 
with an average of 45% among 40 different studies included in a meta-analysis (Klijn, 1992) 
and up to 50% in triple negative breast cancers. (Nogi, 2009) EGFR expression was reported 
to be one of the poor prognostic factors and was associated with other risk factors. (Nieto, 
2007) EGFR expression was correlated with the poor treatment response and the shorter 
survival compared to no expression.  (Nieto, 2007) (Park K, 2007) (Nogi, 2009) EGFR 
expression was believed to be mostly limited to the basal like, HER2 and luminal B type 
cancers. (Meche, 2009) Arnes et al reported association between EGFR expression and CK-5 
and P-cadherin positivity but not with overall survival in basal like cancers.  28% of CK-5 
positive cases showed EGFR gene expression. (Arnes, 2008) Nielsen et al suggested EGFR 
expression as an alternative to CK-5/6 to define the basal phenotype. (Nielsen, 2004) EGFR 
expression by IHC was found in 54% of cancers that expressed basal cytokeratin genes and it 
was associated with the poor survival. (Nielsen, 2004) In a study by Park et al, IHC 
expression of EGFR protein was found in 20.6% of 165 cases while the gene amplification 
was found in only 7.9% of the cases. (Park, 2007) 
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Inhibition of the tyrosine kinase enzymatic activity of EGFR is a clinically relevant treatment 
option for breast cancer patients. Cetuximab, alone or in combination with cisplatin, was 
effective in vitro on breast cancer cells. (Nofech-Mozes, 2009) Small molecule TKIs such as 
Erlotinib, Lapatinib and Gefitinib have shown activities in breast cancers too. Gefitinib 
enhanced the effectiveness of tamoxifen and fulvestrant in breast cancer cell lines. (Gee, 
2003) Phosphorylation of EGFR detected in triple negative tumours could be blocked by 
Gefitinib in vitro. (Gori, 2009) In a tamoxifen resistant, HER2 overexpressing MCF-7 breast 
cancer cell line (MCF-7/HER2-18) Gefitinib pre-treatment was shown to block ER-EGFR 
receptor cross talk, re-establish co-repressor complexes with tamoxifen-bound ER on target 
gene promoters, eliminate tamoxifen agonistic effects, and restore tamoxifen antitumor 
activity both in vitro and in vivo.  (Shou, 2004) A combined treatment with EGFR inhibitor 
and HER2 inhibitor showed a synergistic growth inhibition in breast cancer cell lines that 
over express both EGFR and HER2 proteins. (Normanno, 2002)  
Erlotinib and Gefitinib as monotherapy in patients with breast cancer, however, have been 
reported to have limited activities, with response rates of less than 5%. (Green, 2009) 
(Dickler, 2009) The combination of Erlotinib and Bevacizumab also had limited activities in 
unselected, previously treated metastatic breast cancers. (Dickler, 2008) Erlotinib with 
Capecitabine and Docetaxel gives an overall response rate of 67% in metastatic breast cancer 
patients. (Twelves, 2008) In a phase 2 study with 41 patients, a response rate of 54% (95% CI 
45–75%), a stable disease 14%, and a progressive disease 32% were reported for Gefitinib 
plus Docetaxel. (Ciardiello, 2006) Serum HER2 and EGFR are suggested to be a predictor for 
early response, PFS, and OS in patients with advanced breast cancer treated with the 
metronomic chemotherapy. (Sandri, 2007)  
EGFR expression is a potentially useful tool for prognostic and therapeutic purposes. It is not 
possible to say if EGFR is more commonly associated with other risk factors or EGFR 
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expression itself contributes to the presence of other poor prognostic factors. More research is 
needed to use it as a standard prognostic/ predictive factor in the daily practice for breast 
cancer. 
 
 
HER/ EGFR family signalling pathways and their inhibitors (This illustration was borrowed 
from the article by Kikalsen, 2006) 
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HER2 
 
HER2/neu protein is a member of HER family that contains four transmembrane receptor 
tyrosine kinases (as mentioned in the EGFR section) that mediate cell growths, 
differentiations and survivals. HER2/neu gene is located on the chromosome 17q and it was 
first discovered in 1984. Incidence of overexpression of the HER protein or amplification of 
HER2 gene or both has been reported as 9.7% in node negative, <10 mm tumours (Albert, 
2010), 14% in 10,000 patients participated in 12 different clinical studies (Blow, 2010), 
22.7% in a very large cohort study involving 61,309 patients (Parise, 2009) and 44% among 
very high risk (>4 lymph nodes positive or inflammatory cancer) patients who participated in 
a high dose chemotherapy clinical trial. (Nieto, 2004)  When a ligand binds to the 
extracellular domain, HER2 protein either homodimerise with another HER2 protein or 
hetrodimerise with other members of the family and phosphorylates the intracellular tyrosine 
kinase residue. Signal propagation then occurs as the enzymatic activity of one protein 
activates the next protein in the pathway. The main signal transduction pathways are 
Ras/mitogen-activated protein kinase pathway (MAPKinase), the phosphatidylinositol 3 
kinase (PI3K)/Akt pathway, the Janus kinase/signal transducer and activator of transcription 
pathway, and the phospholipase C pathway that promotes cell proliferation, survival, 
motility, and adhesion. 
HER2 protein over expression can be assessed by IHC using two commercially available kits, 
the HercepTest R (Dako, Carpinteria, CA) and Pathway™ HER-2 (Ventana, Tucson, AZ). 
HER2 gene overexpression can be assessed by various methods including Fluoresence in situ 
hybridisation (FISH), chromogenic in situ hybridisation (CISH) which has a 100% 
concordance with FISH and a good concordance with IHC in the 0–1+ and 3+ categories, 
Silver In Situ Hybridisation (SISH), Southern and Slot blotting, RT-PCR, mRNA by 
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microarray, dimerisation assays, phosphorylated HER2 receptor in the tissue and serum by 
ELISA. The concordance between IHC and FISH is nearly 98% in the laboratories that 
perform high volume testings. (Paik, 2002) Disadvantages of IHC method are subjective 
interpretations and semiquantitative results. 
Patients with IHC 3+ expression (DAKO scoring), gene copy number > 6.0 per nucleus or 
gene ratios of HER2/CEP17 > 2.2 are considered as HER2 positive. (Wolff, 2007) HER2 
protein overexpression or gene amplification was shown to have adverse prognostic effect in 
multivariate analysis independent of all other prognostic factors in 68 out of 107 studies with 
39,730 patients in a metanalysis. The correlation between HER2 overexpression and poor 
prognosis could be established in 85% of studies that used FISH analysis and 100% of studies 
that used CISH analysis. (Ross, 2009) 
HER2 overexpression is associated with other risk factors such as intermediate or high 
histology grade, negative ER and PR, positive lymph nodes, DNA aneuploidy, high cellular 
proliferation rate, p53 mutation, topoisomerase IIa amplification, alterations in a variety of 
other molecular biomarkers of breast cancer invasion and metastasis. HER2 positive breast 
cancer is also found to have a high rate of recurrence and shorter disease free and overall 
survival despite adjuvant chemotherapy.  (Slamon, 1987) (Wright, 1989) 
The coamplification of c-myc and HER2 was found to be correlated with the worse outcome 
than the amplification of either protein. Patients with c-myc co-amplification had a worse 
outcome if they were treated with chemotherapy alone, but had a 4-year recurrence free 
survival rate of 90% when treated with chemotherapy and trastuzumab in the NSABP-31 trial 
(Kim, 2005) although similar positive effect was not found in the N9831 trial. (Perez, 2011a) 
The topoisomerase-II alpha (topo-IIa), a target protein for anthracycline, gene is located in 
close proximity to HER2 oncogene on chromosome 17q12-q21 and is amplified or deleted in 
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almost 90% of HER2 amplified primary breast cancers, making cancers to either sensitive or 
resistant to anthracycline chemotherapy. (Muss, 1994) (Paik, 1998) HER2 positive cancers 
are more sensitive to aromatase inhibitors and resistant to tamoxifen. (Houston, 1999) 
(Lipton, 2002) HER2 overexpressed breast cancers are also more sensitive to local 
radiotherapy. RFS benefit from CMF chemotherapy is smaller in HER2 positive cancers 
compared to HER2 negative cancers. (Stal, 1995) 
Trastuzumab, monoclonal antibody that targets HER2 protein has changed the course of the 
HER2 overexpressed breast cancers. It can give objective response in more than one third of 
the HER2 positive cancers as a single agent and more than 50% in conjunction with the 
chemotherapy. In the adjuvant setting, one year of trastuzumab in conjunction with adjuvant 
chemotherapy improves both disease free and overall survivals. (Baselga, 2006) (Salmon, 
2011) (Perez, 2011b) (Gianni, 2011) Lapatinib, another anti-HER2 antibody, together with 
chemotherapy or endocrine therapy, has also shown significant activity in metastatic breast 
cancers. (Cameron, 2010) New treatments targeting HER2 signalling such as HER2 vaccine, 
Pertuzumab, Ertumaxomab, MDX-H210, TDM-1 (Trastuzumab + fungal toxin Maytansine) 
and novel tyrosine kinase inhibitors are in the development stages. 
Despite its own unique actions and effects, HER2 gene expression is not exclusive to the 
HER2 enriched molecular subtype. It is still seen in other subtypes such as luminal A and B.  
In the basal-like phenotype which is regarded as ER/PR/HER2 negative by IHC, HER2–
positive status is found in about 10% of cases. (Harris, 2007) 
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Bcl-2 
 
Anti-apoptic protein Bcl-2 has two isoforms - “a” (26 kDa) which is detected commonly and 
“b” (21 kDa) which is rarely detected. At least 17 Bcl-2 family members have been identified 
in mammalian cells and viruses. All members possess at least one of four conserved motifs 
known as Bcl-2 homology domains (BH1 to BH4). Bcl-2 family proteins can homo- or 
heterodimerise with each other. When anti-apoptotic Bcl-2 level is higher than pro-apoptotic 
Bax level, Bcl-2 is able to neutralise the ability of Bax to promote cytochrome C release and 
subsequent apoptosis. 
Bcl-2 protein mainly localises in the nuclear membrane, outer mitochondrial membrane, 
nuclear pore complexes, mitochondrial junctional complexes and some parts of the 
endoplasmic reticulum.  Bcl-2 can prevent apoptosis induced by various factors such as 
chemotherapeutic drugs, gamma irradiation, neurotrophic factor withdrawal from neurons, 
cytotoxic cytokines such as tumour necrosis factor-α, Fas-ligand, transforming growth factor-
β, heat shock, calcium ionophores and chemicals that induce oxidative injury. (reviewed by 
Reed, 1994) It prevents cytochrome C release into the cytoplasm by forming mitochondrial 
pore complexes upon receiving apoptotic stimulus, preventing formation of the cytosolic 
apoptosome complex, and activation of the downstream caspase cascade. Bcl-2 induced 
resistance to apoptosis following chemotherapy can be reversed with Bcl-2 targeting therapy. 
Many anti-apoptotic Bcl-2 family proteins are found to be able to inhibit cell proliferation. 
This could be the reason for the good prognostic effect of Bcl-2 protein.  
Bcl-2 expression was detected in about 80% of breast primary lesions regardless of the nodal 
status. (Gee, 1994) (Krajewski, 1995) Bcl-2 gene expression is found to be regulated by 
oestrogens in mammary epithelial cells and ER positive breast cancer cell lines. (Johnston, 
1994) (Barbareschi, 1996) (Zapata, 1998) Increased Bcl-2 expression was correlated with 
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other good prognostic factors such as ER, PR, well differentiation, low nuclear grade, 
absence of positive lymph nodes, better response to endocrine therapy, and inversely 
correlated with p53 expression and the apoptotic index. (Won, 2010) (Lee, 2007) (Planas-
Silva, 2007) Bcl-2 expression was predictive of tamoxifen sensitivity in breast cancer 
patients. (Elledge, 1997) (Ciocca, 2000) In a study of 13 biomarkers in 930 breast cancers on 
a tissue microarray, Bcl-2 was found to be predictive of better 10 years survival in univariate 
and multivariate analysis along with NPI and ER. Bcl-2 was also found to be a significant 
prognostic factor independent of NPI and the effect was maximal in the first 5 years. 
(Callagy, 2006)  
There have been reports on association between Bcl-2 expression and better as well as worse 
survival outcomes following adjuvant and neoadjuvant chemotherapies.  (Gasparini, 1995) 
(Bonetti, 1998) (Vargas-Roig, 2008) (Ogston, 2004)  A lack of association between Bcl-2 
expression and the survival benefit from dose dense adjuvant chemotherapy has also been 
reported. (Malamou-Mitsi, 2006) Correlation between high Bcl-2 expression and a better 
survival has been reported in high risk patients including those with over 10 positive lymph 
nodes. (O’Driscoll, 2003)  (Kroger, 2006) (Lee, 2007) Although Bcl-2 expression did not 
change significantly following the chemotherapy, post neoadjuvant chemotherapy Bcl-2 
expression was found to be predictive of better disease free and overall survivals. (Vargas-
Roig, 2008) Bcl-2 expression is not currently used as a standard prognostic or predictive 
marker in breast cancers.  
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Apoptosis pathway and drugs targeting the pathway (Borrowed from the published article by 
de Vries, 2006) 
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Bag-1 
 
Bcl-2-associated anthanogene 1 (Bag-1) is a pro-survival protein that was first identified as a 
binding partner of Bcl-2 and the activated glucocorticoid receptor. (reviewed in Cutress, 
2002) It is expressed in most normal human tissues. Bag-1 gene encodes three major 
isoforms namely Bag-1S, Bag-1L and Bag-1M that share a common carboxy terminus. The 
Bag-1S is preferentially located in the cytoplasm. Bag-1L is predominantly located in the 
nucleus. The Bag-1M is located in both nuclear and cytoplasmic compartments, but it 
relocates from the cytoplasm to nucleus in response to heat shocks and hormonal 
stimulations. Therefore nuclear Bag-1 expression may indicate either high levels of Bag-1L 
or re-localisation of Bag-1M to the nucleus in response to specific signals in the tumour 
microenvironment. 
Bag-1 is a multifunctional anti-apoptotic protein. It binds to proteins from four different 
subcellular compartments:  
1. cytosolic domains of tyrosine kinase hepatocyte growth factor (HGF) receptor and 
platelet derived growth factor (PDGF) receptor on outer cell membrane to increase the 
protection from apoptosis by HGF and PDGF, respectively;  
2. Bcl-2 on inner cell membrane to enhance the inhibition of apoptosis;  
3. heat shock protein (Hsp) in the cytoplasm to inhibit the Hsp70-mediated refolding of 
denatured proteins, and protect cells from the heat shock induced apoptosis; 
4. RAF-1 and hormone receptors such as glucocorticoid, androgen, oestrogen and 
thyroid receptors in the nucleus to modulate their functions.  
Bag-1 promotes cellular proliferation in normal conditions but causes cell cycle arrest under a 
stressful condition. (Song, 2001) Overexpression of Bag-1 suppresses the activation of 
caspases and apoptosis induced by many factors such as Fas and TRAIL death-receptors, 
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kinase inhibitors, vitamin D, retinoic acid, withdrawal of growth factors, heat shock, 
dexamethasone, radiation, anti-cancer drugs such as cisplatin and etoposide. Over-expression 
of Bag family proteins has been shown to increase the resistance to chemotherapy. Bag-1 
enhances metastasis in experimental cancer models. (Shindoh, 2000) ZR-75-1 breast cancer 
cells transfected with Bag-1 have increased survival in the culture, and form larger tumours 
than non-transfected cells when injected into mammary fat pads of mice. ZR-75-1 cells with 
mutated Bag-1 show retarded growth in vivo and in vitro. (Kudoh, 2002) Over-expression of 
Bag-1 was also found to enhance cell migration and the survival in two gastric cancer cell 
lines. (Naishiro, 1999) 
Bag-1 has been linked with the aggressiveness of breast, gastric, pancreatic, head and neck, 
endometrial and colorectal cancers.  In breast cancer, relatively high level of Bag-1 
expression by IHC was located to the cytoplasm in more than two thirds, nucleus in 0.5% to 
70% and both nucleus and cytoplasm in 1% to 60% of the cases. (Tang, 1999) (Turner, 2001) 
(Sjostrom, 2002) (Townsend, 2002) Nuclear Bag-1 was inversely associated with the tumour 
grade and cytoplasmic Bag-1 was associated with the ER status. High grade tumours exhibit 
weak nuclear Bag-1 expression. (Tang, 2004) Bag-1 expression was more frequently found in 
node positive breast tumours compared to node negative tumours - 89% vs. 38% - and was 
predictive of good prognosis in node positive patients in the univariate analysis. There are 
also strong associations between Bag-1, Bcl-2, ER and PR expressions. (Nadler, 2008b) 
Positive, negative or no correlations between Bag-1 expression and other molecular markers 
such as Ki-67, Bcl-2, ER, PR and Bcl-x had also been reported. (Xie, 2004) (Sjostrom, 2002) 
(Tang, 2004) (Townsend, 2002) (Turner, 2001) (Brimmell, 1999) (Cutress, 2003) 
The correlation between Bag-1 expression and the survival outcome was reported 
inconsistently.  Tang et al. reported an association between high nuclear Bag-1 expression 
and decreased survival among 140 breast cancer patients (Tang, 2004) while Krajewski et al 
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reported better overall survival for Bag-1 overexpression (>20%). (Krajewski, 1999) Turner 
et al reported a strong association between high cytoplasmic Bag-1 and a better survival in 
both univariate and multivariate analysis (Turner, 2001) while Townsend et al. found no 
significant association between nuclear or cytoplasmic Bag-1 and survival in 160 patients. 
(Townsend, 2002) High nuclear Bag-1 expression was found to increase anti-oestrogen 
induced growth arrest in MCF-7 cells and was predictive of lower local recurrence, distant 
metastases and death from breast cancers in tamoxifen-treated ER+ cancer patients in 
univariate analysis and predictive of distant metastases in multivariate analysis (Millar, 
2009). Bag-1 was found not to be predictive of a response to a chemotherapy that contains 
docetaxel or methotrexate and fluorouracil in advanced breast cancers. (Sjostrom, 2002)  
Reduction of Bag-1 expression by antisense cDNA leads to the sensitization to apoptosis 
induced by many apoptotic inducers including staurosporine, paclitaxel, ATRA, and 4-HPR. 
(Takahashi, 2003) Only Bag-1L regulates ERα function and the expression of nuclear Bag-1L 
might be particularly important in determining a response to hormonal therapy in breast 
cancers. (Cutress, 2003) As all Bag-1 isoforms possess anti-apoptotic activity, cytoplasmic 
Bag-1S might be particularly important in determining responses to chemotherapy that exerts 
its effect via apoptosis. 
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Bag-1 binding partners and functions (Borrowed from the published article by Cutress, 2002) 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 65 
 
Aurora A 
 
Aurora A - also known as serine threonine kinase 15 (STK15), BTAK, Aurora kinase A or 
Aurora-2 - is a kinase protein, encoded for by a gene located at chromosome 20q13.2. It is a 
member of Aurora kinase family which also includes Aurora B and C. Aurora proteins need 
phosphorylation to become active and several different activators for Aurora A such as 
TPX2, Ajuba, PAK1, HEF1, hBora and ASAP have been identified. Auroras are degraded 
through the D (destruction) box – a sequence in the protein’s structure. Aurora A is expressed 
in most rapidly dividing tissues like testis and thymus, and found to be low in most adult 
tissues likely due to the low proliferation rates.  
Main function of Auroras is the regulation of cell cytokinesis. Aurora A regulates phases of 
mitosis that include centrosome maturation and separation, mitotic entry, bipolar spindle 
assembly, chromosome alignment on the metaphase plate and cytokinesis by phosphorylating 
different substrates. Aurora-B is a subunit of the chromosomal passenger protein complex 
and functions to ensure accurate chromosome segregation and cytokinesis. Aurora-C is a 
chromosomal passenger protein and co-localizes with Aurora-B. Aurora C is found only in 
the normal testicular tissue. 
Auroras level is undetectable in G1 phase but increases during S phase, reaches peak at G2/M 
phase and then rapidly decreases at the end of mitosis. A perfect timing of Aurora activation 
and destruction is necessary for an effective cytokinesis. Disruption of Aurora-A function 
leads to G2-M arrest and severe mitotic defects such as delayed entry into mitosis, monopolar 
spindles, defective centrosome maturation and misalignment of chromosomes during 
metaphase and apoptosis.  Aurora-A over expression results in a centrosome duplication, 
multipolar spindle, failure to complete spindle microtubule attachment, bypass of the G2-M 
DNA damage-activated checkpoint permitting cells to inappropriately enter anaphase despite 
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the presence of these abnormalities resulting in numerous chromosomal separation defects. 
With additional cycles this leads to an aneuploidy and progressive chromosomal instability. 
Aurora A over expression also leads to the increased p53 degradation, which facilitates the 
oncogenic transformation. 
In normal cells, Aurora A is present on duplicated centrosomes and mitotic spindles from late 
S phase until early G1 phase during the mitosis. (Fu, 2007) (Marumoto, 2005) In malignant 
cells, Aurora A is detected diffusely throughout the cell as aberrant phosphorylated 
cystoplasmic proteins, regardless of the cell cycle position. (Gritsko, 2003) Aurora A over 
expression, with or without amplification, has been observed in up to 62% of breast cancers. 
(Miyoshi, 2001) (Tanaka, 1999) (Zhou, 1998) Potential mechanisms of Aurora A over 
expression include gene amplification, mRNA over expression and phosphorylation on serine 
51 that prevent proteolysis. (Kitajima, 2007)  
It has been shown that Aurora A over expression induces cancer cells resistant to taxane by 
disrupting the spindle checkpoint activated by paclitaxel or nocodazole treatment. (Anand, 
2003) High Aurora A mRNA levels are associated with a lower response rate to docetaxel 
compared to low Aurora A mRNA levels especially in ER negative tumours (33% vs 83%). 
(Miyoshi, 2001) (Hata, 2005) In early breast cancer, Aurora A over expression is associated 
with a poor survival and also with other poor prognostic factors such as high nuclear grade 
and positive HER2 expression, ER/PR negativity and centromere abnormality. (Loddo, 2009) 
(Nadler, 2008a) (Hoque, 2003) (Royce, 2004) Cytoplasmic or nuclear localisation of Aurora 
A has been reported to be a critical factor for its effect on the various cancers.  (Tatsuka, 
2009) (Ogawa, 2008)  
Aurora A inhibitors have been developed and investigated in various human cancers. JNJ-
7706621 and PHA-680632 (Keen, 2004) (Plyte, 2007) are shown to decrease Aurora kinases 
activities by inhibiting the histone H3 phophosrylation which is a substrate for Aurora A. An 
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inhibitor of Aurora A and B quinazoline ZM447439 (Ditchfield, 2003) and phenylamide VX-
680 are reported to target ATP-binding site of the Aurora kinases. It has been shown to be 
effective in leukemia, prostate, colon and pancreatic cancers. (Harrington, 2004) (Lee E, 
2006) Aurora A kinase selective inhibitor MLN8054 has shown robust growth inhibition of 
human tumour xenografts. (Manfredi, 2007) MK615 exerts an anti-neoplastic effect on 
human pancreatic cancer cells in vitro by dual inhibition of Aurora A and B kinases. (Okada, 
2008) Aurora A kinase inhibitor VE-465 synergizes with paclitaxel to induce 4.5-fold greater 
apoptosis than paclitaxel alone in 1A9 cells. Higher doses are needed to induce apoptosis in 
paclitaxel resistant PTX10 cell. (Scharer, 2008) 
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Plk-1 
 
Polo like kinase (Plk) belongs to a family of serine/threonine kinases isoenzymes. There are 4 
isoforms namely Plk-1, Plk-2, Plk-3 and Plk-4. These kinases have a conserved N-terminal 
catalytic domain and a C-terminal phosphopeptide-binding polo-box domain (PBD) that 
allows them to localize to mitotic structures. In the absence of a bound ligand, the PBD forms 
an intramolecular interaction with the kinase domain inhibiting its kinase activity.  
Among all Plks, Plk-1 was studied most extensively in cancers. Main functions of Plk-1 are 
involvement in the regulation of centrosome maturation, bipolar spindle assembly, sister 
chromatid cohesion, activation of anaphase promoting complex, initiation of cytokinesis and 
regulation of the G2/M transition. Plk-1 is essential for the cell cycle to restart after a 
successful or failed repair of damaged DNA. The depletion of Plk-1 induces apoptosis in 
various cancer cell lines by affecting cell cycle profile and by damaging DNA. (Ando, 2004) 
(Liu, 2003) (Spankuch-Schmitt, 2002a)  
Plk-1 expression is lowest during the S phase but increases in late G2, highest during mitosis, 
and degraded during mitotic exit. It is predominantly cytoplasmic during the S phase but is 
associated with condensed chromosomes during mitosis. Aurora A is responsible for the 
initial phosphorylation of Plk-1 at the G2/M transition. Plk-1 also regulates the localization of 
Aurora A to the centrosomes for proper maturation. 
Plk-1 expression has been reported to be a poor prognostic factor in various carcinomas 
including lung, head and neck, oesophagus, stomach, endometrium, ovary, brain, skin and 
breast cancers.  King et al. reported expression of Plk-1 in 11% of primary breast cancers and 
it was associated with P53 mutation and triple negativity in early breast cancers. (King, 2012) 
Weichert et al. reported the expression of Plk-1 and Plk-3 in 42.2% and 47.4% of breast 
cancers. A positive correlation was found between the Plk expression and the tumour grade, 
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vascular invasion, HER2 expression and proliferation markers while inverse correlation was 
reported between the Plk isoform expression and the estrogen receptor status. Overexpression 
of Plk-3 but not of Plk-1 was significantly associated with the reduced median overall and 
relapse free survival in multivariate analysis. (Weichert, 2005) 
Because of its crucial role in the cancer pathogenesis, many agents have been investigated to 
target Plk-1 as a treatment. Examples are Plk-1 enzymatic inhibitors - Scytonemin, 
Wortmannin, Staurosporine, Morin and Quercetin; PBD inhibitors such as Thymoquinone 
and Purpurogallin; and agents that suppress Plk-1 expression such as Genistein, Vanillin, 
Silibinin, Trichostatin A and Indirubin. (reviewed by Schmit, 2010) 
Several studies have shown that the down regulation of Plk-1 by several anti-sense and small 
interfering RNA (siRNA) as well as cytotoxic compounds caused cell-cycle arrest, apoptosis 
and decreased the growth in cancer cell lines. (Liu, 2003) (Spankuch-Schmitt, 2002a&b) 
(Kawata, 2008) i.v. administration of Plk-1 siRNA/atelocollagen had been shown to decrease 
the growth of liver metastases from lung cancer in a mouse model. (Kawata, 2008) The 
intravesical administration of Plk-1 siRNA inhibited the growth of bladder cancer in an 
orthotopic murine model. (Nogawa, 2005) Plk-1 siRNA transfection of prostate cancer cells 
resulted in a mitotic cell cycle arrest, failure of cytokinesis, and defects in centrosome 
integrity and maturation. In melanoma cells, Plk-1 inhibition resulted in a significant decrease 
in the viability and clonogenic survival, multiple mitotic errors, G2/M cell cycle arrest, and 
apoptosis. (Schmit, 2009) ON01910, a non-ATP-competitive small molecule inhibitor of Plk-
1 was found to result in an induction of mitotic arrest characterized by spindle abnormalities 
leading to their apoptotic death in a wide variety of human tumour cells. (Gumireddy, 2005) 
In HER2+ breast cancer cell lines, primary human cancer cells and orthotopic breast cancer 
models, intravenously injected F5-P/Plk1-siRNA complexes inhibited Plk-1 gene expression, 
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reduced proliferation and metastasis, induced apoptosis, and prolonged survival without 
evident toxicity. (Yao, 2012) 
Inhibiting Plk-1 with siRNA or BI 2536 blocked the growth of triple negative breast cancer 
cells including the CD44high/CD24-/low TIC subpopulation and mammosphere formation.  
(Hu, 2012) In a breast cancer brain metastatic xenograft model (231-BR), GSK461364A was 
found to inhibit the development of large brain metastases by 62% (P = 0.0001) and 
prolonged the survival by 17%. GSK461364A also sensitized tumour cells to radiation 
induced cell death in vitro. (Qian, 2011) Treatment of breast cancer cells with siRNAs 
targeting Plk-1 improved the sensitivity to paclitaxel and trastuzumab in a synergistic 
manner. (Spankuch, 2007) 
                  
Plk-1 interaction with other proteins (Borrowed from the published article by Strebhardt, 
2006) 
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MCM-2 
 
Minimichrosome maintenance proteins (MCM) were first found in the yeast as mutants 
defective in maintenance of minichrosomes. Six highly conserved members of MCM proteins 
(MCM 2 – 7) have been identified. They interact with each other to form a hetrohexamer 
complex. This complex binds to the DNA at specific sites known as replication origins in 
early G1 phase. Proteins namely origin recognition complex (ORC), Cdc 6 and Cdt 1 
functionally interact with MCM 2-7 complex to form a pre-replication complex.   MCM 
complex unwinds the DNA through its helicase activity that makes the binding sites on the 
DNA become accessible for replication and then the DNA is said to be licensed for 
replication. MCM complex dissociates from ORC in the S and G2 phases and they remain as 
a soluble nuclear pool during G2 phase and early mitosis. MCM complex makes sure the 
DNA replication occurs only once in each cell cycle. MCM complex is present in all phases 
of cell cycle and disappear when cell exits from the cell cycle, rapidly in the case of cell 
differentiation or more slowly in the case of quiescent G0 state.  
MCM-2 expression by immunohistochemistry is localised to the nucleus. It was found in 
abundance in all phases of the cell cycle, but they are degraded in cells that have abandoned 
the cell cycle, such as quiescent or senescent state and differentiated cells. MCM-2 labelling 
index (LI), like Ki-67, identifies a unique licensed but non-proliferating population of tumour 
cells that increased significantly with tumour grade and was also of prognostic value. 
(Dudderidge, 2005) There was a positive correlation between the MCM-2 and Ki-67 LIs in 
normal breast although expression of MCM-2 was significantly higher than that of Ki-67 and 
showed greater variability and said to be able to identify more cells in the cell cycle than Ki-
67 in a range of normal and malignant tissues. This may be because of the presence of cells in 
the early G1 phase of the cell cycle which may not express Ki-67. Hence, any tissue with a 
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high proportion of cells that are progressing slowly through G1 phase or held in G1 would be 
predicted to show a higher LI for MCM-2 than for Ki-67.   
MCM-2 protein overexpression using different cut off values in different studies had been 
reported in various malignant tumours including colon, cervix, breast, oesophagus, kidney, 
brain, lung, thyroid, and prostate and was correlated with bad pathological features such as 
higher clinical stage, poor survival and NPI (in case of breast cancer). (Gonzalez, 2003) 
MCM-2 LI >50% was shown to be associated with significantly poor survival outcomes in 
breast cancers. (Kato, 2003) MCM-2 expression with a cut off point of 40% was an 
independent predictor of disease recurrence in the multivariate Cox regression analysis in 
Ta/T1 Bladder cancers. (Burger, 2007) Ki-67 LI >5% and MCM-2 LI >10% were strongly 
predictive of inferior disease specific survival in GISTs. (Huang, 2006) In gastric carcinoma 
patients, high MCM-2 LI was a poor prognostic factor in the diffuse types but not in the 
intestinal types. (Tokuyasu, 2008) Non-small cell lung cancer patients with less than 25% 
MCM-2 LI had a longer median survival compared to patients with > 25%. (Ramnath, 2001) 
In renal cell cancer, MCM-2 expression level is much higher than other proliferative markers 
such as Ki-67 and Geminin, and is correlated with the tumour grade and reduced disease free 
survival. MCM-2 expression is increased in prostate cancer tissues and correlated with a 
shorter disease free survival. (Meng, 2001) 
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Ki-67 
 
Ki-67 is a large nuclear protein associated with the cellular proliferation although the exact 
function remains unknown. It was identified following the discovery of the prototype 
monoclonal antibody Ki-67, which was generated by immunising the mice with the nuclei of 
the Hodgkin lymphoma cell line L428. (Gerdes, 1983) The name is derived from the city of 
origin (Kiel) and the number of the original clone in the 96-well plate. (Scholzen, 2000) Ki-
67 protein was present in the nuclei of cells in the G1, S and G2 phases of the cell division 
cycle as well as in mitosis. Quiescent or resting cells in the G0 phase did not express the Ki-
67 proteins. (Gerdes, 1984) Therefore Ki-67 is useful to identify a cell population in the 
active cell cycling or tumour proliferation state. Ki-67 expression was reported to be a better 
marker than the mitotic count to evaluate the tumour proliferation and the prognosis. 
(Clahsen, 1999) However it can only give the estimate of the growth fraction but not the rate 
of proliferation which is also a very important factor. 
Ki-67 overexpression was found to be a poor prognostic factor for the disease relapse and 
death in various cancers including breast cancers. Ki-67 >10% was predictive of poor 
survival in stage 1 and 2 breast cancer patients and also in a subset of low risk group defined 
by “Adjuvant!” and St. Gallen risk criteria. (Jung, 2009) Metastases in axillary nodes are 
likely to have higher Ki-67 expression compared to its primary breast lesions suggesting 
more active proliferative properties of metastasising cells. (Cabibi, 2006)  
Ki-67 overexpression is predictive of a response to the chemotherapy (Penault-Llorca, 2008) 
(Darb-Esfahani, 2009) (Li, 2011) and endocrine therapy.  (Viale, 2008) (Yamashita, 2006) 
(Kai, 2006) However some studies suggested that pre-treatment high expression may no 
longer be a poor prognostic factor after the chemotherapy or endocrine therapy. (Clarke, 
1993) (MacGrogan, 1996) Instead post treatment residual Ki-67 expression may be a more 
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significant prognostic factor (Jones, 2009) as Ki-67 expression was found to decrease after 
various primary chemo, endocrine and other anticancer therapies. (Johnston, 1994) Decrease 
in Ki-67 expression index following neoadjuvant chemotherapy was more significant in the 
primary tumour than the lymph nodes metastases. (Koda, 2007a) Median reduction in Ki-67 
expression following neoadjuvant FEC was 21.2%. Tumours having >75% reduction in Ki-
67 expression following chemotherapy were more likely to get complete pathological 
response. (Burcombe, 2005)  Early decrease in Ki-67 index after 10 –21 days of 
chemoendocrine therapy or chemotherapy alone was associated with a good clinical response, 
achieving either complete response or minimal residual disease. (Chang, 1999) (Assersohn, 
2003) Higher Ki-67 expression after 2 weeks of endocrine therapy was statistically 
significantly associated with the worse RFS in a multivariate analysis in the IMPACT trial 
while high Ki-67 expression at baseline was not. (Dowsett, 2007) Changes in Ki-67 
expression and apoptotic index at day 21 of neoadjuvant anthracycline chemotherapy did not 
however manage to predict the response. (Burcombe, 2006)  
Post primary chemotherapy lymph node positivity and ki-67 index more than 15% are 
significant poor prognostic factors in breast cancer patients with hazard ratio for recurrence 
and death of 3.1 and 2.4 for one factor only, and 9.3 and 6.5 for both factors, compared to 
other patients. (Guarneri, 2009) Following neoadjuvant chemotherapy with doxorubicin + 
docetaxel, ER negativity and Ki-67 index above 1% are the poor prognostic factors, being the 
worse when both factors were present. Ki-67 index 1 or below was the only significant 
prognostic factor in multivariate analysis. (Lee, 2008) 
ER/PR positive cancers with Ki-67 index of 13.25% was defined as luminal B subtype for 
which 10 years relapse free survival was 67% while that for luminal A subtype was 74% 
without systemic adjuvant therapy among low risk breast cancers. 10 years breast cancer 
specific survival was 79% and 92% respectively.  (Cheang, 2009) Some studies have used 
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10% (Keshgegian, 1995) (Bevilacqua, 1996) or 20% (Clahsen, 1999) (Joensuu, 2003) or the 
mean (Goodson, 2000) or the median (Liu, 2001) as a cut off point to define the Ki-67 
overexpression.  
Transfection of Ki-67 cDNA resulted in 60-70% reduction in the proliferation of MDA-MB-
435s cells which highly expressed Ki-67 mRNA and protein. The mobility and invasion 
capability were also reduced by 50 – 60% and the cell cycle analysis showed a higher 
proportion in G2/M and G0/G1 phases with markedly increased ratio of apoptotic cells. 
Therefore anti-sense Ki-67 cDNA might be a treatment option for cancers with high Ki-67 
expression. (Wang, 2008) 
Overall, the concordance between the RT-PCR and IHC analysis for ER, PR, and HER2 
determinations was high. In contrast, the concordance between the RT-PCR measurements 
and IHC assay for Ki-67 was poor. (Cobleigh, 2005) (Potemski, 2006) Ki-67 expression 
score from TMA cores are shown to be in good agreement with that from whole tumour 
sections. (Giltnane, 2004) (Camp, 2000) (Nocito, 2001) 
Although Ki-67 protein has been consistently shown to be a prognostic and predictive factor 
for treatment response and survival, there are many variations in assessment techniques and 
the cut off points used for dichotomisation. There is a need for an international 
standardization of the IHC procedures and a clinicalpathological validation by randomized, 
multicentre prospective studies.  
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CK-5/6 
 
 
Intermediate-sized basic (type II) polypeptides CK-5 and 6 are members of the cytokeratin 
family that forms the intermediate filament cytoskeleton in epithelial cells. Their absence 
gives rise to a blistering skin disorder in neonatal epidermis, and haemorrhages within the 
embryonic liver. Mutations in CK-5 gene have been associated with epidermolysis bullosa 
simplex. The CK-5, CK-14 and CK-17 - high molecular weight cytokeratins - are known as 
basal keratins because they are expressed in the mitotically active basal layer of stratified 
epithelial tissues.  The cells that express these keratins are also known as basal cell regardless 
of their position. The CK-5⁄6 is useful, especially in conjunction with the ER expression, to 
distinguish between the epithelial hyperplasia of usual type in a papilloma and the atypical 
hyperplasia or malignant epithelium. CK-5 is negative in the malignant epitheliums as they 
don’t arise from the progenitor cells. (Otterbach, 2000) (Grin, 2009) 
The genes for CK-5 and 6 are clustered in the region of chromosome 12q12-q13. In normal 
tissue, CK-5/6 is mainly expressed in keratinizing (epidermis) and nonkeratinizing (mucosa) 
squamous epithelium as well as in basal myoepithelial cell layer of the prostate, breast and 
salivary glands. CK-5/6 was positive in the vast majority of squamous cell carcinoma, basal 
cell carcinoma, thymoma, salivary gland tumour, biphasic malignant mesothelioma, 
transitional cell carcinoma, pancreatic , breast , ovarian and endometrial carcinomas.   
CK-5 mRNA and protein are shown to be expressed in normal mammary epithelial cells 
culture and a few tumour cell lines (MCF-12A, MCF-10A and MCF-10F). (Subik, 2010) 
Therefore CK-5 expression is useful to differentiate normal from the malignant tissue.  
Decreased expression also correlates with the tumourgenic progression. In breast cancer, CK-
5/6 expression was correlated with other poor prognostic factors although the biological 
function of CK-5 and 6 remained unknown.   
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In molecular subtype profiling, Core Basal Phenotype (CBP) was defined as tumours with 
overexpression of basal cytokaretins CK-5/6, CK-14, CK-17, EGFR and vimentin among 
ER/PR/HER2 negative patients. (Dabbs, 2006) However the definition of CBP as 
ER/PR/HER2 negative, CK-5/6 or EGFR positive has only 76% sensitivity to detect basal-
like tumours defined by multi genes assays where CK-5/6 expression was found in only 
57.6% - 62% of basal cancers. (Nielsen, 2004) (Livasy, 2006) (Lakhani, 2005) There were 
also discordances between mRNA and IHC methods to identify CK-5/6 positivity. Up to 48-
55% cases could be CK-5/6 positive by IHC, but negative by mRNA examination. Similarly, 
14% of cases with high mRNA levels were negative on IHC examination. Similar 
discordances were observed for CK-14 and CK-17 as well. (Kordek, 2010) CK-5/6 can be 
reliably analysed in the FNA specimen blocks containing at least 10 tumour cells suggesting 
basal like breast cancer can be identified at the time of the breast cancer diagnosis. (Delgallo, 
2010) 
Basal like cancers have poorer prognosis compared to other molecular subtypes. (Sorlie, 
2001) Many studies found that CK-5, CK-14 and/or CK-17 are associated with higher tumour 
grade, poor survival and triple (ER/PR/HER2) negativity especially in node negative 
tumours. (Korsching, 2002) (Reis-Filho, 2008) When CK-5/6 and/or EGFR expressing 
tumours were analyzed without consideration of ER/PR status, the reduction in the survival 
increased with time, becoming more pronounced at 10 years than at 3 years.  (Tischkowitz, 
2007) Breast cancer patients who went on to develop brain metastases were more likely to 
have primary tumours that expressed CK-5/6 (P<0.001), EGFR (P=0.001) and HER2 
(P=0.001). (Hicks, 2006) 
As much as 15 - 54% of basal-like tumours defined on mRNA level still express at least one 
of the ER/PR/HER2 proteins. (Reis-Filho, 2008) (Nielsen, 2004) (Calza, 2006) (Sotiriou, 
2003) (Jumppanen, 2007) 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 78 
 
The hazard ratio for development of distant metastasis in bilateral breast cancer patients in 
whom at least one cancer was CK-5⁄6+ was 99.8 (P = 0.037). (Piekarski, 2006) There are also 
reports of correlation between basal cytokeratin expression and atypical and typical 
medullary carcinomas. (Gusterson, 2005) CK-5/6 expression is associated with a higher pCR 
rate in breast cancer patients treated with neoadjuvant anthracycline/ taxane based 
chemotherapy compared to others. (Darb-Esfahani, 2009) (Li, 2011)  
Although CK-5 is a recognised protein to define the basal like cancer, CK-6 is not. There are 
also some evidence suggesting CK-6 is not expressed in normal and basal-like breast cancers. 
(Moll, 1998) (Bocker, 2002) Yet in some studies CK-6 and 17 expressions were used to 
define the basal phenotype. (Stingl, 2007) The antibody directed against CK-5 alone was said 
to be more sensitive than common CK-5/6 antibody - 97% vs. 59%. For positive cases, the 
percentage and intensity of staining was much higher with CK-5 than with CK-5/6. 
(Bhargava, 2008) However, CK-5/6, rather than CK-5, is commonly used in molecular 
subtype profilings. 
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CD-68 
 
 
CD-68 (Cluster of Differentiation 68) is a glycoprotein with a molecular weight of 110 Kda 
that binds to the low density lipoprotein. It is encoded for by a gene located on the 
chromosome 17p13. CD-68 protein is expressed primarily as an intra-cytoplasmic molecule 
associated with lysosomal granules. Monoclonal mouse antibody against CD-68 labels 
human monocytes and macrophages. (Tran, 1998) CD-68 antibody is used to identify 
macrophagic cells or cells of macrophagic origin. CD-68 expression by the cancer cell was 
reported only in a few cancer types. In a study involving 127 breast cancers, 
immunohistochemistry staining for macrophage markers CD-163 and MAC387 in cancer 
cells was detected in 48% and 14%, respectively, of cases but CD-68 staining in cancer cells 
was not detected in any of the cases. (Shabo, 2008) Immunostaining for CD-68 was reported 
in melanoma cells in 10% of cases and was correlated with the relapse free survival. (Jensen, 
2010) Malignant glioma cells showed CD-68 expression more commonly than benign glioma 
cells and the higher expression was associated with the poor prognosis. (Strojnik, 2009)  
Tumour associated macrophages (TAMs) are one of the major components of the breast 
cancer stroma being seen in 90% of the cancers.  (Scholl, 1994) CD-68+ macrophages 
infiltration is seen more commonly in invasive breast cancers compared with DCIS, benign 
hyperplasia or normal breast tissue. (Hussein, 2006) Decrease in CD-68+ monocytes count 
was seen in tumours following neoadjuvant chemotherapies. (Hornychova, 2008) However 
an increase in macrophages in the tumour mammary duct has been reported following an 
endocrine therapy. (Chen, 2009)  
TAMs regulate the tumour growth in a positive or negative way through interactions between 
TAMs, stroma and the tumour cells. (Yoshimura, 1989) (Mantovani, 1992) Tumour cells 
stimulate the formation of stroma that excretes a variety of growth factors, cytokines and 
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proteases. Certain cytokines and chemokines promote macrophage infiltration into the 
tumour. Tumour cells stimulate macrophages to produce various growth factors, angiogenesis 
factors and matrix-degrading enzymes that in turn promote angiogenesis, tumour growth, 
invasion, tumour cell migration, metastasis and survival. (Bingle, 2002) (Huang, 2002) CD-
68+ TAMs were shown to secrete epidermal growth factor while other cells or malignant 
cells did not. (O’Sullivan, 1993) Some studies suggested that the prognostic value of TAM is 
probably due to their positive involvement in the tumour angiogenesis and the proliferation. 
(Leek, 1996) (Tsutsui, 2005) (Jonjic, 1998) Macrophages express uPA that leads to the 
plasmin dependent release of matrix-bound heparan sulphate proteoglycan - a basic fibroblast 
growth factor - and transforming growth factor beta, both of which are strong angiogenic 
factors. A positive correlation between microvessel density, vascular invasion, uPA level, 
macrophage content and the proliferation rate has been reported. (Hildenbrand, 1995)  
TAMs can be activated from a quiescent non-angiogenic state to an angiogenic state. 
(Assoian, 1987) By releasing vasoactive substances, macrophages increase vascular 
permeability that enables extravasation of fibrinogen. Plasmin-cleaved fibrinogen fragment E 
has a strong angiogenic activity. TAMs increase the synthesis of nitric oxide which is 
converted into active genotoxicant peroxinitrite (Maeda, 1998) (Schaffer, 2006) and cause 
dysregulation of production of fat derived hormones and hormone-like substances. (Lin, 
2005) Macrophages content of adipose tissue is found to be higher in obese patients 
(Weisberg, 2003) and in patients with insulin resistance/ decreased glucose tolerance as a 
result of certain hormonal and non-hormonal signals. (Neels, 2006)  
The active immune response, such as macrophage infiltration, to the poor tumour cell 
differentiation was believed to be responsible for the increase in the proliferative activity, 
angiogenesis and dissemination of the tumours. (Pupa, 1996) (Tsutsui, 2005) (Lin, 2007) On 
the other hand, inflammatory changes could be just a reflection of high grade proliferating 
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tumours that excrete more cytokines attracting macrophages and T lymphocytes. Higher 
tumour grade and proliferative activity were found to be associated with CD-68+ 
macrophages infiltrations. (Al Murri, 2008) Inflammatory cell infiltrates were correlated with 
the better cancer specific survival (Toi, 1999) although some studies failed to confirm that. 
(Griffith, 1990) (Wintzer, 1991) Higher density of CD-68+ macrophages and antigen 
presenting cells are correlated with the increasing vascularisations and decreasing 
differentiations in follicular, papillary and anaplastic thyroid carcinomas. (Hermann, 1994) 
There are conflicting results on correlations between CD-68+ macrophages infiltration and 
the breast cancer survival. In a study by Lee et al (Lee, 2006) involving 679 stage 1 and 2 
breast cancer patients with a median follow-up period of nearly 10 years moderate to marked 
intratumoral diffuse inflammation (both macrophage and lymphocytic infiltration) was seen 
only in 11% of the cases and associated with the better survival in grade 3 but not in other 
grade cancers.  Some studies suggested that it was inferior to the microvessel density in 
predicting the disease free survival. (Tsutsui, 2005) (Shabo, 2008) (Uzzan, 2004) Murri et al 
reported that breast cancer survival was not associated with CD-68+ macrophages infiltration 
but with the positive Ki-67 labelling index, higher tumour grade, higher proliferative activity, 
microvessel density and negative hormonal receptor expression. (Al Murri, 2008)   In 
colorectal cancers, 5 years cancer specific survival rate was shown to be better in patients 
with higher CD-68+ cells density in the lymph nodes compared to the lower CD-68+ cells – 
60% vs. 38%. (Oberg, 2002) High CD-68 gene expression by RT-PCR was one of the gene 
expression used as a poor risk factor to calculate 10 years distant recurrence rate in Oncotype 
Dx prognostic gene assay. (Paik, 2004)  
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CD-71 (Transferrin Receptor) 
 
CD71 - also known as Transferrin receptor (TfR) - is a type II transmembrane glycoprotein 
that consists of a large extracellular C-terminal domain with a binding site for the ligand 
transferrin, a transmembrane domain and a short intracellular N-terminal domain. (Jing, 
1987) The CD-71 is an essential protein involved in the iron uptake and the regulation of cell 
growth and also has immunoregulatory properties.  
The CD-71 expression is found at low level in cells with a low proliferation rate such as those 
in the vascular endothelium of brain capillaries, endocrine pancreas, seminiferous tubules of 
the testes, pituitary gland, luminal membranes of the breast, hepatocytes, hepatic Kupffer 
cells and renal tubules, but at high level in cells with a high proliferation potential such as 
cells in the intestinal epithelium.  The CD-71 is also expressed on cells that require large 
amounts of iron such as placental trophoblasts and maturing erythroid cells. 
There are two different TfRs - namely TfR1 and TfR2 - being produced by alternative 
splicing. They have some similarities in their domains except cytoplasmic domains. TfR1 has 
25 folds higher affinity for the transferrin (Tf) than TfR2. (Kawabata, 1999) TfRs can form 
hetrodimers but commonly form homodimers. (Vogt, 2003) Expression of TfR1 was highest 
in the late G1 and G2/M phases. TfR1 but not TfR2 expression is regulated by intracellular 
iron levels. (Kawabata, 2001) (Kawabata, 2000) In normal tissues, TfR2 expression is 
confined to the hepatocytes and enterocytes of the small intestine. Surface expression of TfR2 
was detected in a wide variety of human cancer cell lines such as HepG2 (human hepatoma), 
K562 HEL-R (Kawabata, 2001) (Kawabata, 1999) and selected B and myeloid cell lines. 
(Deaglio, 2002)  
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CD-71 expression is found to be much higher in malignant cells such as breast cancer, 
transitional cell carcinomas of the bladder, gliomas, pancreas, lung adenocarcinoma, chronic 
lymphocytic leukemia and non-Hodgkin’s lymphoma compared to non-malignant cells. High 
expression of CD-71 in malignant cells is believed to be a response to meet the increased 
demand for iron as a cofactor of the ribonucleotide reductase enzyme involved in the DNA 
synthesis of rapidly dividing cells. In breast cancer cells CD-71 expression was up to 4 to 5 
folds higher than that of non-malignant cells. Increased CD-71 expression was associated 
with poor NPI score, tumour proliferation, basal cytokeratins, p53, EGFR, HER2, steroid 
receptor negativity and shortened breast cancer specific survival. On multivariate analysis, 
CD-71 was found to be an independent prognostic factor in the ER+ cancers.  Elevation of 
CD-71 was seen in cell models of acquired resistance to tamoxifen. Exogenous Tf was found 
to significantly promote the growth especially in oestrogen deprived MCF-7 cells. 
Deprivation of iron by disrupting CD-71 function can be detrimental to rapidly growing 
tumour cells. Monoclonal antibodies of IgG, IgA, and IgM isotypes against human transferrin 
receptor have been successfully used to inhibit the growth of neoplastic cells. The murine 
monoclonal anti-human CD-71 IgA antibody 42/6 has shown some cytotoxic activities 
against most human malignancies by preventing Tf from binding to its receptor by non-
competitive inhibition, leading to iron deprivation and subsequent growth arrest. High 
expression of CD-71 was found in the drug resistant cells and down regulation of these 
receptors by calcium channel blockers diminished the drug resistance. (Barabas, 1993) 
When iron bound ligand Tf binds to TfRs (CD-71) on the cell membrane, the whole complex 
is internalised through the receptor mediated endocytosis. Then the iron is released inside the 
cytoplasm and Tf/TfR (CD-71) complex returns to the cell surface where Tf dissociates from 
TfR (CD-71), leaving the latter available for the next cycle of endocytosis. This mechanism 
of endocytosis has been exploited to deliver various substances into the cell including 
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cytotoxic drugs in malignancy.  CD-71 conjugates with chemotherapy agents such as 
gemcitabine, daunorubicin, doxorubicin and cisplatin have shown to increase the 
chemotherapy toxicity in the cancer cells compared to the chemotherapy alone. The 
therapeutic window of cytotoxic drug was also increased due to the lack of cytotoxicity in 
normal cells. The Tf-doxorubicin conjugate can overcome the resistance to doxorubicin in 
human oral carcinoma cells. (Fritzer, 1996) Modified Tf-doxorubicin conjugates reversed the 
resistance of MCF-7 human breast cancer doxorubicin resistant cells where doxorubicin was 
found sequestered in cytoplasmic vesicles. (Wang, 2000) Cisplatin-Tf conjugate showed 
some responses in advanced breast carcinomas. Treatments with CD-71 ligand targeted toxin 
conjugate (Tf-CRM107) showed some complete and partial responses in malignant glioma 
patients. (Weaver, 2003) (Laske, 1997) Therefore the analysis of CD-71 expression in the 
breast cancer tissue can be of benefit for both prognostic and therapeutic purposes. 
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PDGFR-α 
 
PDGFRs are dimeric molecules consisting of alpha and beta sulfate bonded chains. They 
have an extracellular region with five immunoglobulin-like domains, a transmembrane 
region, an intracellular region with a regulatory juxta membrane domain, and a catalytic 
tyrosine kinase domain. PDGFRα had been found to play a major role in growth factor 
signalling pathways in various cancers. The binding of ligand Platelet Derived Growth 
Factors (PDGFs) to PDGFR induces dimerization of the receptor leading to auto-
phosphorylation of tyrosine residues and stimulation of kinase activity with subsequent 
activation of downstream intracellular cascades RAS/RAF/MAPK, PI3K/AKT and STATs, 
that regulate cell proliferation, differentiation, migration and survival. Vascular Endothelial 
Growth Factor A (VEGF-A) can activate both PDGFRs. (Ball, 2007) Activated PDGFRs 
interact intracellularly directly with components from different PDGFRs and their ligands 
and form various autocrine and paracrine loops for activation. Autocrine PDGFR stimulation 
has been well documented in various tumours including breast cancers. (Jechlinger, 2006)  
There are 4 different PDGFs that contain one of four different polypeptide chains: PDGF-A, 
PDGF-B, PDGF-C and PDGF-D. The chains are linked with amino acid disulphide bonds to 
form homo or hetro dimers. PDGF expression has been reported in various neoplasms 
including glioblastomas, ovarian, prostate and up to 90% of breast cancers. High level of 
PDGF in breast tumours has been shown to correlate with the high invasiveness, low 
response to chemotherapy and decreased survival. PDGF-BB is reported to be important for 
the cancer cells to metastasise to the bones. (Lev, 2005) Reduction in cell migration and 
proliferation had been observed following the blockage of PDGF activities. (Ball, 2007)  
PDGFRs are expressed on erythroid and myeloid precursors in the bone marrow, monocytes, 
megakaryocytes, fibroblasts, endothelial cells, osteoblasts and glial cells. In malignant 
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tissues, it was also found to be expressed in the stromal tissue including pericytes that support 
blood vessels. (Ostman, 2004) Aberrant or over-expression of PDGFRs is associated with a 
variety of disorders including atherosclerosis, fibrotic disease and neoplasia. Aberrant activity 
of PDGFR and their ligands have been reported in gastric, prostate, lung, melanomas, ovarian 
and colorectal cancers, (Drescher, 2007) (Ebert, 1995) (Antoniades, 1992) (Wehler, 2008) 
and it was associated with poor outcomes. PDGFR-α mutations had also been reported in 
some tumours such as GISTs (exon 12 and 18) lacking c-Kit mutation and glioblastomas 
(amplification of PDGFR-α genes). (Joensuu, 2005)  PDGFR-α was associated with 
increased cell proliferation in some non-small cell lung carcinomas and rhabdomyosarcoma 
cell lines. (McDermott, 2009)  
In human colorectal cancer, PDGFR-α, PDGFR-β and co-expression were found in 83%, 
60% and 57%, respectively, of cases. PDGFR-α was mainly found in the cytoplasm of cancer 
cells and pericytes. PDGFR α and β expressions are significantly correlated with the lymph 
node metastasis and advanced UICC stages III/IV in older patients. (Wehler, 2008) PDGFRα 
expression was found in high frequency among metastatic prostate cancer cells taken from 
the bone. (Chott, 1999) (Ko, 2001) (Dolloff, 2007) More than 70% of hepatocellular 
carcinoma (HCC) tissues had elevated PDGFR-α. Its inhibition significantly affected HCC 
cell survival by modestly reducing the proliferation suggesting PDGFR-α’s main function is 
for the survival rather than the proliferation. (Stock, 2007) 
Invasive breast carcinomas expressed cytoplasmic staining of PDGFR-α in 65% and PDGFR-
β in 75% of samples. (Jechlinger, 2006) Endothelial cells of breast cancer tissues express 
more PDGFR-β than PDGFR-α compared to the endothelial cells of normal breast tissue. 
(Carvalho, 2005) However, no objective responses to treatement with Imatinib were observed 
among the 13 metastatic breast cancer patients with PDGFR-β overexpression. 
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(Christofanilli, 2008) Imatinib is believed to exert its function in non-small cell lung cancer 
through the PDGFR-α. (Zhang, 2003)  
Inhibition of PDGFR-α signalling by siRNA, small molecule inhibitor or neutralizing 
antibody has been shown to have anticancer effect in various cancers including GISTs, 
ovarian cancer, non-small cell lung cancer, rhabdomyosarcoma, mudalloblastoma, breast 
cancer and prostate cancer both in vitro and in vivo. But the resistance developed in one third 
of rhabdomyoblastomas in one study. (McDermott, 2009) (Taniguchi, 2008) (Armistead, 
2007) (Schneider, 2005) Tyrosine kinase inhibitors such as Sunitinib can inhibit many 
proteins such as VEGFR-2, PDGFR-α, PDGFR-β, and fibroblast growth factor receptor 1 
(FGFR1) tyrosine kinases involved in PDGFRs signalling cascade. 
 
 
PDGFR-α signalling in glioma cell (Borrowed from the published article by Feng, 2012)  
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VEGFR-2 
 
Angiogenesis is one of the major pathways involved in the pathogenesis of malignancy. One 
of the key components of this pathway is vascular endothelial growth factor receptors 
(VEGFRs), which upon binding with its ligand vascular endothelial growth factor (VEGF) 
produce a cascade of signals for cell proliferation and angiogenesis. VEGF is produced by 
many tumour cells and positively regulated by cytokines, activation of oncogenes, loss of 
tumour suppressor genes and hypoxia.There are mainly two VEGFRs – VEGFR-1 (flt-1) and 
VEGFR-2 (KDR/flk-1). These tyrosine kinase receptors promote cancer cell growth 
indirectly through the stimulation of microvascular endothelial cells and directly by 
stimulating tumour cells in an autocrine fashion. Activation of VEGFR-2 alone is sufficient 
to elicit all proangiogenic, proliferation and survival effects associated with VEGF indicating 
its dominant role over VEGFR-1. (Gille, 2001) 
VEGFR-1 and VEGFR-2 expressions have been widely reported in endothelial cells, bone 
marrow derived elements and various cancers. VEGFR-2 was found to be 3 to 5 folds higher 
in the endothelial cells of tumour vasculature compared to the normal tissue vasculature.  
VEGFR-2 and VEGF-A are found to express together in several malignant epithelial cells 
such as prostate, breast, pancreas and stomach. (Takahashi, 1996) (von Marschall, 2000) 
(Kollermann, 2001) (Ryden, 2003) The VEGF level was found to be higher than VEGFR-2 
level. (Dias, 2001) (Ferrer, 1999) High expression of VEGFR-2 was also reported in 
colorectal, renal and genitourinary cancers. (Giatromanolaki, 2007) (Heng, 2007) (Pouessel, 
2008)  
VEGFR-2 dimerises upon activation by VEGF and auto-phosphorylates in the cytoplasmic 
kinase domain. (Kendall, 1999) This phosphorylation triggers a cascade of events through 
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Raf/Mek/Erk, PI3K/Akt and PI3K/Akt/nitric oxide pathways, leading to endothelial cell 
proliferation, migration, apoptosis inhibition, maturation of vascular structures and vascular 
permeability. Blocking VEGF/VEGFR signal pathways inhibits tumour growth by decreasing 
the vascular density and subsequent cell death by apoptosis. (Des Guetz, 2006) The function 
of VEGFR-1 is not well established but it has been reported to induce protease activity in 
endothelial cells and stimulate the migration of macrophages into the tumour tissue. 
However, it has no effect on the proliferation. (Veikkola, 2000) 
In breast cancers, VEGF, VEGFR-1 and VEGFR-2 all showed a predominantly 
membrane/cytoplasmic distribution in the tumour, and their high levels were significantly 
associated with poor survivals in the univariate analysis. (Ghosh, 2008) VEGF stimulates the 
proliferation of VEGFR-2 positive tumour cells; promotes the survival via the expression and 
activity of Bcl-2; and overrides the growth suppressive effects of anti-hormones. (Liang, 
2006) 17β-estradiol (E2) was found to induce VEGFR-2 expression in ERα-positive ZR-75 
breast cancer cells. (Higgins, 2006) Tamoxifen decreases VEGFR-2 expression more in the 
ER/PR negative cancers compared to ER/PR positive cancers. (Garvin, 2005) In patients with 
ER positive and VEGFR-2 low tumours, adjuvant tamoxifen significantly increased the 
recurrence free survival. But tamoxifen was found to have no effect in VEGFR-2 highly 
expressed tumors. In multivariate analyses, this VEGFR effect on the tamoxifen efficacy was 
seen in all hormone receptor positive cancers. (Ryden, 2005) 
High VEGFR-2 expression was correlated with other poor risk factors such as VEGF, p38 
MAPK, negative ER, triple negative cancers, larger tumours, nuclear grade 3, distant 
metastasis, shorter RFS and breast cancer specific survival.  High intratumoral level of 
VEGFR-2 was suggested to be predictive of an intrinsic resistance to the adjuvant endocrine 
therapy. (Linderholmn, 2011) (Ryden, 2010)  
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 90 
 
In combination with anti-VEGFR-2 antibody DC 101, metronomic chemotherapy (one tenth 
of maximum tolerated dose) with doxorubicin, vimblastin, taxane and cisplatin  showed a 
significant breast cancer cell death in a xenograft model, even in the absence of the tumour 
shrinkage, that contain high level of P-glycoprotein and multi drug resistance protein against 
which chemotherapy alone failed to show any effectiveness. (Klement, 2002)  
The VEGFR inhibitors such as vandetanib, sorafenib and sunitinib had been successfully 
tested in various cancers.  Objective tumour response with oral tablet vantenatib was seen in 
refractory non-small lung cancer patients. (Tamura, 2006) (Holden, 2005) VEGFR-2 
antagonist peptid, GU81, was found to enhance the anti-tumour activity of doxorubicin in 
spontaneous murine MMTV-PyMT breast tumours. (Lynn, 2010) In a phase II study, single-
agent sunitinib revealed 14% response rate in breast cancers resistant to anthracycline and 
taxane. (Miller, 2005) More than three-fold increases in VEGF relative to the baseline, and 
decreases in soluble sVEGFR-2 levels by 30% in at least 88% of the patients treated with 
sunitinib had been reported. VEGF and VEGFR-2 levels returned to the baseline after 2 
weeks off treatment. (Deprimo, 2006) 
The addition of tamoxifen to epirubicin showed a significant reduction in VEGF expression 
in T2-4, N0-1 breast cancer patients in the neoadjuvant setting while epirubicin alone failed 
to do so. However, VEGFR-2 expression in the residual caner tissue was found to have 
increased from the base line level.  The decrease in the VEGFR-2 expression was 
significantly associated with the response rate. This data suggests a potential synergism of 
these two drugs. (Mele, 2010) In a small study consisting 21 patients with the inflammatory 
and locally advanced breast cancers, a treatment with bevacizumab was found to be 
associated with a median decrease of 66.7% in phosphorylated VEGFR-2 (Y951) in tumour 
cells and a median increase of 128.9% in the tumour apoptosis. There were no significant 
changes in the microvessel density or VEGF-A expression. (Wedam, 2006) 
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VEGFR-2 expression by IHC was not associated with the better survival outcome in breast 
cancer patients treated with neoadjuvant VEGF inhibitor bevacizumab in combination with 
doxorubicin and docetaxel chemotherapy compared to chemotherapy alone.  (Yang, 2011) 
Adding gefitinib to pre-operative chemotherapy paclitaxel and epirubicin in early breast 
cancers did not result in any different effects on the EGFR dependent pathway, proliferation, 
apoptosis and the VEGFR-2 expression as compared to the placebo.  (Guarneri, 2008) 
 
 
                               
VEGFRs pathway (Illustration borrowed from <pubmed>16104843</pubmed> 
[http://www.clinsci.org/cs/rights.htm Copyright) 
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EGFR, PDGFR and VEGFR pathways and their inhibitors (Borrowed from the published 
article by Argyriou, 2009) 
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GSTM-1 
 
Glutathione S-transferases (GST) are phase 2 metabolising enzymes involved in catalysing 
detoxification of electrophilic compounds including carcinogens, therapeutic drugs (eg. 
alkylating agents and platinum compounds), environmental toxins and products of oxidative 
stress for subsequent removal from the body. Failure to clear electrophilic carcinogenics 
could lead to the DNA damage and subsequent carcinogenesis.  Variations within GST genes 
can cause a loss or reduction in the enzymatic activity and have been associated with the 
increased risk of several cancers. Elevated DNA adducts, sisterchromatid exchanges and 
somatic genetic mutations have been demonstrated in carriers of some null GST genotypes. 
(Rebbeck, 1999) 
GSTs are divided into four classes - Alpha, Mu, Pi and Theta - based on the protein sequence 
similarities. At least five distinct GST-Mu (GSTM 1 - 5) isoforms have been described. 
GSTM-1 is the dominant isoenzyme among them and the biophysiological functions of the 
other isoenzymes may become conspicuous only when GSTM-1 is absent. The most reported 
GSTM-1 polymorphism is a gene deletion variant, known as GSTM-1- null (GSTM1-/-) with 
a complete absence of GSTM-1 enzyme activity.  
The GSTM-1 and GSTT-1 null genotypes have been linked to the increased risk of 
developing cancers in lung, bladder, stomach, bowel and skin. (Setiawan, 2000) (Katoh, 
1996) (Gao, 2002) (Choi, 2003) (Epplein, 2009) (Inoue, 2001) (Piao, 2009) (Carlsten, 2008) 
There are also studies that reported no association between the null genotype and cancers of 
lung, colorectal, breast, prostate and oesophagus. (Welfare, 1999) (Sivonova, 2009) 
(Lavender, 2009) (Zhou, 2009) Some studies suggested that GSTM-1 polymorphism alone 
did not increase the risk of colorectal cancer but together with GSTM-3 polymorphism it 
increased the risk of distal colon cancer. (Loktionov, 2001)  
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A meta-analysis on 59 studies involving 20,993 cases and 25,288 controls, significantly 
elevated breast cancer risk was found to be associated with GSTM-1 null genotype (Odd 
Ratio = 1.10, 95% CI = 1.04–1.16). The increased risk was noted in Caucasians, Asians and 
postmenopausal women. The author concluded that GSTM-1 null genotype was a low-
penetrant risk factor for developing breast cancers. (Qiu, 2009) Combined effect of all three 
GSTT-1, GSTM-1, and GSTP-1 polymorphism have been reported to have > 3-fold increase 
in the breast cancer risk compared with the common genotypes. (Helzlsouer, 1998) (Steck, 
2007) 
However, Kadouri et al reported GSTM-1 null genotype to be associated with the low breast 
cancer risk although it was not statistically significant and it did not increase the risk of breast 
cancer in BRCA carriers. (Kadouri, 2008) (Spurdle, 2009) Null GSTM-1 gene was found not 
to be associated with the increased risk of breast cancer among postmenopausal women who 
used HRT.  (The Marie-Genica consortium, 2010) When GSTM-1 gene was present, no 
Single Nucleotide Polymorphism (SNP) or haplotypes in the GSTMs cluster conferred 
conspicuous risk to the breast cancer.  (Yu K-D, 2010) No increased risk of breast cancer was 
found among smokers with GSTM-1 null genotype although the absent GSTM-1 activities 
should have led to the lack of inactivation of polycyclic aromatic hydrocarbons from 
smoking. (McCarty, 2009) A SNP in the promoter region of GSTM-3 gene had a strong 
association with breast cancers when GSTM-1 was genetically deleted. Null GSTM-1 was 
reported to be associated with a better response to neoadjuvant chemotherapy in stage 2 and 3 
breast cancers. (Oliveria, 2010)  
Correlations between the risk of breast or other cancers and GSTM-1 protein expression by 
immunohistochemistry have never been studied.
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Cathepsin L2 
 
Cathepsins - meaning “to digest” in Greek - are lysosomal cystein proteases, a family made 
up of 11 different types - B, C, F, H, K, L, O, S, V ,W,  and X/Z. Most cathepsins are 
endopeptidases whereas some are exopeptidase. Most cathepsins have a property of 
catalysing the cleavage of peptide bonds in the proteins in the majority of cell types. They 
play a role in a variety of intracellular and extracellular processes including antigen 
presentation, pro-hormone activation, sperm maturation and bone resorption. The activity of 
cathepsins is regulated by the balance between their endogenous inhibitors and the activators 
of their inactive precursors. Over-expression of cathepsins has been reported to be involved 
in glomerulonephritis and osteoarthritis. Cathepsins promote tumour invasion and metastasis 
by degrading components of the extracellular matrix especially the basement membrane, 
helping cancer cells to invade the surrounding tissues, lymphatic and blood vessels to 
metastasise. Cathepsins were also significantly correlated with UPA and PAI-1 enzymes that 
played an important role in the metastasis. (Herszenyi, 1999)  
Cathepsin L2, also known as Cathepsin V, has a high sequence homology to Cathepsin L. It 
is encoded for by CTSL2 gene located on the chromosome 9q21-22 which is the same site as 
Cathepsin L. The sequences of the two enzymes are quite similar sharing 80% of the identity. 
Cathepsin L2 is predominantly expressed in the thymus, testis and cornea. Although 
Cathepsin L has been extensively studied in various cancers, Cathepsin L2 expression has not 
been studied for its prognosis and predictive outcomes in cancer patients.  
Cathepsin L has been reported to be upregulated in a variety of malignancies including 
breast, lung, gastric, colon, ovary, head and neck carcinomas, melanomas and gliomas but not 
in normal or peri-tumoural tissues.  (Santamaria, 1998) Cathepsin L is functionally active in 
the acidic environment. The acidification of tumour environment by the increased anaerobic 
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glycolysis in cancer cells is believed to promote the activities of Cathepsin L to degrade 
components of extracellular matrix such as collagens, fibronectins and laminins for 
subsequent metastasis. High expression of cathepsin L was found to be associated with 
deeper invasions (muscularis propria vs. mucosa) and venous invasions in gastric cancers. 
(Dohchin, 2000) Oral mucosal dysplasia with overexpressed cathepsin L is found more likely 
to progress to oral cancer than the dysplasia with no overexpression. (Macabeo-Onga, 2003) 
Urinary Cathepsin L level is found to be predictive of the presence and invasiveness of the 
bladder cancer. (Svatek, 2008)  High blood level measured by ELISA is reported to be 
associated with a poor prognosis in colorectal cancers. (Herszenyi, 2008) 
Cathepsin L was reported to be a poor prognostic factor for breast cancer recurrence that was 
comparable to the nodal status and the tumour grade both in node positive and negative 
cancers. It was inversely correlated to the hormone receptor status and the tumour necrosis. 
(Thomssen, 1995) (Lah, 2000) In a study of 276 breast cancer patients (52 = chemo; 95 = 
endocrine; 9 chemo + endocrine; 119 = no adjuvant therapy) with a median follow up of 109 
months Cathepsin L was found to be prognostic of DFS and OS in all patient groups. In node 
positive patients, Cathepsin L was the only prognostic factor for DFS and OS. (Harbeck, 
2001) This suggests that Cathepsin L is a prognostic rather than a predictive factor. 
By using genetically modified antisense cDNA, Cathepsin L mRNA and protein expression 
level and subsequently, metastatic tumour development can be decreased. (Lah, 2006) Many 
drugs such as Thiosemicarbazone analouges and small molecules (peptidic compounds such 
as thiocarbazate, aldehyde, epoxide, nitrite, cyanopyrrolidine; and non-peptidic compounds 
such as azepanon, cyanamides and Cathepsin L specific CLIK-148) have been developed as 
cathepsin inhibitors. (Kumar, 2010) Down regulation of Cathepsin L by its antisense cloning 
showed decreased effects on the invasiveness of murine melanoma (Yang, 2007) and human 
glioblastoma cells. (Zajc, 2006) Cathepsin L specific inhibitor CLIK-148 could prevent the 
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cancer induced hypercalcemia and bone metastases. (Katunuma, 2002) However, some 
studies suggested that when Cathepsin L was inhibited by its specific inhibitors, its function 
may be compensated by other Cathepsins. (Hagemann, 2004) 
Cathepsin L has been shown to play a major role in the sequestration of drugs. Therefore, 
inhibition of Cathepsin L may enhance the chemotherapeutic agents reaching the nucleus 
increasing the therapeutic ratio. (Lah, 2006) (Rebbaa, 2005) (Zheng, 2009) Inhibition of 
Cathepsin L might delay the cell cycle progression to the S phase (Goulet, 2007) or induce 
the senescence (Zheng, 2004) or apoptosis. Combination of chemotherapy and Cathepsin L 
inhibitor (Z-FF-FMK) was able to induce the senescence in various murine and human drug 
resistant cancer cell lines. (Zheng, 2004) (Levicar, 2003) Transfection with Cathepsin L 
siRNA also could reverse the drug resistance. In vivo, a combination of chemotherapeutic 
drugs with either broad-spectrum or Cathepsin L specific inhibitors showed favourable 
results. (Bell-McGuinn, 2007) (Zheng, 2009)  However, the findings were not consistent and 
one study paradoxically reported a 50% increase in the tumour burden as compared to the 
chemotherapy alone. (Zhanaeva, 2005) 
Some studies suggested that Cathepsin L induced the apoptosis by cleaving Bid - a Bcl-2 
family member - (Stoka, 2001) resulting in the release of Cytochrome C from the 
mitochondria. (Green, 1998) Yet, there was no conclusive data to confirm if Cathepsin L was 
a pro or antiapoptotic protein. (Di Piazza, 2007) (Gocheva, 2006) (Navab, 2008) 
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Functional roles of Cathepsin L in cancers (Borrowed from the published article by 
Lankelma, 2010) 
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7.0 Objectives 
 
Metastatic breast cancer is incurable. Adjuvant chemotherapy can increase the number of 
patients who can be cured of breast cancer by preventing or abrogating the metastasis. Breast 
cancer mortality has declined over the last decade due to the early diagnosis through 
screening programmes and better treatments. (Sant, 2006) Although it has been suggested 
that this improvement is partly due to a “lead time bias” from the early diagnosis of screen 
detected low risk cancers that would never become detectable clinically in the lifetime of an 
individual, there is evidence suggesting the overestimate due to the potential “lead time bias” 
is actually very small. (Jonsson, 2007) (Seigneurin, 2011) Despite significant advances in the 
adjuvant treatments for breast cancer, a large number of women still continue to relapse and 
die each year from breast cancer. To push the current survival successes to the next level, it is 
of paramount importance to identify patients who are at especially high risk of cancer 
recurrence and death despite adjuvant therapies, so that novel treatments can be explored for 
this group of patients. Because of potential toxicities, the oncology community has focused 
its efforts on selecting patients in whom adjuvant chemotherapy could be safely omitted or 
patients with a certain level of risk for which toxic chemotherapies are justified. In contrast, 
this study aims to identify patients in whom adjuvant chemotherapy is most likely to fail. 
Alternative treatments through participation in clinical trials will be most appropriate for 
them to improve their survival outcomes.  
Current prognostic tools that based on clinicopathological features and genes/protein 
expression profilings aim to evaluate prognostic risks to aid making decision on adjuvant 
chemotherapy. Analysis of protein expression at the tissue level for this purpose will be 
cheaper and quicker than gene expression analysis. It is also more sensible to analyse the 
phenotypic profile of a cell through the proteins that are directly involved in the cellular 
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processes and test the benefit of targeting these proteins with novel therapeutic agents. 
Therefore this study evaluates the expressions of a panel of proteins that would appear to play 
a vital role in different cellular pathways essential to therapeutic resistance.  
The following hypotheses are made based upon our understanding of these cellular proteins: 
1. The group of patients that will relapse within 5 years of adjuvant chemotherapy (or)  5 
years relapse free survival and/ or overall survival benefit could be predicted by analysis 
of expression of a panel of: 
a. proteins identified from the literature for molecular sub type profiling 
b. proteins coded for by genes used in Oncotype Dx gene prognostic assay  
c. proteins involved in the angiogenesis pathway 
d. proteins involved in cell cycle phase progression 
2. Combined analysis of above proteins from key molecular pathways will be able to 
indicate the strongest candidates for future evaluation via therapeutic means, in clinical 
trials. 
3. Integration of molecular markers and conventional clinical and pathological features 
might have stronger predictive power.   
The different expression patterns of biomarkers in patients with different relapse free and 
overall survival periods may indicate the chemotherapy ineffectiveness (predictive effect) or 
unfavourable tumour biology (prognostic effect) or both as was the case in most biomarkers. 
This information is expected to be at least useful for hypothesis generation and the further 
research for better treatments. 
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8.0  Methods 
 
Study design, study population and clinical data collection 
This is a matched case controlled study. Cases are patients who had breast cancer recurrence 
(local or distance) within 5 years of curative surgery for early breast cancer (either wide local 
excision or mastectomy) followed by adjuvant chemotherapy. A period of 5 years was chosen 
because the main benefits of adjuvant chemotherapy for recurrence emerge during the first 5 
years after the treatment. (EBCTCG, 1998) Recurrence was defined as the first reappearance 
of breast cancer at any site (local, contralateral or distant), as is customary in the clinical 
literature (for example EBCTCG, 1998). Patients in the “case” group had the breast surgery 
between January 1998 and October 2008. Controls were selected to be the patients who 
remained free of recurrence for a minimum of 5 years following curative surgery and 
adjuvant chemotherapy. This study started in 2008. To achieve minimum of 5 years relapse 
free survival, only patients who had their curative surgery before December 2003 could be 
selected. The patients selected for the control group had their curative surgery between 
August 1996 and December 2003. All patients received adjuvant radiotherapy and endocrine 
therapy appropriately as per standard practice at that time. All the patients were treated in a 
single cancer centre although the surgeries were done in 3 different hospitals and the 
chemotherapies were delivered on two sites within the network. The controls were matched 
to the cases for the 10 years recurrence risk (RR) according to “Adjuvant!” tool. 
(www.adjuvantonline.com) Controls have positive nodal status and RR at least 50%. Each 
control should have RR not more than 10% point lower than the matched “case”. This is to 
increase the chances of finding unknown prognostic/ predictive factors. As a low risk second 
control, patients with recurrence risk <50% (with positive nodes) were selected in a ratio of 2 
cases to 1 low risk control. The patients in this group had their curative surgery between May 
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1996 and October 2003. Eligible patients were identified from the department database. All 
patients whose paraffin embedded tissue blocks were available were screened for best 
matching and selection. Where there was more than one control available for a case, the 
control that most closely resembled the case in terms of known risk factors was selected. 
Type of surgery, adjuvant chemotherapy, endocrine therapy, survival data and pathological 
features were collected from the hospital case notes. Disease free status and survival status 
were confirmed by the records of patients’ attendance at hospital clinics and the primary care 
surgeries. 
During the study period, new prediction tool “OPTION” became available. The “OPTION” 
tool offers 5 years and 10 years recurrence risk before and after adjuvant therapies. The 
recurrence risks according to OPTION tool were calculated and analysed to verify that cases 
and controls were well matched according to the recurrence risk.    
Local ethic committee reviewed and approved the study. The comittee agreed that obtaining 
consent from the individual patient for the use of cancer tissues was not feasible as most of 
the patients in the “cases” group were already deceased. Also some of the patients in the 
“control” group had moved to different areas.  
 
Construction of tissue microarrays blocks 
H & E slides were prepared from the archived FFPE pathology blocks. The areas that 
contained invasive cancers and were suitable for this study were marked on the H & E slides 
with the help of an experienced pathologist. 0.6 mm cores were taken from the blocks 
corresponding to the marked areas. A total of 3 cores, if possible, were taken from different 
areas of each block. The cores were transferred to the recipient paraffin blocks and tissue 
microarrays blocks were constructed manually using Beecham® tissue micro-arrayer.  
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Immunohistochemistry  
Each TMA block was cut into 4µm thick sections and mounted on to the Superfrost Plus® 
glass slides.  IHC staining was carried out using Ventana BenchMark XT automated staining 
machine. It is a fully automated slide preparation system. The slide kinetics have been 
optimised through the precisely controlled reaction environment of the BenchMark staining 
module with Air Vortex Mixers, Liquid coverslip, heater pad, and the E-Bar code slide label 
system. Air-Vortex Mixers blend the aqueous layer under the Liquid Coverslip, mixing 
reagents and ensuring uniform reaction kinetics across the entire surface of the slide, 
controlling evaporation and protecting tissue integrity. The individual slide heater pads 
provide highly precise heating across the entire surface of each slide. The clone and dilution 
of antibodies, antigen retrieval methods are as shown in the table. The procedure is as follow: 
1. Formalin Fixed Paraffin Embedded TMA blocks were cut into 4 micron thick sections 
and mounted onto Superfrost Plus® slides (Visions Biosystems, Newcastle Upon 
Tyne, UK).  
2. The slides were dewaxed in EZ preparation (Ventana catalogue no. 950-100) at 75º C 
for 4 minutes and 76º C for 4 minutes and rehydrated with buffer solution. 
3. Antigen retrieval was performed by heating the slides to 100º C in buffer cell 
conditioner solution (CC1) for the specified duration which is shown in the table 
below for each antibody. The CC1 Solution is composed of 
Ethylenediaminetetraacetic acid 0.04%, Tris (Base) 0.12%, Boric Acid 0.05%, water 
and other ingredients that are below detectable level.   
4. For EGFR, the slide was incubated with protease 1 enzyme for 8 minutes, and then 
heated to 37º C for 4 minutes.  
5. I-View inhibitor (hydrogen peroxide 1.1%) was applied to block the endogenous 
peroxidise activity. 
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6. The slides were incubated with primary antibody for specified duration and 
temperature which is shown in the table below. 
7. 0.6% gluteraldehyde was applied to fix the antibody binding to the protein. 
8. Amplifier was applied to increase the signal intensity of staining. Avidin Blocker was 
applied to bind to endogenous excess biotin present in the tissue block to reduce non-
specific staining caused by endogenous biotin present in cells and tissues. Biotin 
Blocker saturates the remaining binding sites of Avidin Blocker. 
9. I-View Biotin Ig (Biotinlyated Ig) was applied as secondary antibody.  
10. I-View Streptavidin-HRP conjugate was applied to replace the complex of avidin-
biotin peroxidase. 
11. The slide was incubated with I-View DAB (3,3' diaminobenzidine tetrahydrochloride) 
chromogen and its activator I-view H2O2 (DAB activator), which results in a dark 
brown precipitate at the antigen site.  
12. I-View copper was applied for background colour of yellow.  
13. The slides were counterstained with Haematoxylin & Eosin to visualize the nucleus.  
14. The slide was then washed in Scotts tap water, dehydrated using alcohol, made clear 
using xylene and then the coverslip was mounted using DPX.  
15. As positive controls, breast cancer tissue composites (cancer tissues with known 
expressions status - low, medium and high) were used for ER, PR, HER-2; Tonsil for 
Ki-67, MCM-2, Aurora A, CD-68 and Bcl-2; skin for CK 5/6 and EGFR; colon for 
PDGFR-A. 
16.  Negative controls were done by omitting primary antibodies. 
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IHC protocol for Bag-1 and CD-71 
For CD71 and Bag-1 proteins, manual staining technique was used as described below. 
1. Sections are collected onto Surgipath X-tra adhesive slides and dried at 37° C 
overnight prior to assay. Breast cancer tissues with known positive expression for 
Bag-1 and CD-71 were used as positive controls. The slides were dewaxed with 
xylene and rehydrated through graded alcohol and water as below: 
a. Xylene   1 x 20 minutes 
b. Xylene   1 x 10 minutes 
c. 100%  Ethanol 2 x 2 minutes 
d. 90%  Ethanol 2 x 2 minutes 
e. 70% Ethanol 2 x 2 minutes 
f. Distilled water 1 x 5 minutes 
g. PBS   1 x 5 minutes 
2. Endogenous peroxidises activity was blocked by applying 3% hydrogen peroxide 
solution to the sections for 5 minutes. Then the slides were rinsed using distilled water 
for 5 minutes. To retrieve the antigen, the slides were heated in pH6 sodium citrate 
buffer solution in the pressure cooker for 1 minute for Bag-1 protein and microwave 
for 23 minutes at 560 watts for CD-71 protein. The slides were cooled under running 
tap water for 10 minutes. 
3. To block binding interaction of antibody to non-specific sites 0.02% PBS/Tween was 
applied for 5 minutes. Excess block from the sections was wiped away before 
applying primary antibody.  
4. Primary antibody was applied as below.  
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a. CD-71 (Mouse monoclonal IgG2: 10F11 Abcam) 1/30 in 0.1% BSA. PBS for 
75 minutes at temperature 23° C 
b. Bag-1 (Mouse monoclonal IgG1; SC56003 Santa Cruz) 1/150 in 0.1% BSA. 
PBS for temperature, 23° C duration overnight.  
The slides were then washed in PBS for 1 x 3 minutes, PBS/Tween 2 x 5 minutes.    
5. Dako mouse EnVision HRP-labelled polymer was applied to the sections for 45 
minutes at room temperature. The slides were then washed in PBS for x 3 minutes and 
PBS/Tween 2 x 5 minutes. 
6. Dako DAB K3468 chromogen was applied to sections for 8 minutes to give dark 
brown colour to the antigen antibody complex. The slides were then rinsed in distilled 
water 2 x 3 minutes. 
7. The sections were counterstained with haematoxylin. The slides were then ‘blued’ 
under gently running tap water, air dried and covered with coverslip using DPX 
mountant. 
8. Breast cancer tissue and cell lines with known expression status were used as positive 
controls. 
9. Negative controls were performed by omitting primary antibodies. 
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Verification of specificity and sensitivity of antibodies used for IHC 
 
Antibodies for ER, PR, EGFR, HER2, Bcl-2, CK 5/6, CD68 and Ki67 are for in vitro 
diagnostic use and antibodies for Aurora kinase A, MCM-2, CD-71, PDGFR alpha and Bag-1 
are for research purpose only. IHC staining was carried out as per manufacturers’ instructions 
and as per previous publications. Optimal staining protocol was achieved by staining serial 
tissue sections with different dilutions of antibody, different antigen retrieval conditions 
(heating method, temperature, duration, buffer solutions etc), different incubation periods 
with the antibody, use of enhancers such as AB block to minimise excess biotin and amplifier 
to magnify the signals, and negative controls by omitting primary antibodies. For specificity 
and sensitivity quality assurance, tissues or cell pellets with known negative, low, medium 
and high expression status were used as external controls. The staining of control sections 
were checked and compared with that of the previous analysis to detect minor variations in 
the staining intensity. When a decreased intensity was observed, the procedure was repeated. 
The negative tissue controls were examined after the positive tissue controls to verify the 
specific labelling of the target antigen by the primary antibody. The presence of an 
appropriately coloured reaction product within positive control cells is indicative of positive 
reactivity. The absence of specific staining in the negative tissue control confirms the lack of 
antibody cross reactivity to cells or cellular components. Also the cores on the TMA acted as 
internal controls. 
IHC assays for MCM-2, CD-71 and Bag-1 were already developed previously for similar 
research projects. IHC assays for PDGFR alpha and Aurora kinase 2 were developed by 
using colon and tonsil tissues, respectively, as positive control tissues as per manufacturer’s 
instructions. Optimisation was done as described above. 
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Monoclonal antibodies used in this study, the antigen they specifically bind to, 
manufacturers’ recommended dilution and the references are shown in the table below. 
Manufacturer Antibody clone Specificity 
Recommended 
dilution 
References 
Leica 6F11 
Nuclear ER 
alpha 
1:40 – 1:80 Bevitt, 1997 
Leica 
16 
(NCL-PGR-
312) 
Nuclear PR 
alpha 
1:100 – 1:200 Bevitt, 1997 
Ventana 4B5 
c-erbB-2 protein 
internal domain 
Pre-diluted Akiyama, 1986 
Ventana 3C6 
EGFR protein 
external domain 
Pre-diluted 
Ventana data 
sheet, Cat no. 
790-2988 
Leica MM1 
Human Ki-67 
nuclear antigen 
1:200 
Leica data sheet, 
product code 
NCL-L-Ki67-
MM1 
Dako D5/16 B4 
Isolated 
cytokeratin 5 
and 6 
Pre-diluted Otterbach, 2000 
Dako 124 
Bcl2 
oncoprotein 
1:50 – 1:100 Hirakawa, 1996 
Santa Cruz 3.10G3E2 
Human Bag 1 
protein 
1:50 – 1:500 Millar, 2009 
Novocastra CRCT2.1 
Human MCM2 
protein 
1:100 Ishimi, 1998 
Leica JLM28 
Human Aurora 
Kinase 2 
1:50 Bishoff, 1998 
Abcam ab61219 
Total PDGFR 
alpha protein 
1:50-1:100 Chan, 2010 
Dako PG-M1 
Macrophage 
CD-68 antigen 
1:50 – 1:100 Falini, 1989 
Abcam 10F11 CD-71 protein - Habashy, 2010 
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Antigen retrieval methods and antibody incubation conditions (*In Vitro Diagnostic 
assays) 
 
Protein 
Antigen retrieval Method 
Temperature and duration 
Antibody incubation    
Temperature and Duration 
Optimised 
dilution 
ER 100 °C; 60 min in CC1 solution* 37°C; 36 min 1:30 
PR 100 °C; 60 min in CC1 solution* 37°C; 36 min 1:100 
HER2 100 °C; 60 min in CC1 solution* 37°C; 36 min Pre-diluted 
EGFR 
Portease 1 at room temperature x 
8 min; 37 °C for 4 min* 
37°C; 36 min Pre-diluted 
Ki-67 100 °C; 60 min in CC1 solution* 40°C; 32 min 1:20 
CK-5/6 100 °C; 60 min in CC1 solution* 37°C; 32 min 1:50 
Bcl-2 100 °C; 60 min in CC1 solution* 37°C; 36 min 1:50 
Bag-1 
Pressure cooked in pH6 Na 
Citrate for 1 min at boiling 
temperature 
23 °C; over night 1:150 
MCM-2 100 °C; 60 min in CC1 solution 40°C; 44 min 1:30 
Aurora A 100 °C; 60 min in CC1 solution RT; 48 min 1:50 
PDGFR-α 100 °C; 60 min in CC1 solution RT; 48 min 1:100 
CD-68 
100 °C; 300 min in CC1 
solution* 
37°C; 24 min 1:50 
CD-71 
Microwave  in pH6 Na Citrate 
for 23 minutes at 560 watts 
23° C; 75 min 1:30 
Cathepsin L2 NA NA NA 
Plk-1 NA NA NA 
VEGFR-2 NA NA NA 
GSTM-1 NA NA NA 
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Scoring biomarker expression 
TMA slides were scanned and images were digitally stored using MIRAX scanner. Individual 
cores were viewed on the computer screen using MIRAX viewer. All invasive cancer cells in 
the whole core were counted and the percentage was calculated for all cancer cells in the 
entire core. The highest score among 3 cores was chosen as the final expression of that 
particular patient for the study.  (82.8% - 99.2% concondence between highest staining 
intensity or percentage out of three cores and the whole tissue slide reading was reported for 
ER, PR and HER2 expressions in breast cancers by T Thompson et al, 2009) Cut off levels to 
dichotomise patients into positive and negative expression were as per previously published 
validated cut off points for ER, PR, EGFR, HER2, Ki-67, CK-5/6 and Aurora A. The level 
that could best differentiate cases and control was used for CD-68, PDGFR α, Bcl-2 and 
MCM-2. X-tile algorithm was used for Bag-1 and CD-71.  
The main researcher (M Moe) scored all the TMAs. Second observer examined 10% of cores 
at random for each antibody to verify the result. Although there was a degree of difference 
between two observers on individual core results, there was a perfect match after applying the 
cut off point to the highest core result that dichotomised the expression as positive or 
negative. Therefore Kappa statistical test was not performed.  
For Bag-1 and CD-71, M Moe and other two observers from Tenovus laboratory scored all 
the cores independently first, and then together to resolve the discordances by consensus.  
Patient’s characteristics and other histopatholigical data were made unknown to the observers 
at the time of the scoring. 
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IHC Scoring method 
 
 
Protein Staining Method Cut off point 
ER Nuclear Allred 3+ 
PR Nuclear Allred 3+ 
EGFR Membrane Dako 2+ 
HER2 Membrane Dako 2+ 
Ki-67 Nuclear %, any intensity >14% 
CK-5/6 Nuclear %, any intensity >10% 
Bcl-2 Cytoplasmic H score >10 
Bag-1 Nuclear H score >70 
CD-68 
Tumour Associated 
Macrophages 
Semiquantitative 0 – 
4+ 
2+ 
CD-71 Nuclear, cytoplasmic H score >17 
Aurora A Nuclear, cytoplasmic %, any intensity >5% 
MCM-2 Nuclear %, any intensity >20% 
PDGFRa Cytoplasmic %, any intensity >60% 
VEGFR-2 NA NA NA 
GSTM-1 NA NA NA 
Plk-1 NA NA NA 
Cathepsin L2 NA NA NA 
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Statistical analysis 
SPSS v.16 software was used for the statistical analysis. Descriptive statistics were used for 
the range, mean, median and Chi square test was used for the significance tests.  
Univariate and multivariate logistic regressional analyses with Chi-square test were used to 
determine the effect of various protein expressions and survival outcomes. Kaplan Meier 
survival curves and Chi-square tests were used to compare survivals between positive and 
negative protein expressions. Pearson correlation was used to test correlations between 
“Adjuvant!” recurrence risk, “OPTION” recurrence risk, survival outcomes and molecular 
subtypes. Box-whisker plots were used to illustrate the distribution of recurrence risk among 
different molecular subtypes.   Statistical significance was established at a p value of < 0.05.  
 
Molecular subtyping 
Based on the expression of ER, PR, HER2, EGFR, Ki-67 and CK-5/6 proteins, the patients 
are classified into five different molecular subtypes as below; 
 
 
 
 
 
 
 
 
 
 
ER and/ or 
PR 
HER2 
HER2 and/ 
or Ki-67 
CK-5/6 and/ 
or EGFR 
Luminal A + - - - 
Luminal B + NA + NA 
HER2 - + NA NA 
Core Basal - - NA + 
5-Negative - - NA - 
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9.0  Results 
A. Patients Characteristics 
Patient characteristics at the time of data collection are shown in the table below. ER, PR and 
HER2 status were taken from the original pathology reports on the main tumour blocks.   
 Cases 
Matched 
controls 
Low risk 
control 
Number 72 72 34 
Median Age (p = 0.187) 
(Range) 
57 (30 – 77) 52 (28 – 74) 51 (36 – 78) 
Median DFS (months) 
(Range) (p = <0.001) 
23.2 
(4.5 – 59.9) 
103. 5 
(74.3 – 164.4) 
105. 5 
(79 – 161) 
Median OS (months) 
(Range) (p = <0.001) 
39. 7 
(8.1 – 129) 
104.9 
(74.3 – 174.4) 
106.3 
(79 – 161) 
Median Adjuvant!  10 years Recurrence Risk % 
(Range) (p = <0.001) 
65 
(27 – 97) 
67 
(50 -94) 
37 
(29 – 47) 
Mean (Median) (Range) OPTION 5 years 
recurrence risk %  without adjuvant 
chemoendocrine therapy  (p = <0.001) 
60.6 (60.6) 
(27 – 92) 
60.8 (59.6) 
(33 – 87) 
38 (38) 
(22 – 58) 
Mean (Median) (Range) OPTION 5 years 
recurrence risk %  after chemoendocrine therapy  
36.6 (30.5) 
(10 – 73) 
31 (33.9) 
(10 – 81) 
21 (18) 
(7 – 47) 
Surgery (p = 0.405) 
Mastectomy 58 52 16 
WLE 24 20 18 
Invasive cancer cell type  
(p = 0.247)  
IDC 66 59 29 
ILC 6 12 2 
Others 0 1 3 
Histology grade 
(p = 0.141) 
Grade 1 1 (1.4%) 2 (2.8%) 1 (2.9%) 
Grade 2 19 (26.4%) 33 (45.8%) 11 (32.4%) 
Grade 3 52 (72.2%) 37 (51.4%) 22 (64.7%) 
Tumour T stage 
(p = <0.001) 
T1 21 (29.2%) 13 (18.1%) 24 (70.6%) 
T2 44 (61.1%) 54 (75%) 10 (29.4%) 
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T3 7 (9.7%) 5 (6.9%) 0 
Nodal status 
(p < 0.001) 
N0 14 (19.4%) 0 19 (55.9%) 
N1 29 (40.3%) 42 (58.3%) 15 (44.1%) 
N2 10 (13.9%) 18 (25%) 0 
N3 19 (26.4%) 12 (16.7%) 0 
Oestrogen receptor status 
(p < 0.001) 
Positive 32 (44.4%) 45 (62.5%) 13 (38.2%) 
Negative 31 (43.0%) 15 (20.8%) 17 (23.6%) 
Unknown 9 (12.5%) 12 (16.6%) 4 (5.5%) 
Progesterone receptor status 
(p < 0.001) 
Positive 1 (1.3%) 0 1 (1.3%) 
Negative 30 (42.8%) 12 (19.3%) 11 (17.7%) 
Unknown 41 (56.9%) 60 (83.3%) 21 (29.1%) 
HER2  status 
(p = 0.637) 
Positive 24 (33.3%) 6 (8.3%) 2 (2.7%) 
Negative 29 (40.2%) 14 (19.4%) 4 (5.5%) 
Unknown 19 (26.3%) 49 (68.0%) 27 (37.5%) 
Chemotherapy regime 
(p = 0.485) 
CMF 27 (37.5%) 33 (45.8%) 24 (70.6%) 
Anthracycline 34 (47.2%) 27 (37.5%) 9 (26.5%) 
Taxane 11 (15.3%) 12 (16.7%) 1 (2.9%) 
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B. Comparison of Recurrence risk, RFS and overall survival between patient groups 
Independent Samples Student “t” test was used to compare means of recurrence risks, 
recurrence free and overall survivals between different patients groups.  P values shown are 
for the assumption of equal variance. The cases and matched controls are selected in such a 
way that their disease recurrence risk according to Adjuvant and OPTION tools are similar. 
However there are statistically significant differences in the mean recurrence risk after 
adjuvant treatments (chemotherapy and endocrine therapy). This is because of the endocrine 
treatment effect as there were more hormone receptor positive patients in the matched control 
group than the cases. The low risk controls have lower mean RR than the matched controls 
and the cases.  
Patient group Adjuvant! 10 years RR OPTION 5 years RR 
OPTION 5 years post 
adjuvant treatment RR 
Matched control N 72 72 72 
Mean 67.1389 60.8056 30.9722 
Median 66.0000 61.0000 30.5000 
Minimum 50.00 33.00 10.00 
Maximum 94.00 87.00 73.00 
Cases N 72 72 72 
Mean 63.5000 60.5694 36.5417 
Median 65.0000 60.0000 33.5000 
Minimum 27.00 27.00 10.00 
Maximum 97.00 92.00 81.00 
Low risk control N 34 34 34 
Mean 38.0294 37.7353 20.7941 
Median 37.0000 36.5000 18.5000 
Minimum 29.00 22.00 7.00 
Maximum 47.00 58.00 47.00 
Total N 178 178 178 
Mean 60.1067 56.3034 31.2809 
Median 58.0000 55.5000 29.5000 
Minimum 27.00 22.00 7.00 
Maximum 97.00 92.00 81.00 
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Comparing recurrence risks between matched controls and cases 
 
Patient Group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
P (2-tailed 
test) 
Adjuvant! 10 years 
recurrence risk 
Matched 
control 
72 67.1389 12.15198 1.43212 
0.183 
Cases 72 63.4750 19.81514 2.33524 
OPTION 5 years 
recurrence risk 
Matched 
control 
72 60.8056 13.03909 1.53667 
0.929 
Cases 72 60.5694 18.29556 2.15615 
OPTION 5 years 
recurrence risk after 
adjuvant treatments 
Matched 
control 
72 30.9722 12.67244 1.49346 
0.024 
Cases 72 36.5417 16.44448 1.93800 
OPTION 10 years 
recurrence risk 
Matched 
control 
72 72.6111 10.93071 1.28820 
0.888 
Cases 72 72.3056 14.80544 1.74484 
OPTION 10 years 
recurrence risk after 
adjuvant treatments 
Matched 
control 
72 39.7917 14.15302 1.66795 
0.004 
Cases 72 47.3472 16.44467 1.93802 
Relapse free survival 
(months) 
Matched 
control 
72 1.0681E2 22.44024 2.64461 
<0.001 
Cases 72 26.2097 14.71843 1.73458 
Overall survival 
(months) 
Matched 
control 
72 1.0690E2 22.38782 2.63843 
<0.001 
Cases 72 44.3889 26.40500 3.11186 
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Comparing recurrence risks between cases and low risk controls 
 
Patient Group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
P 
(2 tailed 
test) 
Adjuvant! 10 years 
recurrence risk 
Cases 72 63.4750 19.81514 2.33524 
<0.001 Low risk 
control 
34 38.0294 5.46884 .93790 
OPTION 5 years 
recurrence risk 
Cases 72 60.5694 18.29556 2.15615 
<0.001 Low risk 
control 
34 37.7353 8.08031 1.38576 
OPTION 5 years 
recurrence risk after 
adjuvant treatments 
Cases 72 36.5417 16.44448 1.93800 
<0.001 Low risk 
control 
34 20.6765 9.30858 1.59641 
OPTION 10 years 
recurrence risk 
Cases 72 72.3056 14.80544 1.74484 
<0.001 Low risk 
control 
34 53.2353 7.64777 1.31158 
OPTION 10 years 
recurrence risk after 
adjuvant treatments 
Cases 72 47.3472 16.44467 1.93802 
<0.001 Low risk 
control 
34 31.7941 11.97669 2.05399 
Relapse free survival 
(months) 
Cases 72 26.2097 14.71843 1.73458 
<0.001 Low risk 
control 
34 1.0986E2 23.92733 4.10350 
Overall survival 
(months) 
Cases 72 44.3889 26.40500 3.11186 
<0.001 Low risk 
control 
34 1.1070E2 23.33100 4.00123 
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Correlation between recurrence risk and survival outcomes  
There is no correlation between the recurrence risk and the recurrence free and overall 
survivals for the cohort containing cases and matched controls. However when the low risk 
control cohort was added in the analysis, there is a significant correlation between the 
recurrence risk and the recurrence free and overall survivals because the cases and controls 
are not well matched.  This means that the recurrence risk has become a predictive factor. 
Therefore to avoid this cofounding effect, survival analyses for molecular markers were done 
on the cohort after omitting low risk control patients.  
 
 
Correlation between recurrence risk and RFS & OS for the whole cohort (178 patients) 
 
  Relapse free 
survival 
(months) 
Overall 
survival 
(months) 
Adjuvant! 10 years 
recurrence risk 
Pearson Correlation -.167 -.130 
Sig. (2-tailed) .026 .084 
N 178 178 
OPTION 5 years 
recurrence risk 
Pearson Correlation -.215 -.173
*
 
Sig. (2-tailed) .004 .021 
N 178 178 
OPTION 5 years 
recurrence risk after 
adjuvant treatments 
Pearson Correlation -.298
**
 -.286
**
 
Sig. (2-tailed) <.001 <.001 
N 178 178 
OPTION 10 years 
recurrence risk 
Pearson Correlation -.218
**
 -.177
*
 
Sig. (2-tailed) .003 .018 
N 178 178 
OPTION 10 years 
recurrence risk after 
adjuvant treatments 
Pearson Correlation -.313
**
 -.303
**
 
Sig. (2-tailed) <.001 <.001 
N 178 178 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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The whole cohort (178 patients) 
 
The following graphs show that the correlations between recurrence risk and relapse free and 
overall survival. The best fit line and 95% confidence interval lines were also shown. The 
graphs show some correlation between recurrence risk and survival although the degree of 
correlation is small. 
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The cohort containing cases and matched controls only without low risk control (144 
patients) 
 
There was no correlation between recurrence risk and the survivals. However there is some 
correlation between OPTION post adjuvant treatment recurrence risk and the survivals.  
 
 
 
Matched cases and controls (Total = 144 
patients) 
Relapse free 
survival 
(months) 
Overall 
survival 
(months) 
Adjuvant! 10 years 
recurrence risk 
Pearson Correlation .069 .095 
Sig. (2-tailed) .410 .256 
N 144 144 
OPTION 5 years 
recurrence risk 
Pearson Correlation -.023 .012 
Sig. (2-tailed) .784 .884 
N 144 144 
OPTION 5 years 
recurrence risk after 
adjuvant treatments 
Pearson Correlation -.210* -.209* 
Sig. (2-tailed) .012 .012 
N 144 144 
OPTION 10 years 
recurrence risk 
Pearson Correlation -.028 .007 
Sig. (2-tailed) .742 .936 
N 144 144 
OPTION 10 years 
recurrence risk after 
adjuvant treatments 
Pearson Correlation -.255** -.255** 
Sig. (2-tailed) .002 .002 
N 144 144 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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C. Immunohistochemistry for individual biomarker 
 
Immunohistochemistry was successful for ER, PR, HER2, EGFR, CK-5/6, Ki-67, Aurora A, 
MCM-2, Bcl-2, Bag-1, CD-68, CD-71 and PDGFRα. However it wasn’t successful for Plk-1, 
VEGFR-2, Cathepsin L-2 and GSTM-1 despite different antigen retrieval methods and 
different dilutions of the reagents. Number of cores that are either lost or not good enough for 
analysis and the number of patients for whom no expression result is available are shown in 
the following table.  
 
  
Total 178 patients 
Total 467 cores 
Number of cores lost or not 
good enough for analysis (%) 
Number of patients with no 
IHC expression result (%) 
ER 66 (14.1%) 1 (0.6%) 
PR 53 (11.3%) 2 (1.1%) 
HER2 59 (12.6%) 4 (2.2%) 
EGFR 48 (10.3%) 3 (1.8%) 
CK-5/6 58 (12.4%) 3 (1.7%) 
Ki-67 49 (10.5%) 3 (1.7%) 
MCM-2 101 (21.6%) 10 (5.6%) 
Aurora A 0 (0%) 0 (0.0%) 
Bcl-2 40 (8.6%) 2 (0.1%) 
Bag-1 54 (11.6%) 2 (1.1%) 
CD-68 35 (7.5%) 2 (1.1%) 
CD-71 50 (10.7%) 5 (2.9%) 
PDGFRα 51 (10.9%) 5 (2.9%) 
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Immunohistochemistry results for 3 patient groups (Pearson Chi-square test) 
Total = 178 patients 
 
Percentage is for positive and negative expressions within each patient group. 
 
 
 
  Matched control Cases Low risk control 
ER 
P = <0.001 
Positive 55 (76.3%) 34 (47.2%) 17 (50%) 
Negative 16 (22.2%) 38 (52.8%) 17 (50%) 
PR 
P = <0.001 
Positive 41 (56.9%) 14 (19.4%) 13 (38.2%) 
Negative 29 (40.3%) 56 (77.8%) 21 (61.8%) 
HER2 
P = 0.401 
Positive 13 (18.1%) 20 (27.8%) 9 (26.5%) 
Negative 55 (76.4%) 50 (69.4%) 24 (70.6%) 
EGFR 
P = 0.304 
Positive 4 (5.6%) 7 (9.7%) 5 (14.7%) 
Negative 65 (90.3%) 64 (88.9%) 28 (82.4%) 
Ki-67 
P = <0.001 
Positive 25 (34.7%) 52 (72.2%) 16 (47.1%) 
Negative 44 (61.1%) 19 (26.4%) 16 (47.1%) 
CK-5/6 
P = 0.507 
Positive 32 (44.4%) 32 (44.4%) 12 (35.3%) 
Negative 37 (51.4%) 37 (51.4%) 22 (64.7%) 
Bcl-2 
P = 0.088 
Positive 61 (84.7%) 55 (76.4%) 23 (67.6%) 
Negative 9 (12.5%) 17 (23.6%) 10 (39.4%) 
Bag-1 
P = 0.074 
Positive 37 (51.4%) 24 (33.3%) 14 (41.2%) 
Negative 33 (45.8%) 47 (65.3%) 18 (52.9%) 
CD-68 
P = 0.189 
Positive 39 (54.2%) 31 (43.1%) 20 (58.8%) 
Negative 31 (43.1%) 40 (55.6%) 13 (38.2%) 
CD-71 
P = 0.062 
Positive 24 (33.3%) 35 (48.6%) 19 (55.9%) 
Negative 43 (59.7%) 35 (48.6%) 13 (38.2%) 
MCM-2 
P = 0.005 
Positive 27 (37.5%) 13 (18.1%) 5 (14.7%) 
Negative 35 (48.6%) 49 (68.1%) 25 (73.5%) 
Aurora A 
P = 0.001 
Positive 25 (34.7%) 43 (59.7%) 7 (20.6%) 
Negative 45 (62.5%) 29 (40.3%) 22 (64.7%) 
PDGFRα 
P = 0.099 
Positive 58 (80.6%) 68 (94.4%) 27 (79.4%) 
Negative 9 (12.5%) 3 (4.2%) 5 (14.7%) 
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D. Molecular Subtypes  
 
Molecular subtyping was available for 170 patients.  For remaining 8 patients one or more 
necessary biomarker IHC expressions were missing. Most of the matched control patients are 
in the Luminal A group and most of the cases are either in the Luminal B or HER2 enriched 
groups. Molecular subtypes are highly predictive of RFS and OS in both whole cohort as well 
as the cohort without low risk control patients but more significant in the latter.  
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Molecular subtypes and Patient Groups Cross tabulation 
   Patient Group 
Total 
   Matched 
control Cases 
Low risk 
control 
Molecular 
subtypes 
Luminal A Count 35 12 10 57 
Expected Count 22.8 23.1 11.1 57.0 
% within Molecular 
subtypes 
61.4% 21.1% 17.5% 100.0% 
Luminal B Count 19 21 9 49 
Expected Count 19.6 19.9 9.5 49.0 
% within Molecular 
subtypes 
38.8% 42.9% 18.4% 100.0% 
Core Basal Count 6 13 7 26 
Expected Count 10.4 10.6 5.0 26.0 
% within Molecular 
subtypes 
23.1% 50.0% 26.9% 100.0% 
HER2 
enriched 
Count 5 16 5 26 
Expected Count 10.4 10.6 5.0 26.0 
% within Molecular 
subtypes 
19.2% 61.5% 19.2% 100.0% 
5-Negative Count 3 7 2 12 
Expected Count 4.8 4.9 2.3 12.0 
% within Molecular 
subtypes 
25.0% 58.3% 16.7% 100.0% 
Total Count 68 69 33 170 
Expected Count 68.0 69.0 33.0 170.0 
% within Molecular 
subtypes 
40.0% 40.6% 19.4% 100.0% 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 22.551
a
 8 0.004 
Likelihood Ratio 23.280 8 0.003 
Linear-by-Linear Association 7.880 1 0.005 
N of Valid Cases 170   
a. 3 cells (20.0%) have expected count less than 5. The minimum expected count is 2.33. 
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Molecular subtypes and Relapse 
 
 
 
 
Molecular subtypes and mortality 
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Molecular subtypes among relapsed and relapse free patients 
   
Relapse 
Total    Relapsed No relapse 
Molecular 
subtype 
Luminal A Count 13 44 57 
Expected Count 23.4 33.6 57.0 
% within Molecular subtype 22.8% 77.2% 100.0% 
Luminal B Count 22 28 50 
Expected Count 20.5 29.5 50.0 
% within Molecular subtype 44.0% 56.0% 100.0% 
Core Basal Count 12 13 25 
Expected Count 10.3 14.7 25.0 
% within Molecular subtype 48.0% 52.0% 100.0% 
HER2 
enriched 
Count 16 10 26 
Expected Count 10.7 15.3 26.0 
% within Molecular subtype 61.5% 38.5% 100.0% 
5 - Negative Count 7 5 12 
Expected Count 4.9 7.1 12.0 
% within Molecular subtype 58.3% 41.7% 100.0% 
Missing Count 3 5 8 
Expected Count 3.3 4.7 8.0 
% within Molecular subtype 37.5% 62.5% 100.0% 
Total Count 73 105 178 
Expected Count 73.0 105.0 178.0 
% within Molecular subtype 41.0% 59.0% 100.0% 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 14.555
a
 5 .012 
Likelihood Ratio 15.023 5 .010 
Linear-by-Linear Association 8.460 1 .004 
N of Valid Cases 178   
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Molecular subtypes among Alive and Dead patients 
   Alive/ Dead 
Total    Alive Dead 
Molecular 
subtype 
Luminal A Count 46 11 57 
Expected Count 34.6 22.4 57.0 
% within Molecular subtype 80.7% 19.3% 100.0% 
Luminal B Count 27 23 50 
Expected Count 30.3 19.7 50.0 
% within Molecular subtype 54.0% 46.0% 100.0% 
Core Basal Count 13 12 25 
Expected Count 15.2 9.8 25.0 
% within Molecular subtype 52.0% 48.0% 100.0% 
HER2 enriched Count 12 14 26 
Expected Count 15.8 10.2 26.0 
% within Molecular subtype 46.2% 53.8% 100.0% 
5 - Negative Count 5 7 12 
Expected Count 7.3 4.7 12.0 
% within Molecular subtype 41.7% 58.3% 100.0% 
Missing Count 5 3 8 
Expected Count 4.9 3.1 8.0 
% within Molecular subtype 62.5% 37.5% 100.0% 
Total Count 108 70 178 
Expected Count 108.0 70.0 178.0 
% within Molecular subtype 60.7% 39.3% 100.0% 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 15.429
a
 5 .009 
Likelihood Ratio 16.279 5 .006 
Linear-by-Linear Association 8.262 1 .004 
N of Valid Cases 178   
a. 3 cells (25.0%) have expected count less than 5. The minimum expected count is 3.15. 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 142 
 
 
Recurrence Risk among molecular subtypes 
Molecular subtypes 
Adjuvant! 10-year 
RR 
OPTION 5-year 
RR 
OPTION 5-year 
post adjuvant 
treatment RR 
Luminal A N 57 57 57 
Mean 61.8596 56.6842 26.2632 
Median 58.0000 56.0000 24.0000 
Minimum 31.00 22.00 7.00 
Maximum 94.00 87.00 54.00 
Luminal B N 50 50 50 
Mean 62.7400 56.5600 25.3600 
Median 66.5000 56.0000 23.5000 
Minimum 30.00 27.00 9.00 
Maximum 92.00 89.00 56.00 
Core Basal N 25 25 25 
Mean 54.8400 55.8400 41.5600 
Median 52.0000 57.0000 36.0000 
Minimum 27.00 28.00 14.00 
Maximum 91.00 92.00 76.00 
HER2 enriched N 26 26 26 
Mean 58.1154 57.7692 40.8462 
Median 58.0000 58.0000 37.0000 
Minimum 30.00 32.00 19.00 
Maximum 97.00 91.00 81.00 
5-Negative N 12 12 12 
Mean 56.8333 53.5833 38.5000 
Median 58.5000 51.5000 34.0000 
Minimum 30.00 33.00 25.00 
Maximum 89.00 84.00 73.00 
Total N 170 170 170 
Mean 60.1588 56.4706 31.3412 
Median 58.0000 55.5000 29.5000 
Minimum 27.00 22.00 7.00 
Maximum 97.00 92.00 81.00 
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One way ANOVA comparing means of RR among molecular subtypes 
There are no statistically significant differences in mean recurrence risks by Adjuvant! or 
OPTION (before adjuvant treatment) between molecular subtypes. But there is a statistically 
significant difference in mean OPTION 5-year post adjuvant treatment recurrence risks.  
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Molecular subtypes and RFS by Kaplan-Meier’s curve (178 patients) 
 
 
 
 
 
 
P = 0.001 
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Means and Medians for RFS (months) for the whole cohort (178 patients) 
Molecular 
subtypes 
Mean
a
 Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Luminal A 137.526 6.917 123.968 151.084 . . . . 
Luminal B 97.096 8.649 80.144 114.048 . . . . 
Core Basal 83.573 13.271 57.563 109.583 52.200 . . . 
HER2 enriched 66.123 10.299 45.937 86.310 32.200 8.286 15.960 48.440 
5-Negative 57.200 13.066 31.590 82.810 31.400 10.652 10.522 52.278 
Overall 108.203 5.264 97.886 118.520 . . . . 
a. Estimation is limited to the largest survival time if it is censored. 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox)          19.322 4 .001 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 149 
 
Molecular subtypes and OS by Kaplan-Meier’s curve (178 patients) 
 
 
 
 
 
P = 0.001 
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Means and Medians for OS (months) for the whole cohort (178 patients) 
Molecular subtypes 
Mean
a
 Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimat
e 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Luminal A 141.574 5.919 129.973 153.175 . . . . 
Luminal B 102.139 7.517 87.406 116.873 110.000 . . . 
Core Basal 87.638 12.525 63.090 112.187 61.900 . . . 
HER2 enriched 82.169 9.177 64.182 100.156 68.000 18.302 32.129 103.871 
5-Negative 59.958 12.487 35.484 84.432 32.700 15.762 1.807 63.593 
Overall 114.593 4.767 105.250 123.937 . . . . 
a. Estimation is limited to the largest survival time if it is censored. 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox)          18.931 4 .001 
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Molecular subtypes and RFS for cases and matched controls (144 patients) 
 
 
 
 
P <0.001 
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Means and Medians for Relapse Free Survival for molecular subtypes 
Molecular 
subtypes 
Mean
a
 Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estima
te 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Luminal A 131.809 8.149 115.836 147.782 . . . . 
Luminal B 85.485 9.691 66.491 104.479 58.100 . . . 
Core Basal 53.800 12.829 28.655 78.945 15.400 10.012 .000 35.023 
HER2 enriched 44.629 7.883 29.178 60.079 28.000 3.967 20.225 35.775 
5-Negative 46.600 13.358 20.418 72.782 19.900 12.096 .000 43.608 
Overall 94.666 5.981 82.944 106.389 59.900 . . . 
a. Estimation is limited to the largest survival time if it is censored. 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox)          27.406 4 <.001 
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Molecular subtypes and OS for cases and matched controls (144 patients) 
 
 
 
 
P <0.001 
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Means and Medians for Overall Survival for molecular subtypes 
Molecular 
subtypes 
Mean
a
 Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Luminal A 138.440 6.908 124.899 151.980 . . . . 
Luminal B 91.565 8.241 75.414 107.717 86.100 11.716 63.136 109.064 
Core Basal 59.363 12.065 35.716 83.010 30.400 9.068 12.626 48.174 
HER2 enriched 62.176 7.293 47.882 76.470 55.900 15.070 26.363 85.437 
5-Negative 49.910 12.804 24.814 75.006 26.000 7.273 11.744 40.256 
Overall 103.001 5.461 92.297 113.705 110.000 . . . 
a. Estimation is limited to the largest survival time if it is censored. 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox)          29.827 4 <.001 
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RFS and OS analysis for individual biomarker 
 
Kaplan-Meier survival analyses and log rank tests were carried out to evaluate RFS and OS 
between the cases and the matched control groups.  
 
RFS analysis by Kaplan Meire’s curve and Log Rank test 
  Mean Median 
ER 
P = <0.001 
Positive 113.754 Not reached 
Negative 54.7 26.2 
PR 
P = <0.001 
Positive 130.676 Not reached 
Negative 72.074 35.6 
HER2 
P = 0.251 
Positive 75.245 41 
Negative 98.237 Not reached 
EGFR 
P = 0.134 
Positive 54.482 15.4 
Negative 96.287 Not reached 
Ki-67 
P = <0.001 
Positive 63.91 30.8 
Negative 125.157 Not reached 
CK-5/6 
P = 0.955 
Positive 81 59.9 
Negative 95.322 51.1 
Bcl-2 
P = 0.036 
Positive 99.504 Not reached 
Negative 65.819 23.9 
Bag-1 
P = 0.018 
Positive 106.313 Not reached 
Negative 82.543 42.4 
CD-68 
P = 0.424 
Positive 89.366 Not reached 
Negative 89.327 47.3 
CD-71 
P = 0.097 
Positive 79.402 43 
Negative 102.582 Not reached 
MCM-2 
P = 0.014 
Positive 108.292 Not reached 
Negative 83.883 42.9 
Aurora A 
P = 0.001 
Positive 69.591 32.2 
Negative 111.762 Not reached 
PDGFRα 
P = 0.070 
Positive 86.319 51 
Negative 131.608 Not reached 
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Overall survival analysis using Kaplan-Meier’s curve and Log Rank test 
 
  Mean Median 
ER 
P = <0.001 
Positive 120.396 Not reached 
Negative 65.13 37 
PR 
P = <0.001 
Positive 130.495 Not reached 
Negative 84.905 59.9 
HER2 
P = 0.150 
Positive 82.076 80.2 
Negative 106.666 Not reached 
EGFR 
P = 0.123 
Positive 60.964 34.2 
Negative 104.753 118.8 
Ki-67 
P = <0.001 
Positive 77.026 57.1 
Negative 127.449 Not reached 
CK-5/6 
P = 0.869 
Positive 91.031 Not reached 
Negative 102.004 110 
Bcl-2 
P = 0.058 
Positive 106.726 118.8 
Negative 77.734 58.3 
Bag-1 
P = 0.018 
Positive 112.942 Not reached 
Negative 92.508 63.1 
CD-68 
P = 0.131 
Positive 102.758 Not reached 
Negative 95.4 81.9 
CD-71 
P = 0.081 
Positive 88.586 81.8 
Negative 110.065 Not reached 
MCM-2 
P = 0.032 
Positive 109.730 Not reached 
Negative 96.184 63.1 
Aurora A 
P = 0.001 
Positive 77.669 67.4 
Negative 118.713 Not reached 
PDGFRα 
P = 0.085 
Positive 95.164 86.1 
Negative 134.725 Not reached 
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ER 
 
ER positive expression was associated with better RFS (p = <0.001) and OS (p = <0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = Not reached 
Negative = 26.2 months 
P < 0.001 
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Median OS 
Positive = Not reached 
Negative = 37 months 
P < 0.001 
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PR 
 
Positive PR expression was associated with better RFS (p = <0.001) and OS (p = <0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = Not reached 
Negative = 35.6 months 
P < 0.001 
 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 160 
 
 
 
 
 
 
 
 
 
 
Median OS 
Positive = Not reached 
Negative = 59.9 months 
P < 0.001 
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HER2 
 
Negative HER2 expression showed a trend for better RFS (p = 0.268) and OS (p = 0.150). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = 41months 
Negative = Not reached  
P = 0.251 
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Median OS 
Positive = 82.0 months 
Negative = 106.6 months 
P = 0.150 
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EGFR 
 
Negative EGFR expression was associated with a trend for better RFS (p = 0.144) and OS (p 
= 0.123) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = 15.4 months 
Negative = Not reached  
P = 0.134
 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 164 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median OS 
Positive = 34.2 months 
Negative = 118.8 months 
P = 0.123 
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Ki-67 
 
Negative Ki-67 expression was associated with better RFS (p = <0.001) and OS (p = <0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = 30.8 months 
Negative = Not reached  
P < 0.001 
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Median OS 
Positive = 77 months 
Negative = 127.4 months 
P = <0.001 
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CK-5/6 
 
CK-5/6 expression was not associated with RFS (p = 0.971) or OS (p = 0.869). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = 59.9 months 
Negative = 51.1 months 
P = 0.955 
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Median OS 
Positive = Not reached  
Negative = 110 months  
P = 0.869 
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Bcl-2 
 
Positive Bcl-2 expression was associated with better RFS (p = 0.036) and OS (p = 0.058).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = Not reached 
Negative = 23.9 months 
P = 0.036 
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Median OS 
Positive = 118.8 months  
Negative = 58.3 months 
P = 0.058  
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Bag-1 
Bag-1 positive expression was associated with RFS (p = 0.018) and OS (p = 0.018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = Not reached 
Negative = 42.4 months 
P = 0.018 
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Median OS 
Positive = Not reached  
Negative = 63.1 months  
P = 0.018 
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CD-68 
Invasive breast cancer cells did not show reaction with CD-68 antibody. Positive CD-68 
expression as tumour associated Macrophages infiltration showed a trend for better RFS (p = 
0.419) and OS (p = 0.131).  
 
 
 
 
 
 
 
 
  
 
 
 
 
Median RFS 
Positive = Not reached 
Negative = 47.3 months 
P = 0.424 
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Median OS 
Positive = Not reached  
Negative = 81.9 months 
P = 0.131 
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CD-71 
 
Negative CD-71 expression showed a trend for better RFS (p = 0.097) and OS (p = 0.081). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = 43 months 
Negative = Not reached  
P = 0.097 
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Median OS 
Positive = 81.8 months  
Negative = Not reached  
P = 0.081 
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MCM-2 
 
MCM-2 positive expression was associated with better RFS (p = 0.012) and OS (p = 0.032). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = Not reached 
Negative = 42.9 months 
P = 0.014 
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Median OS 
Positive = Not reached  
Negative = 63.1 months  
P = 0.032 
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Aurora A 
Aurora A negative expression was associated with better RFS (p = 0.001) and OS (p = 
0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = 32.2 months  
Negative = Not reached  
P = 0.001 
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Median OS 
Positive = 67.4 months  
Negative = Not reached  
P = 0.001 
 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 181 
 
PDGFR α 
 
PDGFR α negative expression shows a trend for better RFS (p = 0.135) and OS (p = 0.085). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median RFS 
Positive = 51months  
Negative = Not reached  
P =0.07 
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Median OS 
Positive = 86.1 months  
Negative = Not reached  
P = 0.085 
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Binary Logistic regression analysis (Stepwise forward) 
 
Binary logistic regression analysis was carried out for 5 years recurrence free status. 
 
 
 
 
 Predicted 
Patient group 
Percentage Correct 
Matched 
control 
Case 
Step 1 
Patient group 
Matched control 32 25 56.1 
Case 10 48 82.8 
Overall Percentage   69.6 
Step 2 
Patient group 
Matched control 40 17 70.2 
Case 17 41 70.7 
Overall Percentage   70.4 
Step 3 
Patient group 
Matched control 42 15 73.7 
Case 10 48 82.8 
Overall Percentage   78.3 
Step 4 
Patient group 
Matched control 48 9 84.2 
Case 15 43 74.1 
Overall Percentage   79.1 
Step 5 
Patient group 
Matched control 47 10 82.5 
Case 12 46 79.3 
Overall Percentage   80.9 
Step 6 
Patient group 
Matched control 52 5 91.2 
Case 17 41 70.7 
Overall Percentage   80.9 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 184 
 
 
    
 
Binary logistic regression analysis showed that positive expressions of PR, Bag-1, CD-68, 
MCM-2, N1 and N2 were associated with lower risks with hazard ratios of 0.05, 0.18, 0.176, 
0.104, 0.049 and 0.051 respectively and Aurora A positive expression was significantly 
associated with the increased risk (hazard ratio = 10.214) to have breast cancer recurrence in 
the first 5 years. The model has 91.2% specificity and 70.7% sensitivity. 
 
 
B S.E. Wald df Sig. 
Exp(B) 
(Hazard ratio) 
PR + -2.931 .728 16.205 1 <.001 .053 
Bag-1 + -1.685 .680 6.139 1 .013 .186 
CD-68 + -1.735 .665 6.810 1 .009 .176 
MCM-2 + -2.260 .714 10.031 1 .002 .104 
Aurora A + 2.324 .725 10.268 1 .001 10.214 
Nodal stage   12.928 3 .005  
N0 17.924 10529.041 <.0001 1 .999 60865215.432 
N1 -3.014 .862 12.234 1 <.001 .049 
N2 -2.975 .978 9.255 1 .002 .051 
Constant 4.475 1.165 14.752 1 <.001 87.793 
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Multivariate analysis (for cases and matched controls: total = 144 patients) 
In Cox regression forward stepwise likelihood ratio analysis, N1 stage, positive MCM-2 and 
Bag-1 expressions are significantly associated with better RFS while Core Basal and positive 
Aurora A expression are associated with poor RFS. Similar pattern was found for the overall 
survival too. ER, PR, HER2, Ki-67, CK-5/6 and EGFR were not included in the model as 
they were used to classify molecular subtypes. 
 
Relapse Free Survival 
 
B SE Wald df Sig. 
Exp(B) 
(Hazard 
ratio) 
95.0% CI for 
Exp(B) 
Lower Upper 
Molecular subtypes   13.885 4 .008    
Luminal B .843 .461 3.352 1 .067 2.324 .942 5.731 
Core Basal 1.745 .498 12.290 1 <.001 5.726 2.159 15.191 
HER2 enriched .422 .491 .736 1 .391 1.524 .582 3.993 
5-Negative .488 .612 .636 1 .425 1.630 .491 5.411 
Bag-1 + -1.342 .386 12.075 1 .001 .261 .123 .557 
MCM-2 + -1.780 .413 18.575 1 <.001 .169 .075 .379 
Aurora A + 1.251 .327 14.627 1 <.001 3.494 1.840 6.633 
Grade   12.069 2 .002    
Grade 2 -1.871 1.144 2.675 1 .102 .154 .016 1.450 
Grade 3 -.454 1.085 .175 1 .676 .635 .076 5.332 
T stage   7.552 2 .023    
T2 -.089 .356 .063 1 .801 .914 .455 1.836 
T3 1.280 .563 5.169 1 .023 3.596 1.193 10.839 
Nodal stage   20.766 3 <.001    
N1 -1.188 .407 8.502 1 .004 .305 .137 .678 
N2 -.958 .509 3.542 1 .060 .384 .141 1.040 
N3 .396 .471 .709 1 .400 1.487 .591 3.740 
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Overall Survival 
 
B SE Wald df Sig. 
Exp(B) 
(Hazard 
ratio) 
95.0% CI for 
Exp(B) 
Lower Upper 
Molecular subtypes   23.316 4 <.001    
   Luminal B .864 .438 3.889 1 .049 2.374 1.005 5.604 
   Core Basal 2.424 .523 21.522 1 <.001 11.293 4.055 31.449 
   HER2 enriched  1.144 .449 6.486 1 .011 3.140 1.302 7.576 
   5-Negative 2.043 .584 12.219 1 <.001 7.713 2.453 24.251 
Bag-1 + -.691 .327 4.462 1 .035 .501 .264 .951 
CD-68 + -.787 .328 5.744 1 .017 .455 .239 .866 
MCM-2 + -.960 .357 7.211 1 .007 .383 .190 .772 
Aurora A + .971 .311 9.757 1 .002 2.640 1.436 4.853 
Nodal stage   13.101 3 .004    
   N 1 -.894 .424 4.436 1 .035 .409 .178 .940 
   N 2 -.626 .532 1.384 1 .239 .535 .188 1.518 
   N 3 .393 .487 .649 1 .420 1.481 .570 3.849 
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E. Luminal (LA and LB) vs. Non-Luminal subtypes (H, CB, 5-N) 
 
To investigate the effect of biomarkers independently of well recognised oestrogen receptor 
positivity, survival outcomes between luminal and non-luminal cancers were compared with 
Kaplan Meyer curves, and Cox regression multivariate analysis was carried out separately for 
both groups. 
Luminal cancers have less recurrence patients compared to non-luminal cancers – 37.9% vs. 
72%; p < 0.001. The luminal cancers have much better RFS and OS than non-luminal cancers 
as shown in the Kaplan Meyer curves (p < 0.001).   
 
 
 
Median RFS 
Luminal = not reached 
Others = 25.6 months 
P <0.001 
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Luminal (ER/PR positive) vs. Non luminal (ER/PR negative) cancers 
Pearson Chi  square test p < 0.001 
Molecular subtypes 
Total Luminal Non-Luminal 
Patient group 
Matched 
control 
Count 54 14 68 
% within Molecular subtypes 62.1% 28.0% 49.6% 
Case 
Count 33 36 69 
% within Molecular subtypes 37.9% 72.0% 50.4% 
Total 
Count 87 50 137 
% within Molecular subtypes 100.0% 100.0% 100.0% 
 
 
 
Median OS 
Luminal = not reached 
Others = 37 months 
P <0.001 
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Cox regression analysis for Luminal cancers 
Ki-67, Bag-1, MCM-2, Aurora A, grade, size and nodal stage are associated with RFS, and 
CK-5/6, Bag-1, CD-68, MCM-2, Aurora A, grade, size and nodal stage are associated with 
OS. These are statistically significant. Hazard ratios are shown in the table. ER and PR 
expressions are not included in the model as all the patients are ER and/or PR positive. 
 
Cox regression analysis for RFS on Luminal cancers 
 
B SE Wald df Sig. 
Exp(B) 
(Hazard 
ratio) 
95.0% CI for 
Exp(B) 
 Lower Upper 
HER2 + -1.002 1.256 .636 1 .425 .367 .031 4.309 
EGFR+   . 0
a
 .    
Ki-67 + 1.745 .855 4.161 1 .041 5.724 1.071 30.599 
CK-5/6 + -.696 .564 1.523 1 .217 .499 .165 1.506 
Bcl-2 + .781 .856 .832 1 .362 2.184 .408 11.697 
Bag-1 + -1.988 .661 9.037 1 .003 .137 .037 .501 
CD-68 + -.263 .464 .322 1 .570 .768 .309 1.909 
CD-71 + -.663 .622 1.135 1 .287 .515 .152 1.745 
MCM-2 + -3.044 .907 11.255 1 .001 .048 .008 .282 
Aurora A + 1.734 .580 8.936 1 .003 5.661 1.817 17.640 
PDGFR α + 1.450 1.149 1.593 1 .207 4.264 .448 40.545 
Grade   9.367 2 .009    
Grade 2 -3.168 1.475 4.612 1 .032 .042 .002 .758 
Grade 3 -1.228 1.304 .886 1 .346 .293 .023 3.773 
T stage   6.266 2 .044    
T2 .335 .623 .288 1 .591 1.398 .412 4.743 
T3 2.860 1.174 5.938 1 .015 17.456 1.750 174.138 
Nodal Stage   9.016 3 .029    
N1 -3.399 1.534 4.911 1 .027 .033 .002 .675 
N2 -2.845 1.549 3.373 1 .066 .058 .003 1.210 
N3 -1.770 1.524 1.349 1 .245 .170 .009 3.376 
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Cox regression analysis for OS for Luminal cancers 
 
B SE Wald df Sig. 
Exp(B) 
(Hazard 
ratio) 
95.0% CI for 
Exp(B) 
 Lower Upper 
HER2 + .191 1.099 .030 1 .862 1.211 .141 10.430 
EGFR+   . 0
a
 .    
Ki-67 + 1.080 .820 1.735 1 .188 2.945 .590 14.694 
CK-5/6 + -1.248 .608 4.220 1 .040 .287 .087 .944 
Bcl-2 + 1.145 .842 1.850 1 .174 3.142 .604 16.358 
Bag-1 + -2.051 .740 7.679 1 .006 .129 .030 .549 
CD-68 + -1.014 .487 4.327 1 .038 .363 .140 .943 
CD-71 + -.354 .576 .377 1 .539 .702 .227 2.172 
MCM-2 + -1.865 .781 5.708 1 .017 .155 .034 .715 
Aurora A + 1.826 .628 8.470 1 .004 6.211 1.815 21.247 
PDGFR α + 1.367 1.162 1.385 1 .239 3.924 .403 38.237 
Grade   5.070 2 .079    
Grade 2 -3.153 1.508 4.374 1 .036 .043 .002 .820 
Grade 3 -2.144 1.376 2.427 1 .119 .117 .008 1.739 
T stage   4.051 2 .132    
T2 .433 .638 .460 1 .498 1.542 .441 5.389 
T3 2.173 1.080 4.050 1 .044 8.784 1.058 72.907 
Nodal Stage   15.537 3 .001    
N1 -4.307 1.467 8.619 1 .003 .013 .001 .239 
N2 -3.931 1.534 6.566 1 .010 .020 .001 .397 
N3 -1.922 1.435 1.794 1 .180 .146 .009 2.437 
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Cox regression analysis for Non-Luminal cancers 
Cox regression analysis was performed for Non-luminal type cancers. CK-5/6, Bg-1, MCM-
2, Aurora A, grade and nodal stage are associated with RFS, and MCM-2 and Aurora A are 
associated with OS at statistically significant level.  CK-5/6 and Aurora A are bad prognostic 
markers. ER and PR expressions are not included in the model as all the patients have both 
ER and PR negative. 
 
 
 
Cox regression analysis for RFS for Non-luminal cancers 
 
B SE Wald df Sig. 
Exp(B) 
(Hazard 
ratio) 
95.0% CI for 
Exp(B) 
 Lower Upper 
HER2 + -.852 .500 2.898 1 .089 .427 .160 1.138 
EGFR+ .584 .935 .389 1 .533 1.792 .287 11.204 
Ki-67 + .534 .773 .477 1 .490 1.705 .375 7.759 
CK-5/6 + 1.462 .685 4.560 1 .033 4.315 1.128 16.510 
Bcl-2 + -.212 .584 .131 1 .717 .809 .258 2.540 
Bag-1 + -1.244 .555 5.018 1 .025 .288 .097 .856 
CD-68 + -.184 .750 .060 1 .806 .832 .191 3.619 
CD-71 + -.181 .605 .090 1 .765 .834 .255 2.730 
MCM-2 + -1.765 .796 4.914 1 .027 .171 .036 .815 
Aurora A + 1.307 .591 4.895 1 .027 3.695 1.161 11.762 
PDGFR α + .595 1.565 .145 1 .704 1.813 .084 38.930 
Grade 2.146 1.364 2.475 1 .116 8.553 .590 124.000 
T stage   .894 2 .639    
T2 .281 .806 .121 1 .728 1.324 .273 6.419 
T3 .861 .944 .832 1 .362 2.365 .372 15.036 
Nodal Stage   11.438 3 .010    
N1 -1.402 .733 3.663 1 .056 .246 .059 1.034 
N2 -1.225 .968 1.603 1 .205 .294 .044 1.957 
N3 1.041 1.000 1.085 1 .298 2.833 .399 20.101 
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Cox regression analysis for OS for Non-luminal cancers 
 
B SE Wald df Sig. 
Exp(B) 
(Hazard 
ratio) 
95.0% CI for 
Exp(B) 
 Lower Upper 
HER2 + -1.529 .560 7.457 1 .006 .217 .072 .649 
EGFR+ .286 .937 .093 1 .760 1.331 .212 8.343 
Ki-67 + .715 .751 .907 1 .341 2.044 .469 8.902 
CK-5/6 + .610 .565 1.165 1 .281 1.840 .608 5.566 
Bcl-2 + -.433 .604 .515 1 .473 .649 .199 2.117 
Bag-1 + -.823 .544 2.289 1 .130 .439 .151 1.275 
CD-68 + -1.141 .706 2.613 1 .106 .320 .080 1.274 
CD-71 + 1.069 .668 2.562 1 .109 2.914 .786 10.793 
MCM-2 + -1.403 .653 4.609 1 .032 .246 .068 .885 
Aurora A + 1.809 .670 7.302 1 .007 6.106 1.644 22.678 
PDGFR α + -.245 1.553 .025 1 .875 .783 .037 16.433 
Grade .887 1.120 .626 1 .429 2.427 .270 21.809 
T stage   .345 2 .842    
T2 -.369 .698 .279 1 .597 .691 .176 2.718 
T3 -.515 1.036 .247 1 .619 .598 .079 4.551 
Nodal Stage   6.867 3 .076    
N1 -.041 .655 .004 1 .951 .960 .266 3.469 
N2 -.309 .878 .124 1 .724 .734 .131 4.100 
N3 2.153 .969 4.938 1 .026 8.607 1.289 57.459 
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F. Lumina A cancers vs. other subtypes 
Luminal A subtype cancers have statistically significant better RFS and OS compared to 
other cancers. LA group had less recurrence within 5 years compared to other cancers (25.5% 
vs. 63.3%; p < 0.001). None of the protein expression was associated with RFS or OS at 
statistically significant level among Luminal A cancers. Kaplan Meyer and Cox regression 
analysis were done to compare LA against others.  
 
 
 
 
 
 
 
Median RFS 
Luminal A= Not reached 
Others     = 34.7 mo 
P <0.001 
Median OS 
Luminal A= Not reached 
Others    = 61.9 mo 
P <0.001 
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Distribution of Luminal A and other subtypes among cases and matched controls 
Pearson’s Chi square test p < 0.001 
Molecular subtypes 
Total 
Luminal A 
Other than 
Luminal A 
Patient group 
Matched 
control 
Count 35 33 68 
Expected Count 23.3 44.7 68.0 
% within Molecular 
subtypes 
74.5% 36.7% 49.6% 
Case 
Count 12 57 69 
Expected Count 23.7 45.3 69.0 
% within Molecular 
subtypes 
25.5% 63.3% 50.4% 
Total 
Count 47 90 137 
Expected Count 47.0 90.0 137.0 
% within Molecular 
subtypes 
100.0% 100.0% 100.0% 
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Cox Regression analysis for Luminal A and non-luminal A cancers 
 
ER, PR, HER2 and Ki-67 expressions are not included in the model because these 
expressions are used to define Luminal A and non-luminal A tumours. There are no 
biomarkers that can predict RFS or OS at statistically significant level for Luminal A cancers.  
For non-luminal A cancers, CK-5/6 (HR = 2.2), Bag-1 (HR = 0.296), MCM-2 (HR = 0.124), 
Aurora A (HR = 3.9), N2 (HR = 0.313) are significantly RFS, and Bag-1 (HR = 0.37), MCM-
2 (HR = 0.29), Aurora A (HR = 2.7) and N2 (HR = 0.385) are significantly predictive of 
overall survival.  
 
Cox regression analysis for RFS for Luminal A cancers 
 
B SE Wald df Sig. 
Exp(B) 
(Hazard 
ratio) 
95.0% CI for Exp(B) 
 
Lower Upper 
EGFR +   . 0 .    
CK-5/6 + .155 .857 .033 1 .856 1.168 .218 6.264 
Bcl-2 + -.759 1.703 .198 1 .656 .468 .017 13.193 
Bag-1 + -2.191 1.629 1.809 1 .179 .112 .005 2.724 
CD-68 + -.751 1.198 .393 1 .531 .472 .045 4.938 
CD-71 + .761 1.090 .487 1 .485 2.140 .253 18.109 
MCM-2 + -1.596 1.471 1.178 1 .278 .203 .011 3.619 
Aurora A + 1.882 1.275 2.180 1 .140 6.567 .540 79.882 
PDGFR α  + 1.771 1.393 1.617 1 .204 5.876 .383 90.046 
Grade    1.826 2 .401    
Grade 2  -2.065 1.797 1.320 1 .251 .127 .004 4.294 
Grade 3 -.735 1.452 .256 1 .613 .479 .028 8.260 
T stage   2.498 2 .287    
T2 .675 .964 .490 1 .484 1.964 .297 12.997 
T3 3.325 2.113 2.477 1 .116 27.796 .442 1747.127 
N stage   2.032 2 .362    
N2 -.135 1.340 .010 1 .920 .873 .063 12.081 
N3 1.354 1.133 1.427 1 .232 3.873 .420 35.703 
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Cox regression analysis for OS for Luminal A cancers 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
EGFR +   . 0 .    
CK-5/6 + -.689 .997 .477 1 .490 .502 .071 3.545 
Bcl-2 + -.680 2.295 .088 1 .767 .506 .006 45.458 
Bag-1 + -1.448 1.750 .685 1 .408 .235 .008 7.252 
CD-68 + -.808 1.382 .342 1 .559 .446 .030 6.690 
CD-71 + -.484 1.282 .142 1 .706 .617 .050 7.603 
MCM-2 + -1.958 1.878 1.087 1 .297 .141 .004 5.603 
Aurora A + 1.698 1.412 1.445 1 .229 5.460 .343 86.927 
PDGFR α + 1.191 1.384 .740 1 .390 3.289 .218 49.571 
Grade   1.871 2 .392    
Grade 2 -3.267 2.398 1.857 1 .173 .038 .000 4.188 
Grade 3 -2.110 1.880 1.260 1 .262 .121 .003 4.831 
T stage   1.383 2 .501    
T2 .898 1.352 .442 1 .506 2.456 .174 34.745 
T3 2.653 2.297 1.334 1 .248 14.191 .157 1280.276 
Noda stage   2.599 2 .273    
N2 -.426 1.730 .061 1 .806 .653 .022 19.393 
N3 1.486 1.249 1.416 1 .234 4.418 .382 51.052 
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Cox regression analysis for RFS for cancers other than LA 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
 Lower Upper 
EGFR+ .515 .617 .695 1 .404 1.674 .499 5.614 
CK-5/6+ .803 .385 4.362 1 .037 2.232 1.051 4.743 
Bcl-2+ .249 .403 .382 1 .537 1.283 .582 2.828 
Bag-1+ -1.216 .431 7.965 1 .005 .296 .127 .690 
CD-68+ .161 .404 .160 1 .689 1.175 .533 2.592 
CD-71+ -.408 .369 1.221 1 .269 .665 .323 1.371 
MCM-2+ -2.090 .506 17.061 1 <.001 .124 .046 .333 
Aurora A+ 1.362 .399 11.673 1 .001 3.902 1.787 8.522 
PDGFR α+ .658 1.299 .257 1 .612 1.932 .152 24.633 
Grade 1.527 .495 9.503 1 .002 4.604 1.744 12.157 
T stage   4.104 2 .128    
T2 -.438 .380 1.332 1 .248 .645 .307 1.358 
T3 .714 .615 1.348 1 .246 2.041 .612 6.807 
N stage   13.122 3 .004    
N2 -1.161 .468 6.148 1 .013 .313 .125 .784 
N3 -1.091 .673 2.627 1 .105 .336 .090 1.257 
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Cox regression analysis for OS for cancers other than LA 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
 Lower Upper 
EGFR+ .505 .619 .665 1 .415 1.657 .492 5.577 
CK-5/6+ .209 .370 .318 1 .573 1.232 .597 2.545 
Bcl-2+ .082 .413 .039 1 .843 1.085 .483 2.438 
Bag-1+ -.995 .432 5.291 1 .021 .370 .158 .863 
CD-68+ -.331 .375 .780 1 .377 .718 .345 1.497 
CD-71+ -.109 .378 .084 1 .772 .896 .428 1.879 
MCM-2+ -1.237 .419 8.712 1 .003 .290 .128 .660 
Aurora A+ 1.005 .396 6.448 1 .011 2.732 1.258 5.935 
PDGFR α+ -.082 1.306 .004 1 .950 .921 .071 11.900 
Grade .760 .451 2.840 1 .092 2.139 .883 5.177 
T stage   1.841 2 .398    
T2 -.508 .387 1.721 1 .190 .602 .282 1.285 
T3 -.091 .720 .016 1 .900 .913 .222 3.748 
N stage   6.056 3 .109    
N2 -.956 .476 4.028 1 .045 .385 .151 .978 
N3 -.789 .676 1.363 1 .243 .454 .121 1.708 
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Recurrence Risk and relapse free survival among Luminal A patients 
Among the LA patients the relationship between Adjuvant, OPTION RRs and relapse free 
survival are evaluated by scattered plot, independent 2 samples student t test and Pearson 
correlation test. Although the cases have higher mean Adjuvant RR than the controls, the 
difference was not statistically significant. The correlation between Adjuvant! RR and RFS 
did not show any statistical significance either. Mean OPTION 5 years RRs before and after 
adjuvant treatments were higher for cases than controls and the differences were statistically 
significant (p = 0.013 & 0.017,  respectively). The correlation between RFS and OPTION 5 
years RR before adjuvant treatment was significant but after adjuvant treatment was not 
statistically significant.  
Luminal A cancers and recurrence risk analysed by independent 2 samples t test 
 
Patient 
group 
N Range 
Media
n 
Mean 
Std. 
Deviation 
Std. Error 
Mean 
P* 
Adjuvant! 10 years 
recurrence risk 
Matched 
control 
35 
52 - 94 58 
65.0857 12.01561 2.03101 
0.071 
Case 12 37 – 90.5 80 73.1000 15.43084 4.45450 
OPTION 5 years 
recurrence risk 
Matched 
control 
35 
40 - 87 58 
59.0000 12.72330 2.15063 
0.013 
Case 12 52 - 86 71 69.8333 11.90747 3.43739 
OPTION 5 years 
recurrence risk after 
adjuvant treatments 
Matched 
control 
35 
12 - 47 25 
26.7714 9.8431 1.6637 
0.017 
Case 12 14 - 54 37 35.4167 11.8893 3.4321 
*Equal variance is assumed for calculation of p value. 
 
Pearson’s correlation test for RFS and RR for LA cancers 
 Pearson correlation P value (2 tailed test) 
Adjuvant! 10 years RR -0.227 0.125 
OPTION 5 years RR (before adjuvant 
treatment) 
-0.333 0.022 
OPTION 5 years RR (after adjuvant 
treatments) 
-0.254 0.085 
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Below are the scattered dot plots showing relationships between recurrence risks and RFS for 
Luminal A patients. The best fit line and 95% confidence interval lines are also shown. 95% 
confidence interval is much narrower than that of the whole matched case control cohort that 
contains all molecular subgroups. This suggests the relationship between RRs and RFS is 
stronger for LA group than for all groups combined.  
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10. Discussion 
 
In this study the “cases” and the “controls” are matched according to the Adjuvant recurrence 
risk (RR) which is calculated based on the known risk factors of tumour size, nuclear grade, 
nodal stage and oestrogen receptor expression. Adjuvant! RR is routinely used in today’s 
clinical practice to make decisions on adjuvant chemotherapy and endocrine therapy. At the 
time of patients selection, the mean Adjuvant! RR was similar between the cases and the 
controls and no statistically significant correlation could be established between survivals and 
Adjuvant RRs. This would suggest that Adjuvant RR scoring had limited if any benefit when 
used alone to identify those patients for whom adjuvant therapy was ineffective within this 
series. The assessment of a set of specific proteins by IHC analysis has been used within this 
thesis to identify five different molecular subtypes (as described in previous publications) and 
it greatly improves the prediction of RFS and OS in a clinically valid manner. Of the 5 
subtypes; Luminal A (LA) has the best RFS followed by Luminal B (LB), HER2 enriched 
(H), 5 negative (5-N) and Core Basal types (CB). LA again has the best OS followed by LB, 
H, CB and 5-N. This is in agreement with other publications. (Cheang, 2008b) However in 
the multivariate analysis, CB has the worst hazard ratio for RFS and OS among the five 
molecular subtypes but the 95% CIs for CB, H and 5-N overlap each other and therefore the 
statistical significance is not achieved. This may simply relate to a small sample size.  The 
survival benefit for LA over other subtypes seen in this study is statistically highly 
significant.   
In univariate analysis, positive expressions for ER, PR, Bag-1, Bcl-2, MCM-2, negative 
expressions for Ki-67 and Aurora A are correlated with better RFS. Positive expressions for 
HER2, EGFR, CK-5/6, CD-71 and PDGFR-α were associated with poor RFS as described in 
other publications although a statistically significant level was not achieved in this study. 
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Eight molecular proteins (ER, PR, HER2, Ki-67, Bcl-2, Bag-1, Aurora A, CD-68) whose 
genes expression s are used in the Oncotype Dx test for the calculation of recurrence scores 
show similar impact on the survivals (better or worse) although it is statistically significant 
only for ER, PR, Bcl-2 and Bag-1.  Because of unsuccessful immunostainings for Cathepsin 
L2 and GSTM-1 proteins, IHC results were available for the proteins to represent only 5 out 
of 7 functional gene groups utilised in Oncotype Dx. Therefore it is not possible to comment 
if the IHC analysis (ie, protein level) of functional genes groups used by Oncotype Dx could 
produce similar informations for the disease recurrence risk.  
Oestrogen receptor status was not available for some of the patients in the study groups at the 
start of the study (8.3% in cases, 11% in matched controls and 5.6% in low risk controls.). 
These were the patients treated in the late 1990’s. For these patients, “ER unknown” status 
was used to calculate the Adjuvant RR for matching purposes. This would assign lower than 
actual RR for true ER negative patients and higher than actual risk for true ER positive 
patients.  The matching for the cases and controls was done purely based on the Adjuvant RR 
regardless of the ER status. As a result, it was identified that there were more ER/PR positive 
patients in the control group and more ER/PR negative patients in the cases group.  ER/PR 
negative patients are known to have early relapse (ie, in the first five years) and ER/PR 
positive patients are known to have a higher risk of late  relapse after 8 years or longer 
period. (Blows, 2010) To avoid this bias from the higher positive ER/PR distribution in the 
controls group, the analysis was performed for luminal (LA and LB, ie. ER and/ or PR 
positive expressions using cut off level of Allred score 3) and non-luminal (CB, H and 5-N, 
ie, any cancers with negative ER and PR expressions) cancers. 
Luminal cancers had statistically significant better RFS and OS than non-luminal cancers. 
This indicates that ER/PR expression is an important prognostic, predictive factor in this 
group of patients.  There were 54 controls and 33 cases in the Luminal group. In multivatiate 
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analysis, positive expressions of Ki-67 and Aurora A, negative expressions of Bag-1, MCM-
2, higher nuclear grade and nodal stage are correlated with poor RFS. This is in agreement 
with the already known fact that high proliferation index is a poor prognostic factor in ER/PR 
positive patients. (Cheang, 2009) Ki-67 (or HER2) positive tumours are classified as Luminal 
B tumours that have different risk level from other Luminal tumours (ie. Luminal A tumours) 
and have the prospect of benefiting from adjuvant chemotherapy.  Surprisingly the poor 
prognostic effect of HER2 was not seen here. It may be due to the small number of HER2 
positive patients in this group.  
For non-luminal cancers, CK-5/6 was associated with poor RFS. Aurora A was associated 
with poor RFS and OS. Positive PR, MCM-2, Bag-1, lower T stage and nodal stage are 
associated with better RFS and OS. HER2 expression was associated with better overall 
survival. This means when ER/PR is negative, HER2 positive tumours will do better than 
HER2 negative tumours. Finding statistical significance for only OS but not for RFS suggests 
this effect may be due to the availability and use of anti-HER2 therapy for the metastatic 
disease within this study population or perhaps, statistical significance is not reached due to 
the small sample size. (Adjuvant anti-HER2 therapy was not available when the study 
population received its adjuvant therapies.) In the multivariate model positive MCM-2 and 
negative Aurora A were associated with better OS.  
Luminal A patients are reportedly unlikely to gain benefit from adjuvant chemotherapy either 
because of their very good baseline prognosis or the fact that their low proliferation index 
will make them unresponsive to the chemotherapy. In this study, the univariate analysis with 
Kaplan Meyer curve showed that LA had statistically significant better RFS and OS than the 
other molecular subtypes (LA, H, CB, 5-N). However, within the LA group, 74.5% of 
patients are “controls” and 25.5% are “cases”.  In other words, 5 years disease recurrence rate 
for LA cancers in this study population is 25.5%. Theorectically, this figure could have been 
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higher if the adjuvant chemotherapy wasn’t given. If the analysis is limited to the 35 LA 
patients who have OPTION RR >50%, the the recurrence rate will be 12/36 = 33.3%. 
Although this data is a lot higher than 5 years distant recurrence rate of 4.4% (node negative 
patients) – 15.5% (node positive patients) reported for LA tumours as determined by PAM50 
gene expression measurement in a study involving patients treated with tamoxifen alone 
(53% of patiens had positive lymph nodes.) (Prat, 2012), it is similar to the 5 years recurrence 
rate of 29.6% among LA patients treated with the neoadjuvant chemotherapy for high risk 
features.  (Vargo, 2011)  The finding here suggests that the widely recognised notion of very 
good prognosis and the avoidance of adjuvant chemotherapy may not be applicable to 
Luminal A cancers that have OPTION  or Adjuvant RR ≥ 50%.  Mean and median OPTION 
RRs are statistically significantly higher for cases than controls. This statistically significant 
difference was not seen for the whole cohort with mixed subgroups as shown earlier in the 
results.  This finding suggests that combination of molecular subgroup and RR will be more 
powerful than either of two alone to identify the high risk patients. Although more studies are 
required to define the optimal OPTION 5-year RR cut off point for better patient selections, it 
is reasonable to consider novel adjuvant therapies to LA cancers with OPTION or Adjuvant 
RR > 50% as none of the cases in the LA group had RR less than 50% except one patient 
who had Adjuvant RR 37%. RR >50% should also be considered as a stratification factor for 
LA cancers in the clinical trials. None of the proteins evaluated in this study showed any 
significant correlations with RFS or OS in the univariate or multivariate Cox regression 
analysis for Luminal A tumours. This suggests that new predictive markers are urgently 
needed to identify the approximately 25.5% of LA cancers with OPTION 5 years >40% or 
Adjuvant 10 years RR > 50% who would develop the disease recurrence within 5 years of 
adjuvant chemotherapy. 
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The predictive effect of proteins found in this study needs to be verified in a larger 
independent sample set – “validation set”. These proteins expressions can be used for the 
stratification of patients in the future clinical trials. The trend for the poor prognostic effect of 
positive CD-71 expression is a new finding for these types of patients and was in agreement 
with a similar finding in patients treated with tamoxifen. (Habashy, 2010) EGFR, Ki-67, 
Aurora A and CD-71 had important biological functions in cancer cell growth signalling 
pathways and the response to the chemotherapy. The expression of these biomarkers should 
be considered to define a specific risk group for whom a clinical trial with novel agents could 
be designed. Also clinical trials for single or combination of novel agents to target these 
proteins should be considered. Aurora A is the protein involved in the cell cycle progression 
and was consistently shown to be associated with poor RFS and OS in every group analysis. 
Chemotherapy in combination with anti-Aurora A such as MLN 8054 (Macarulla, 2010) and 
Alisertib (Matulonis, 2012) that have been tested in Phase 1 and 2 trials should be evaluated 
in breast cancer patients with RR > 50%.  Single agent Alisertib is currently in phase 2 
clinical trial for metastatic solid tumours including breast cancer.  
In agreement with other studies reported in the literature, the poor survival in this study was 
associated mainly with the expressions of proteins involved in the proliferation – Ki-67 and 
Aurora A. This is not surprising as proliferation has complex associations with treatment 
outcomes. Most of the chemotherapeutic agents such as cyclophosphamide, anthracycline, 
flurouracil and taxanes act as non-specific cell cycle or DNA toxins and therefore the main 
predictive marker would be the proliferation rate. High proliferation is an indicator for a 
better response to neoadjuvant chemotherapy but those who don’t achieve a pCR are at the 
high risk of early disease recurrence and shorter survival.  There were no similar parameters 
to predict pCR of micrometastases in the adjuvant setting although the estimate of failure rate 
can be worked out from the known risk factors. In patients treated with neoadjuvant 
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Docetaxel + Capecitabine chemotherapy, PAM-50 ROR-S scores that mainly reflect the 
proliferation genes expressions decreased in response to the chemotherapy and this change 
was correlated with the clinical response. (Korde, 2010) (Dumbier, 2011) Survival benefits 
from adjuvant endocrine therapy have been seen in patients only when the proliferation index 
falls significantly with the given treatment. “Preoperative Endocrine Prognostic Index” 
(PEPI), which is the Ki-67 index after the neoadjuvant endocrine treatment, is more 
predictive than the baseline Ki-67 for the long term survival for clinical stage 2 and 3 
diseases. (Ellis, 2008) Decrease in Ki-67 expression in response to neoadjuvant anastrazole 
was about 75% in Luminal tumours compared to very little decrease in basal and HER2 
enriched subtypes. Clinical response and surgical outcomes were similar in LA versus LB 
tumours; however, a PEPI of 0 (best prognostic group) was highest in the LA subset (27.1% v 
10.7%; P = .004). (Ellis, 2011) In the untreated population, the prognostic impact of 
proliferation genes is limited to the ER+ HER2− subset since HER2+ or ER−HER2− subsets 
are associated with high proliferation activity. Therefore the clinical utility of most of the 
gene assays that largely depends on the expression of proliferative genes is mainly for the 
ER+ HER2− subset. There is no consensus at present on the gold standard method with a 
division between IHC or multigene assays, to assess proliferation status, but IHC is widely 
used in daily clinical practice mainly due to its lower cost.   
Although, “overall survival” (OS) is regarded as the most important and meaningful end 
point in cancer care, “recurrence status” is the more appropriate end point to endorse the 
complete failure of the adjuvant chemotherapy. OS after the disease recurrence depends on 
the use of systemic therapies, best supportive care and patient’s wishes for further active 
treatments.  Therefore the measurement of the OS may not truly reflect the effectiveness of 
the adjuvant chemotherapy.  However, the adjuvant chemotherapy may improve the OS by 
reducing the micrometastatic disease burden and delaying significant damages to vital organs.  
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Disease recurrence, in no doubt, indicates that the adjuvant chemotherapy did not manage to 
clear the micrometastases like other adjuvant therapies. However when a patient remains free 
of recurrence it is not possible to say if it is solely due to the adjuvant chemotherapy as there 
are many other  possible factors such as:  
1. No distant or locoregional micrometastases at the time of definitive curative surgery 
2. Effect of other adjuvant therapies such as endocrine and anti-HER2 treatments while 
chemotherapy was actually ineffective in a particular patient 
3. Combination effect of chemotherapy and other adjuvant therapies 
4. Late disease recurrence that may occur after the study follow-up period. 
5. Biology of individual tumour that actually dictates above mentioned factors 
As routine investigations for visceral metastases are not recommended in current standard 
follow up practice, some patients in the “controls” group could be “patients with 
asymptomatic recurrent disease” at the time of the study.  But 5 years breast cancer 
recurrence status is a very valid measure to evaluate the effectiveness of adjuvant 
chemotherapy because the breast cancer recurrence benefit from adjuvant chemotherapy is 
seen during years 0 – 4 although the mortality benefit is seen throughout the first decade. 
(EBCTCG, 2012) Therefore it is more reasonable to focus on identifying patients who 
develop a cancer recurrence rather than patients who remained recurrence free, to evaluate 
the effectiveness of the adjuvant chemotherapy.  
More recently the focus has been made on the role of neoadjuvant chemotherapy to evaluate 
the effectiveness of the treatment and to find various predictive biomarkers that are 
associated with pCR which is a very strong indicator for long term survival. However pCR at 
primary tumour site doesn’t mean pCR at micrometastatic site as there are patients who had 
disease recurrence despite achieving pCR of primary tumour. (Untch, 2011) This is also 
supported by the findings of pCR in the breast primary tumour but residual cancer cells in the 
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associated axillary lymph nodes and the negative impact of this on survival as a result (von 
Minckwitz, 2012). This could be due to the differing phenotype expressed between primary 
tumour cells population and the cells that had metastasised. This phenomenon is recognised 
and has been demonstrated by the finding of differing ER, PR, HER2 and other molecular 
proteins expression patterns between matched primary tumours cells, axillary nodes and 
distant metastases. Whilst these changes may occur under the influence of adjuvant therapies 
especially in the case of metachronous metastases, this may simply relate to the process of 
metastasis formation and sub clonal populations. (Sjöström-Mattson, 2009) (Bogina, 2011) 
(Park D, 2007) Intratumour genomic heterogeneity was recently reported in renal tumour 
samples with good and poor prognostic gene signatures being detected in different regions of 
the same tumour. (Gerlinger, 2012)  In breast cancer, the discordance in expression was seen 
in up to 36% of patients for ER and up to 54.2% for PR, and the gain was less common than 
the loss at the metastatic site. (reviewed in Sari, 2010) It was also true for HER2 expression 
in most of the retrospective studies.  (Sari, 2010) (Amir, 2008) Intratumor heterogeneity, 
associated with heterogeneous protein function, may foster tumour adaptation and therapeutic 
failure through Darwinian selection. (Gerlinger, 2012) 
An increase of Ki-67 immunoreactive cells in matching axillary lymph nodes (ALN) 
compared with that of primary tumours (PT) was observed in 84% of cases (mean 17%; vs.  
8%; p<0.001), whereas in 16% of the cases Ki-67 index was  two to six times lower in the 
ALNs than in the corresponding PTs (mean 3.2% vs. 12.5%; p<0.005) according to a study 
involving 160 node positive breast cancer patients. The discordance between ALN and PT Ki 
67 expressions was independent of the histology and the grade. (Cabibi, 2006) Destructive 
effect of neoadjuvant chemotherapy on neoplastic cells was seen to a lesser degree in the 
lymph nodes metastases compared to the primary tumour cells. (Koda, 2007b) Reduction in 
the expression of the Ki-67 and Bcl-2 by neoadjuvant chemotherapy was also relatively 
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smaller in ALN than the PTs indicating the different biology between the primary tumour and 
metastasised tumour cells that respond differently to the same chemotherapy. (Koda, 2007a) 
“Matched case control” design was used here because it requires smaller sample size, lower 
cost, readily available follow up data and is less time consuming. It is however a challenge to 
have an exact matching between cases and controls because of the many known risk factors, 
which create a large number of stratification groups. To overcome this problem Adjuvant tool 
was used to estimate the overall risk based on a number of well recognised risk factors for the 
individual patient. Although the cases are defined as patients with breast cancer recurrence 
within 5 years, Adjuvant 10 year recurrence risk (RR) was used for matchingbecause 
Adjuvant!  5 years recurrence risk was not available.  Each “control” was selected to have RR 
either higher than or equal to or not more than 10% points below that of the matched “case” 
to increase the probability of different survival outcome being due to the factors in question 
other than known risk factors.  When OPTION tool from Oxford became available recently 
for 5 years RR, credibility of the matching was examined by OPTION 5 years RR using final 
ER/PR status from the study and this demonstrated that mean risks between the cases and 
controls were not significantly different.  There was also no difference in OPTION 10 years 
RR. However, there were statistically significant differences in OPTION 5 and 10 years post 
adjuvant therapies RR between cases and controls, the latter having lower risk. This is mainly 
due to the risk reduction from the endocrine therapy as there were more patients with ER or 
PR positive tumours among controls. At the time of the patient selection, ER/PR status was 
not available for some of the the patients treated before year 2000 and “ER unknown” status 
was used to calculate RR. This would have assigned lower than the actual risk for patients 
that eventually turned out to be ER/PR negative but higher than the actual RR for the patients 
eventually turned out to be ER/PR positive. The post adjuvant therapy RR for some ER/ PR 
positive cancers could be lower than the actual risk because OPTION tool allocates same 
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amount of benefit for adjuvant endocrine therapy regardless of Allred score and either single 
ER or PR or both expression. Another reason is that OPTION gives higher benefit for 
aromatase inhibitors than tamoxifen and as a result controls who switch to AI in year 3 or 4 
and who had extended endocrine therapy with AI  were assigned much lower  RR than the 
other patients who had tamoxifen only. The cases did not get this advantage because their 
cancers relapsed before they had an opportunity to switch to AIs. According to the published 
data, nearly half of postmenopausal women actually do not complete the recommended five 
years course of tamoxifen therapy and therefore the endocrine therapy benefit given here for 
full 5 years treatment could be an overestimate. (Owusu, 2008) To avoid this potential 
confounding effect, the analysis was done for ER/PR positive and negative patients 
separately. By analysing that way, however, the sample size gets smaller as a result and this 
could have reduced the power of the study and the chance of finding significant results. By 
assigning more than one control for each case could have overcome this problem but from the 
statistical point of view there is very little to be gained by including more than two controls 
per case. (Lewallen 1998) However, it proved difficult to find enough suitable controls 
because the chemotherapy was not very commonly used in patients whose recurrence free 
status was long enough. There was also an obstacle in identifying suitable tumour blocks to 
retrieve from the storage.  
Tissue Micro Arrays analysis has revolutionised the exploratory translational research. This 
technique saves the labour, cost, time, invaluable limited cancer tissues and ensures 
optimised IHC standardized processing between different samples. The down side, however, 
is the loss of tissue cores during the processing. Loss of up to 5 – 10% cores has been 
reported for 0.6 mm cores. The loss can be minimised by using the bigger size of 1 – 2 mm 
cores or multiple cores for each patient. . The validity of TMA analysis in breast cancer was 
confirmed by the comparison with whole section analysis and two 0.6 mm cores yielding 
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comparable results for ER expression in more than 95% of cases, the figure rising to 99.5% 
when the core number was increased to 5. (Camp, 2000) Even one 0.6 mm core was reported 
to be sufficient to give results equal or even superior to the whole section for ER, PR and p53 
in breast cancer. (Torhorst, 2001) Very good concordance between 3 TMA cores and whole 
slides analysis for ER, PR, HER 2 by both IHC and FISH had been reported (Thomson T, 
2009, 2010) and large scale translational TMA studies had adopted 3 cores protocol. (Ali, 
2013) (Bartlett, 2010) (van der Hage, 2011) (Cuzick, 2011) In the present study loss of cores 
ranged from 0% (Aurora A) to 21.6% (MCM-2) with an average of 10.9% for all antibodies. 
However the final expression result was not available only for maximum 5.6% of patients in 
the case of MCM-2 protein with an average of 1.8% for all proteins.   
Immunohistochemistry was chosen as the method to evaluate this range of biomarkers 
because of a number of advantages such as its wide availability, relatively low cost, easy 
preservation of stained slides and preservation of morphology. However the disadvantages 
include different expression pattern from potential variability in technical issues such as 
tissue fixation in formaldehyde, tissue processing and embedding procedure in heated 
paraffin wax, storage condition and duration, intensity of antigen retrieval, type of antibody 
(polyclonal versus monoclonal), lack of a positive internal control signal and system control 
samples etc. As a standard for tissue fixation, neutral buffered formalin 10%, which contains 
4% formaldehyde, is used to induce the formation of crosslinks between proteins or between 
proteins and nucleic acids involving hydroxymethylene bridges, masking the antigen-binding 
sites by altering the 3-dimensional structure of proteins. Such masking of epitopes needs to 
be reversed by several antigen retrieval methods before antigen antibody reaction can occur. 
Delay to fixation can cause proteolytic degradation and loss of immunoreactivity. Insufficient 
fixation time can cause incomplete process as the crosslinking is a slow process requiring 24 
to 48 hours to complete. This could lead to coagulation fixation during the tissue dehydration 
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by alcohol resulting in a variable admixture of crosslinking and coagulation fixations that 
accounts for many of the observed variations in IHC. Therefore it has been recommended 
that the tissue is fixed within one hour from collection point in 10% neutral pH, phosphate-
buffered formalin for a minimum of 6 hours to improve standardization and reliability of 
IHC. In invasive breast cancer, tissue fixation for a period just beyond 72 hours does not 
result in diminished sensitivity of ER, PR, or HER-2 IHC assays when compared with tissue 
fixed for a shorter period. (Tong, 2011) American Society for Clinical Oncology (ASCO) and 
College of American Pathologists (CAP) implemented guidelines for IHC processing for ER 
and PR (between 6 – 72 hours fixation time) and HER2 (at least for 6 hours but not more than 
48 hours).  (Wolff, 2007) (Yaziji, 2008) (Hanna, 2007) (Hammond, 2010) (Walker 2008) 
There was no similar guidance for other proteins included in this study.  By using the samples 
stored in the pathology departments in the same cancer network and automated highly 
accurate IHC machine to process TMA slides reduce these confounding factors.  
Another issue with IHC is the measurement of staining index and applying a semi-
quantitative subjective slide scoring system to dichotomise the results for positive and 
negative expression. There is no consensus on which part of the whole tissue slide, which 
usually contains very heterogenous cancer tissue, should be selected for the scoring although 
this is not an issue for the 0.6mm core tissues on the TMA. There are well established scoring 
methods for ER, PR and HER2 but not for the other molecular proteins that have been 
studied extensively to date. Many published studies used different cut-off value to define 
positive/ negative or over/ under expression of a particular molecular protein. “X-tile” 
statistics, the median or mean value, “no or any staining” or “previously reported cut off 
value” have been used to define the cut-off point in various studies. Different cut off levels 
make it difficult to compile the results from different studies and make a valid conclusion. 
 
Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 214 
 
On the other hand multi-gene assays are said to be more accurate and reproducible compared 
to IHC methods that do not use internal reference proteins for normalization. These assays 
are based on RNA analysis and the credibility of the assays depends on the good quality and 
quantity of RNA. Several factors, including prolonged time from excision to freezing or 
fixation and prolonged storage in formalin fixed paraffin blocks can produce wide variability 
in mRNA quality.  Therefore high standard processing, storage, and preparation techniques 
are essential for the success of multigene assays. Dutch multi-institutional pilot study 
suggested that good quality RNA can be harvested from the material maintained in high salt 
fixative solutions (RNAlater; Ambion, Austin, TX) in over 95% of cases.  
There are discordances between gene expression assays and IHC expression analysis.  Of the 
626 ER positive tumours analysed in a microarray test set, 73% were luminal (A or B), 11% 
were HER2 enriched, 5% were basal-like, and 12% were normal-like by gene analysis. The 
ER negative tumours comprised 11% luminal, 32% HER2-enriched, 50% basal like, and 7% 
normal-like. 64% and 6% of clinically HER2 positive cases are classified as HER2 enriched 
and basal subtypes, respectively, by gene analysis. 56%, 24% and 9% of clinically HER2 
negative cases are reclassified as luminal, basal like and HER2 enriched cancers, 
respectively, by the gene analysis. (Parker, 2009) The similar discordance was found for 
dichotomised IHC expressions and RT-PCR gene analysis method for CK-5/6, CK-14 and 
CK-17. 14% of cases dichotomised based on quartiles and ROC as negative on IHC 
examination for CK-5/6 are found to have high CK-5 mRNA levels. (Kordek, 2010) Ki-67, 
whose expression contributes significantly to the positive recurrence score of Oncotype Dx, 
was found to overexpress in some of the patients in low risk group of the Oncotype Dx. 
(Gwin, 2009)  
There are also discordances between risk assessments by multigene assays and 
clinicopathologic prognostic tools such as St. Gallen, National Institute of Health (US) 
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guidelines, OPTION and Adjuvant tool. “High risk” as determined by gene assay could be 
defined as “low risk” by clinicaophathologic tools/ guidelines and vice versa.  (van de Vijver, 
2002) (Campbell 2010) Analysis of 97 genes classifies breast cancers into 2 distinct 
molecular grades – Genomic Grade Index 1 and 2 which are strongly associated with 
histologic grade 1 and 3 respectively. (Sotiriou, 2003 & 2006) Histologic grade 2 tumours 
were thought to be a mixture of GGI 1 and 2.  Classifying histologic grade 3 into 2 by IHC 
could be because of the loss of mitotic figures as mitosis managed to complete before the 
tumour specimen was fixed in the formalin. 
Performances of 6 different multigene assays - Oncotype Dx recurrence score (GHI), PAM-
50 ROR-S/P, Mammaprint (NKI70), Rotterdam  76 (ROT76), Genomic index of Sensitivity 
to endocrine therapy (SET) and oestrogen induced gene set (IE-IIE) - were tested in ER+ 
patients who had only adjuvant tamoxifen. All the assays mainly differentiate Luminal A 
subtypes from the other subtypes. The high hormonal sensitivity groups (SET-high and IE-
like) and low risk of recurrence groups (PAM50-RORS-low, PAM50-RORP-low, GHI-low, 
ROT76-good and NKI-good) were largely composed of luminal A tumours (>71%–100%). 
All predictors identified groups of node-negative patients with 93.7%–97.9% and 88.4%–
96.2% distant recurrence free survival at 5.0 and 8.5 years, respectively, although the number 
of patients in each group differed. (Prat, 2012) Multivariate analyses including two predictors 
at a time revealed that, in most cases, many of these correlated predictors, in particular the 
PAM50-RORP, GHI, NKI70 and SET, remained statistically independent of each other. The 
risk group assignment concordance among these predictors was found to be 36% for PAM50-
RORP versus GHI, 54% for PAM50-RORP (low/medium versus high) versus NKI70 and 
74% for GHI (low/intermediate versus high) versus NKI70. (Prat, 2012) Less than 25% of the 
genes were shared between signatures, except for 9 and 11 genes of the GHI signature (n = 
21) that were present in the IE-IIE and PAM50, respectively, and 15 genes of the IE-IIE 
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signature that were present in PAM50. In spite of relatively little gene overlap, all predictors 
were significantly correlated with PAM50-RORS, IE-IIE and GHI showing the highest 
correlation between them. (Prat, 2012) 
Intrinsic subtypes, 70-gene signature, wound response signature, and Recurrence Score were 
found to be highly concordant in classifying patients into low and high-risk groups. But 
combining these signatures did not yield a significant improvement in the predictive 
accuracy, suggesting that the prognostic information provided by these signatures is largely 
overlapping. (Fan, 2006) However, in a study with 295 breast cancer patients, wound 
response signature was detected in tumours of patients who died of breast cancer regardless 
of 70-genes poor prognosis signature status.  Almost all of the basal-like tumours were found 
to express both 70-gene poor prognosis signature and the activated wound-response 
signature. (Chang, 2005) Patients with both the activated wound-response signature and the 
70-gene poor prognosis signature had a risk of metastatic disease 6.4-fold higher than patients 
with 70-gene good prognosis signature with 10 years distant metastases free survival rate of 
only 47%, a good indication for most aggressive adjuvant chemotherapy.  (Chang, 2005) 
There have been reports on correlations between different molecular subtypes according to 
IHC or multi-genes based expression assays and the chemotherapy effectiveness. More than 
20% improvement in 5 year OS and RFS from CEF over CMF was found in HER2 enriched 
tumours while the benefit was only 2% in other molecular subtypes. Within clinically defined 
HER2 + tumours, 79% were classified as the HER2 Enriched subtype by the gene expression 
and this subset was strongly associated with better response to CEF versus CMF (62% vs. 
22%, P < 0.001). There was no significant difference in survival benefits between CEF and 
CMF in basal-like tumours. (Cheang, 2012)  
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 In a study involving 62 breast cancer patients treated with neoadjuvant chemotherapy 
(paclitaxel followed by CAF) the basal-like and HER2 enriched subgroups were associated 
with the highest rates of pCR, 45% for both,  while the luminal tumours had a pCR rate of 
only 6 %. No pCR was observed among the normal-like cancers. The molecular class was not 
independent of the conventional cliniocopathologic predictors of response such as ER status 
and the nuclear grade. None of the 61genes associated with pCR in the basal-like group were 
associated with pCR in the HER2 enriched group, suggesting that the molecular mechanisms 
of chemotherapy sensitivity may vary between these two ER negative subtypes. (Rouzier, 
2005a) There were no studies to evaluate the effect of drug pharmacokinetics or cellular 
transmembrane transport system in individual patient for each molecular subtype. pCR (no 
residual disease in breast or lymph nodes) is suggested as a suitable surrogate end point for 
patients with luminal B/HER2-negative, HER2-positive (non-luminal), and triple-negative 
disease but not for those with luminal B/HER2-positive or luminal A tumours by a study that 
retrospectively evaluated 6,337 patients treated with the neoadjuvant chemotherapy. (von 
Minckwitz, 2012)  
Using inexpensive IHC method for molecular protein expressions many studies have been 
carried out to reproduce the different risk levels defined by expensive multigenes assays such 
as Oncotype Dx test. A mitotic count score greater than 1 combined with a negative PR 
expression by IHC was shown to be predictive of an intermediate or high Oncotype DX 
recurrence risk group. (Auerbach, 2010) IHC4+C score (ER, PR, HER2, Ki-67 IHC 
expressions and clinicopathological features) was shown to give recurrence risk very similar 
to Oncotype Dx recurrence risk score in ER+ patients participated in an adjuvant endocrine 
trial that compared anastrozole against tamoxifen. (Cuzick, 2011) By applying IHC4+C score 
to intermediate risk group defined by Adjuvant! RR, 15 of the 26 patients was reclassified as 
low risk and no patient was reclassified as high-risk group. Of the 59 patients classified as 
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intermediate risk group by the NPI, 24 were reallocated to a low risk group and 13 to a high 
risk group.  
In Oncotype Dx test, ER, PR, Bag-1 and Bcl-2 expressions contribute to the minus score 
(lower recurrence risk) while HER2, Ki-67, Aurora A and CD-68 expressions contribute to 
the plus score (higher recurrence risk). Findings in this study are in agreement with that 
pattern except CD-68 IHC expression (as tumour associated macrophage infiltration) which 
was correlated with good prognosis in this study, similar to better prognostic effect reported 
in the colorectal cancer. (Oberg, 2002) However the contribution by CD-68 expression to the 
Oncotype Dx recurrence score (+0.05 x CD-68 expression) was the smallest among all the 
other genes in the assay. (Paik, 2004) Paradoxically N0 stage was significantly associated 
with higher risk of disease recurrence in this study. This was probably because only node 
positive patients were selected for the control group while there were some node negative 
patients in the “case” group. 
IHC was not successful for Cathepsin L-2, GSTM-1, Plk-1 and VEGFR-2 proteins. This was 
due to a number of factors including limited TMA tissues with core losses, time, financial 
constraints for consumables, techniques which needed further optimisation or the antibodies 
that are not considered specific enough. The other available methods such as heat induced 
epitope retrieval in Sodium citrate buffer or 1 mM EDTA buffer adjusted to pH 8 or Tris-
EDTA buffer using either pressure cooker or microwave, enzymatic retrieval methods such 
as pipetting and immersion and different antibody dilution are worth trying for the successful 
IHC staining for these potential biomarkers, if circumstances had allowed.  
Agendia has marketed many gene assays for clinical use. TargetPrint
®
 and MammaPrint
® 
can 
report ER, PR and HER2 expression status by single gene expression. BluePrint is an 80-gene 
expression signature that classifies breast cancer into Basal-type, Luminal-type and ERBB2-
type cancers. The BluePrint Molecular Subtyping Profile in combination with MammaPrint 
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test result provides a greater level of clinical information to assist in therapeutic decision-
making.  TheraPrint is a microarray-based gene expression panel of 56 genes that have been 
identified as potential targets for prognosis and predictor for response to therapeutic 
treatments. DiscoverPrint
® 
is a tool for the development of companion diagnostics in clinical 
trials of oncology therapeutics for the biotechnology and pharmaceutical industry. 
(www.agendia.com)  
Recently a new web based tool “www.recurrenceonline.com” has been launched.  It is 
accessible online and available free of charge. It is based on analysing standard genome-wide 
microarrays and is able to compute varied prognostic parameters simultaneously. It supports 
only Affymetrix HGU133A and HGU133plus2 microarrays in raw CEL files format. This 
tool automatically evaluates uploaded microarray data to provide Oncotype Dx recurrence 
risk for node negative, ER positive patients, independent recurrence risk classification by 
using the 6 strongest genes for any nodal and ER status, 4 strongest genes for node negative 
ER positive patients, 3 strongest genes for node positive patients, and also expression of ER 
and HER2 receptors. The tool has been validated using data from 2,472 publicly available 
microarrays. (Gyorffy, 2012)
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Samples of web pages for one step online interface for input (A) and result (B) of 
“Recurrence online” (This illustration was borrowed from the published article by Gyorffy, 
2012) 
 
 
 
Patient ID: GSM177892.CEL 
Lymph node status: Negative 
Date: 2012-07-29 
Microarray platform: HGU133A 
Array Quality Test: passed 
 
Risk category using strongest genes: low risk (mean expression: 540) 
Category: lymph node negative ER positive 
Genes used in the analysis: MELK,CDC2,TOP2A and PRC1 
 
Computed Recurrence Score: 14 (low risk) 
Eligibility Test: passed. 
The recurrence score can be used to predict the probability of distant recurrence in patients with breast cancer 
who have estrogen-receptor positive tumors with no lymph nodes involved: 
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ER status: Positive. (MAS5 normalized gene expression: 9541) 
 
HER2 Status: Negative. (MAS5 normalized gene expression: 1493) 
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11. Conclusion 
 
In conclusion this matched case control study has shown that molecular subtypes have 
predictive effect for survival and are superior to the clinical prognostic tools such as Adjuvant 
and OPTION in breast cancer patients with RR >50 who had adjuvant chemotherapy. 
However, in this population, Luminal A cancers have significantly higher recurrence risk 
despite adjuvant chemotherapy, which is a completely different finding to Luminal A patients 
found in other breast cancer population. Therefore, this would suggest that Luminal A 
patients with OPTION 5-year recurrence risk >50 should be offered adjuvant chemotherapy. 
No predictive markers could be found to predict the recurrence in this Luminal A group. New 
predictive markers/ factors are urgently needed to identify such patients. IHC expressions of 
proteins coded for by the genes used in the Oncotype Dx show similar positive/negative 
effect on the survival outcomes although statistically significance level is reached only for a 
few proteins. There was an opposite finding for CD-68 when it was analysed as an expression 
of macrophages. Aurora A expression is predictive of poor outcome regardless of ER/PR 
status and may be useful to identify patients suitable for evaluation of combined 
chemotherapy and Aurora A kinase inhibitors. As the gene assay based prognostic tools will, 
almost inevitably, become more affordable in the future, the integration of genes assay 
analysis, IHC analysis and clinicopathological parameters should help create better risk 
stratification and prediction of treatment outcome. In this way breast cancer adjuvant trials 
could be better informed grouping appropriate patients into appropriate therapies, leading to a 
significant improvement in breast cancer survival for the future. 
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14.  IHC images 
 
 
 
 
 
Aurora A positive (above) and negative (below) 
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Bag-1 positive (above) and negative (below) 
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CD-68 (Tumour associated microphages infiltration) positive (above) and negative (below) 
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CD-71 positive (above) and negative (below) 
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CK-5/6 positive (above) and negative (below) 
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EGFR positive (above) and negative (below) 
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HER-2 positive (above) and negative (below) 
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ER positive (above) and negative (below) 
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PR positive (above) and negative (below) 
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Ki-67 positive (above) and negative (below) 
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MCM-2 positive (above) and negative (below) 
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PDGFR-α positive (above) and negative (below) 
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Bcl-2 positive (above) and negative (below) 
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15. Appendix 
 
 
 1. Contribution list to this research work 
 
M Moe developed the hypothesis after a thorough literature review, designed the study, 
secured the funding from Pfizer, reviewed the patients’ clinicopathologic data in the hospital 
database, selected the study population, retrieved the FFPE blocks, actively involved in 
marking the area on H & E stained slides for TMA cores with the help of consultant 
pathologists, construction of the TMA blocks with the help of the technician,  automatic (XT 
Benchmark machine) and manual IHC staining with the help of senior technicians from 
Singleton hospital pathology laboratory and senior scientists from Tenovus Centre for Cancer 
Research laboratory in Cardiff, respectively. M Moe analysed all the TMA cores for 
expression of individual protein and the supervisor Dr Richard Adams independently scored 
10% of random TMA cores to verify the results. Bag-1 and CD-71 expressions were scored 
by M Moe together with Dr J Gee and Dr P Finlay from Tenovus centre for cancer research, 
Cardiff. M Moe analysed the data using SPSS v.16 and a senior statistician from Tenovus 
laboratory in Cardiff examined the results. M Moe wrote the thesis. The whole research 
project was carried out under the supervision of Dr Richard Adams (Oncology, Velindre 
Hospital, Cardiff) and Professor Robert Mansel (Surgical department, University hospital of 
Wales, Cardiff). 
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2. Abbreviations list  
 
5N: 5 markers negative  
AC-Taxol: Adriamycin, cyclophosphamide - taxol 
AJCC: American Joint Committee on Cancer  
ALN: Axillary lymph nodes 
ASCO: American Society for Clinical Oncology 
ATAC: Adjuvant Tamoxifen, Anastrozole combination trial. 
ATP: Adenosine triphosphate    
Bag-1: Bcl-2 associated anthanogene 1 
BCSS: Breast cancer specific survivals  
BRCA: Breast Cancer gene 
CAP: College of American Pathologists 
CB: Core Basal 
CBP: Core basal phenotype 
CC1 solution: cell conditioner 1 solution 
CD-68: Cluster of differentiation 68 
CD-71: Cluster of differentiation 71  
cDNA: complimentery DNA 
CEL: CIMFast Event Language (file format) 
CI: Confidence interval  
CISH: Chromogenic in situ hybridisation 
CK-5/6: Cytokeratin 5/6 
CMF: Cyclophosphamide, Methotrexate, 5-Fluorouracil  
CRUK: Cancer research, UK 
CSR: Core serum response 
CYP2D6: Cytochrome p450 2D6 
DCIS: Ductal carcinoma in-situ 
D-CMF: Doxorubicin – CMF 
df: degree of freedom  
DNA: Deoxyribonucleic Acid 
DPX: Di-N-Butyle Phthalate in Xylene  
DRFS: Distant relapse free survivals 
EBCTCG: Early Breast Cancer Treatment and Collaborative Group  
E-CMF: Epirubicin - CMF 
ECRIC: Eastern Cancer Registration and Information Centre  
EDTA: Ethylenediaminetetraacetic acid 
EGF: Epidermal growth factor 
EGFR: Epidermal growth factor receptor 
ELISA: Enzyme linked immunosorbent assay 
ER: Oestrogen receptor  
ERE: Oestrogen response element 
FAC: 5-Flurouracil, Adriamycin, Cyclophosphamide 
FASG: The
 
French Adjuvant Study Group 
FEC:  5-Flurouracil, Epirubicin, Cyclophosphamide  
FFPE: Formalin fixed paraffin embedded  
FGFR1: Fibroblast growth factor receptor 1 
FISH: Fluoresence in situ hybridisation 
FNA: Fine needle aspiration 
GGI: Genomic Grade Index 
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GHI: Genomic Health Index 
GIST: Gastrointestinal stromal tumour 
GSTM-1: Glutathione S transferase Mu 1 
H & E: Haematoxyline & Eosin 
H score: Histochemical score 
H: HER2 enriched 
HCC: Hepatocellular carcinoma 
HER2: Human epidermal growth factor receptor 2 
HGF: Hepatocyte growth factor 
HOXB13: Homeobox gene B 13  
HR: hazard ratio 
HRP: Horseradish peroxidase 
HRT: Hormone replacement therapy 
Hsp: Heat shock protein 
IBCSG: International breast cancer study group 
IGF-I: Insulin like growth factor-I 
IHC: Immunohistochemistry 
IMAC 30: Immobilized metal affinity capture 30 
IMPACT: Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen 
(trial) 
IUC: International Union Against Cancer 
LA: Luminal A  
LB: Luminal B 
LI: Labelling index 
MAPKinase: Ras/mitogen-activated protein kinase 
MCM-2: Minichrosome maintenance protein 2 
MGI: Molecular grade index 
MISS: Membrane initiated steroid signalling 
N: Nodal stage 
NCCN: National Colleborative Cancer Network 
NISS: Nuclear initiated steroid signalling   
NKI: Netherlands Cancer Institute (in Amsterdam) 
NPI: Nottingham Prognostic Index 
NSABP: National surgical adjuvant breast and bowel project 
ORC: Origin recognition complex 
OS: Overall survival 
PAI-1: Plasminogen activator inhibitor 1 
PAM: Prediction Analysis of Microarray 
PAM50-RORP: PAM50 risk of recurrence (based on) proliferation 
PAM50-RORS: PAM50 risk of recurrence (based on) subtype 
PBD: Polo-box domain 
PBS: Phosphate Buffered Saline 
pCR: Pathological complete response 
PDGF: Platelet derived growth factor  
PDGFRα: Platelet derived growth factor receptor alpha 
PEPI: Preoperative endocrine prognostic index 
PI3K/Akt: Phosphatidylinositol 3 kinase 
Plk-1: Polo like kinase 1 
PR: Progesterone receptor 
PRE: Progestin response elements  
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PRR: Proportional risk reduction  
pT: Pathological tumour stage 
PT: Primary tumours 
PVI: Peritumoural vascular invasion 
qRT-PCR: Quantitative reverse transcriptase polymerase chain reaction 
RFS: Relapse free survival 
RNA: Ribonucleic acid 
ROR: Risk of recurrence 
ROR-C: ROR in conjunction with the clinical features 
ROR-S: ROR based on the subtype classification alone 
ROT76: Rotterdam 76 
RR: Recurrence risk 
RS: Recurrence score 
RT: Room temperature 
RT-PCR: Reverse transcriptase polymerase chain reaction 
S.E: Standard Error 
SEER: Surveillance, Epidemiology and End Results 
SET: Sensitivity to Endocrine Therapy 
Sig.: Significance 
siRNA: Small interfering RNA 
SISH: Silver In-Situ Hybridisation 
SNP: Single Nucleotide Polymorphism 
SPSS v.16: Statistical Product and Service Solutions (software) version 16 
T: Tumour size stage 
TAM: Tumour associated macrophages 
Tf: Transferrin  
TfR:  Transferrin receptor 
TKI: Tyrosine kinase inhibitor 
TMA: Tissue microarray 
TNM: The tumour-node-metastasis system  
TNP: Triple negatives phenotype  
UICC: Union for International Cancer Control 
UK: United Kingdom 
uPA: urinary Plasminogen Activator 
US: United States 
VEGFR-2: Vascular endothelial growth factor receptor 2 
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3. AJCC staging 
 
This AJCC staging poster was downloaded on 08.07.2013 from the website 
http://www.cancerstaging.org/staging/index.html. 
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4. Intended publications from this research work 
 
Intended publications from this research are: 
1. Molecular markers by IHC to predict 5 years recurrence in early breast cancer patients 
who received adjuvant chemotherapy 
2. Could IHC expressions of molecular proteins coded for by the cancer related genes used 
in Oncotype Dx be predictive of 5 years recurrence in early breast cancer patients who 
received adjuvant chemotherapy? 
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5. Presentations of this research work to cancer conferences 
 
A. The abstract of the poster presented to 2
nd
 IMPAKT breast cancer conference, 2011 
(Poster number: 89p). (Published as an abstract in Annals of Oncology 
supplement:22:S2:ii46. (2011) 
 
89P. A STUDY SUGGESTING SUPERIORITY OF IMMUNOHISTOCHEMICAL 
(IHC) MOLECULAR SUBTYPES BASED UPON ARCHIVED FORMALIN FIXED 
PARAFFIN EMBEDDED (FFPE) BLOCKS, PREDICTING 5 YEARS RELAPSE 
FREE SURVIVAL (RFS) AND OVERALL SURVIVAL (OS) IN EARLY BREAST 
CANCER PATIENTS WHO RECEIVED ADJUVANT CHEMOTHERAPY, 
COMPARED TO ADJUVANT! RECURRENCE RISK (RR) 
M. Moe1, R. Adam2 1. Oncology, Singleton Hospital, Swansea/UNITED KINGDOM, 2. 
Oncology, Velindre Hospital, Cardiff/UNITED KINGDOM 
 
Aim: To predict 5 years RFS and OS (months) by analysing molecular subtypes based 
on ER, PR, HER2, EGFR, Ki67, CK 5/6, MCM2, Aurora A, Bcl-2, PDGFRa protein 
expression by IHC in a matched case control study. 
Method: 72 cases (R) (relapsed within 5 years of curative surgery), 72 (C) controls 
(matched to cases by Adjuvant! RR and node+), 34 low risk control (LC) (Adjuvant! 
RR <50%) were identified. (Control = no relapse > 5 years). Tissue Micro Arrays were 
constructed with cores from invasive cancer tissue. IHC staining was performed for 
each antibody. Protein expression was evaluated on digitised images (Mirax _) (by first 
author) and independently validated. 5 molecular subtypes were analysed based upon 
IHC [Luminal A (LA = ER/PR+, HER2-,Ki67-) and B (LB = ER/PR+, HER2/Ki67+), 
HER2 enriched (H = ER-,PR-, HER2+), core basal (CB = ER-, PR-, HER2-, CK5/6/ 
EGFR+), 5 negative (5N = ER-,PR-,HER2-,EGFR-,CK5/6-)] together with MCM2, 
Aurora A, Bcl2 and PDGFRa. SPSS v.16. was used for statistical analysis. 
Findings: For R:C:LC groups, age (median) = 30-77 (57): 28 – 74 (52): 36 – 78 (51); 
RFS (median) = 4.5 – 59.9 (23.7): 74.3 – 164.4 (103.5): 79 – 161 (104.5); OS (median) = 
8.1 – 139.4 (41.2): 74.3 – 164.4 (104.9): 79 – 161 (105); Adjuvant! RR (median) = 26.9 – 
96.7 (65): 50 – 94 (66): 29 – 47 (37). All but 4 patients of R group had died from breast 
cancer. 3 patients from C & LC died from non-breast cancer causes. Subtypes are: LA = 
57 (32%), LB = 49(27.5%), H = 26 (14.6%), CB = 26 (14.6%), 5N = 12 (6.7%), missing 
= 8 (4.5%). For subtypes LA: LB: H: CB: 5N, mean Adjuvant! RR = 62: 62: 56: 58: 56 (p 
= 0.54), median RFS = (has not reached): (has not reached):32.2: 52.2: 31.4 (p = 0.001), 
and OS = (has not reached): 110: 68: 61.9: 32.7 (p = 0.001), (Kaplan-Meier analysis, 
log-rank test) respectively. 
Conclusions: The data suggests five molecular subtypes are more predictive of 5 years 
RFS and OS than Adjuvant! RR. N has lowest survival followed by H (RFS) or CB (OS). 
Data on overall analysis including MCM2, Aurora A, Bcl2 and PDGFRa will be 
presented. 
Disclosure: M. Moe: I received research grant from Pfizer. All other authors have declared 
no conflicts of interest. 
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B. The abstract of the poster presented to 7
th
 NCRI conference, 2011 (poster number: 
B71) 
Defining and optimising risk stratification in early breast cancer using a focused panel 
of Immunohistochemical (IHC) molecular markers: a single institution study. 
Maung Moe
1
, Robert Mansel
4,3
, Richard Adams
2
 
1
Singleton Hospital, Swansea, UK, 
2
Velindre Hospital, Cardiff, UK, 
3
Cardiff University, 
Cardiff, UK, 
4
UHW, Cardiff, UK  
Background 
An inexpensive, readily available technique that utilises IHC expressions of proteins involved 
in breast cancer cell molecular pathways, seems a logical way to stratify patients for risk 
assessment and choice of successful treatments. Here we explore a panel of markers in a case 
control study. 
Method 
72 cases (relapse within 5yrs of curative surgery), 72 controls, (recurrence free > 5yrs), 
matched to cases by Adjuvant! recurrence risk. Tissue microarrays constructed with cores 
from formalin fixed paraffin embedded tissue. Optimised protein IHC expression was 
evaluated on digitalised images (Mirax). 5 molecular subtypes [Luminal A (LA = ER/PR+, 
HER2-,Ki67-) and B (LB = ER/PR+, HER2/Ki67+), HER2 enriched (H = ER-,PR-, HER2+), 
core basal (CB = ER-, PR-, HER2-, CK5/6/EGFR+), 5-negative (5N = negative for 
ER,PR,HER2,EGFR,CK5/6)] together with MCM2, Aurora A, Bcl2, PDGFRa and CD68 
expressions were analysed. SPSS 16v. used for statistical analysis. 
Results 
All had adjuvant chemotherapy. All but 3 cases had died from recurrent disease. Median (m) 
RFS and mOS =  23.2mo & 39.7mo. All but 3 controls remain free of recurrence: median 
follow-up = 103.5mo (74.3 – 164.4). mRFS and mOS for subtype LA = not yet & not yet; LB 
= 58.1 & 86.1; CB = 15.4 & 30.4; H = 28 & 55.9; 5N = 19.9 & 26 (p = <0.0001 & <0.0001 
by Log rank test).   Better mRFS and mOS were found for positive Bcl2 (p = 0.036 & 0.058) 
and MCM2 (p = 0.022 & 0.048), negative Aurora A (p = 0.01 & 0.001) and PDGFRa (p = 
0.07 & 0.086) expressions. Results of multivariate analysis and CD68 expression will be 
presented. 
Conclusion 
Subtypes CB & 5N, negative Bcl-2 & MCM2, positive Aurora A and PDGFRa expressions 
were predictive of poor RFS and OS and should be used as stratification factors for novel 
prospective biomarker led adjuvant studies.
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C. The Abstract of the poster presented in 34
th
 Annual San Antonio Breast Cancer 
Symposium (poster number: P1-07-21); published in Supplement to Cancer 
Research:71:24:p-196s. 
 
Analysis of Molecular Markers by Immunohistochemistry (IHC) Method on Formalin 
Fixed Paraffin Embedded (FFPE) Tissues Could Predict Shorter Recurrence Free 
Survival (RFS) and Overall Survival (OS) among Patients Who Have Received 
Adjuvant Chemotherapy for Early Breast Cancer. 
Moe M, Gee J, Finlay P, Mansel R, Adams R. Singleton Hospital, Swansea, United Kingdom; 
Velindre Hospital and Cardiff University, Cardiff, United Kingdom; Cardiff University, 
Cardiff, United Kingdom 
Background: Various molecular markers assessed by IHC (ER, PR, HER2) and gene 
expression profiling (e.g. Oncotype Dx) have been developed as prognostic and predictive 
tools for breast cancer. Gene profiling is said to be superior to IHC but at a considerable cost 
with limited availability. IHC is relatively inexpensive and more readily available. If early 
breast cancer patients who are going to relapse within 5 years of curative surgery despite 
adjuvant chemotherapy could be identified by IHC on FFPE tissue alternative adjuvant 
therapies could be explored. In this context, here we evaluate IHC for expression of a panel 
of molecular markers implicated in: growth signalling pathways (ER, PR, HER2, EGFR, 
CD71, Ki67, MCM2), cell survival (Bcl-2, Bag 1), angiogenesis (PDGFRa) and cell cycle 
progression (Aurora A, MCM2). Of note, this study includes markers of breast cancer 
molecular subtype (ER, PR, HER2, Ki67, EGFR, also CK5/6) and several proteins encoded 
by genes in the Oncotype Dx test (ER, PR, HER2, Ki 67, Bcl2, Bag1 and CD68). 
Materials and Method: 72 cases (R) relapsing within 5 years of curative surgery, 72 
controls (C), relapse free > 5 years were identified from the hospital records. All patients had 
adjuvant chemotherapy. Controls were matched to cases by Adjuvant! recurrence risk (ARR). 
Optimised IHC was performed on FFPE TMA slides using a Ventana autostainer. Protein 
expression was evaluated on digitalised images (Mirax scanner). Survival analysis by 
molecular markers expression and also 5 molecular subtypes, Luminal A (LA = ER/PR+, 
HER2-, Ki67-), Luminal B (LB = ER/PR+, HER2/Ki67+), HER2 enriched (H = ER-, PR-, 
HER2+), Core Basal (CB = ER-, PR-, HER2-, CK5/6/EGFR+) and 5-negative (5N = 
negative for ER,PR,HER2,EGFR,CK5/6)], were performed. SPSS 16v. was used for 
statistical analysis. 
Findings: All but four cases had died at the time of analysis. Four controls developed relapse 
at 83.8, 90.6, 107.7, 127.6 months respectively. Two controls died from non-breast cancer 
causes. Median (m) follow-up for the controls group ( ie. mOS)was 104.9 mo (72.8 - 164.4). 
For cases, mRFS and mOS were 23.2 (4.5 - 59.9) and 39.7(8.1 - 129). mRFS and mOS for 
IHC molecular subtypes were: Subtype LA = not yet & not yet; LB = 58.1 & 86.1; CB = 15.4 
& 30.4; H = 28 & 55.9; 5N = 19.9 & 26 (p < 0.0001 & <0.0001 by Log rank test). Better RFS 
and OS were found for positive Bcl2 (p = 0.036 & 0.058) and MCM2 (p = 0.022 & 0.048), 
negative Aurora A (p = 0.01 & 0.001) and PDGFRa (p = 0.07 & 0.086) expressions. For this 
study cohort there was no correlation between ARR and survival outcome or molecular 
subtypes. Result of ongoing multivariate analysis and correlation between survival and 
CD68, CD71 and Bag 1 expressions will be presented in the conference.  
Discussion: Subtypes CB & 5N, negative Bcl-2 & MCM2, positive Aurora A & PDGFRa 
expression as measured by IHC were predictive of poor RFS and OS. While these findings 
need to be verified in an independent cohort, IHC profiles nevertheless have potential to 
stratify different risk groups for clinical trials and effective adjuvant treatments. 
